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Abstract:		
	
Objectives:			
	
Glucocerebrosidase	mutations	represent	genetically	the	most	significant	risk	factor	for	
Parkinson	disease,	however	their	penetrance	is	incomplete	and	variable	such	that	only	a	
minority	of	glucocerebrosidase	mutation	carriers	will	develop	Parkinson	disease.	In	this	
thesis	I	aimed	to	investigate	the	basis	for	this	incomplete	penetrance,	to	identify	indices	
which	may	be	used	to	predict	Parkinson	disease		conversion	amongst	glucocerebrosidse	
mutation	carriers	and	to	test	a	putative	neuroprotective	drug	designed	to	modify	the	
glucocerebrosidase	pathway.		
	
Methods:	
	
In	chapter	2	we	used	meta	and	joint	analyses	to	calculate	the	odds	ratio	of	developing	
Parkinson	disease	with	individual	glucocerebrosidase	mutations.	In	chapter	3	we	
prospectively	assessed	a	cohort	of	glucocerebrosidase	mutation	carriers	without	Parkinson	
disease	for	prodromal	signs	of	Parkinsonism.	In	chapter	4	we	sought	to	extend	the	scope,	
scale	and	sustainability	of	this	study	by	producing	a	prototype	study	to	assess	these	patients	
remotely	through	the	internet.	In	chapter	5	we	investigated	whether	novel	imaging	(PET	
using	the	PK-1195	and	DAT	ligands),	serum	(alpha	synuclein,	tau	and	inflammatory	markers)	
and	urine	(hypothesis	generating	screen)	could	be	used	to	predict	PD	conversion.	In	chapter	
6	we	used	single	cell	calcium	imaging		in	a	primary	neuronal	mouse	model	carrying	the	
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N370S	glucocerebrosidase	mutation	to	investigate	whether	deranged	calcium	homeostasis	
might	be	the	basis	for	the	selective	vulnerability	of	dopaminergic	neurons	in	
glucocerebrosidase	mutation	carrying	cells.	In	chapters	7	and	8	we	present	optimisation	and	
preliminary	data	from	AiM	PD,	a	phase	II,	open	label,	non	placebo	controlled	trial	of	
ambroxol,	a	small	molecular	chaperone	of	the	glucocerebrosidase	enzyme.		
	
Results:	
	
Chapter	2:	We	derived	quantifiable	estimates	of	Parkinson	disease	risk	for	84GG,	E326K	
N370S,	L444P,	D409H,	RecNcil	as	well	as	important	data	relating	to	the	ethnic	distribution	of	
these	mutations.	
Chapter	3:	The	University	of	Pennslyvannia	smell	identification	test	and	Montreal	cognitive	
assessment	scores	of	glucocerebrosidse	mutation	carriers	were	worse	than	those	of	
controls.	There	is	a	clustering	effect	amongst	glucocerebrosidse	mutation	carriers	whereby	
poor	scores	in	these	assessments	and	the	Beck’s	depression	index	seemed	to	be	present	
together	in	a	subset	of	participants.	
Chapter	4:	We	show	the	rapsodi	portal	is	able,	using	validated	assessments,	to	detect	
Parkinson	disease	features.	Preliminary	data	shows	cognitive	deficits	amongst	
Glucocerebrosidase	mutations	carriers	exist	compared	to	controls.	
Chapter	5:	PK11195	signal	is	increased	in	the	substantia	nigra	of	glucocerebrosidase	
mutation	carriers	compared	to	controls	and	this	signal	increase	correlates	with	olfactory	
loss.	Serum	alpha	synuclein	levels	in	glucocerebrosidase	carriers	correlate	with	the	number	
of	severe	(neuronopathic)	mutations	and	a	risk	score	derived	from	prospective	assessment	
of	prodromal	Parkinson	disease	features.	The	hypothesis	generating	urine	proteomics	
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screen	identified	a	number	of	potential	markers	of	Parkinson	disease	conversion	including	
elements	of	the	IgG	kappa	light	chain.		
Chapter	6:			We	found	no	evidence	of	deranged	calcium	homeostasis	
Chapter	7:	The	glucocerebrosidase	enzyme	activity	assay	has	been	optimised	to	be	
reproducibly	used	in	cerebrospinal	fluid	samples	in	our	hands.	The	optimal	time	to	carry	out	
the	assay	to	prevent	degradation	of	activity	following	freezing	is	within	2	weeks	of	
collection.	In	vitro	addition	of	ambroxol	to	control	CSF	at	physiologically	relevant	
concentrations	caused	a	50%	reduction	in	activity	levels,	due	presumably	to	anatagonistic	
binding	to	the	active	site	of	the	enzyme.		
Chapter	8:	Preliminary	results	show	that	ambroxol	delivers	a	statistically	significant	increase	
in	leucocyte	glucocerebrosidase	activity	amongst	glucocerebrosidase	mutation	carriers	with	
Parkinson	disease.	These	patients	seem	to	have	worse	features	of	non	motor	Parkinson	
disease	symptoms	than	idiopathic	Parkinson	disease	cases.	
	
	
Conclusions:	
	
Our	results	collectively	suggest	it	may	be	feasible	to	stratify	risk	of	Parkinson	disease	
conversion	amongst	glucocerebrosidse	mutation	carriers	on	the	basis	of	genetic,	clinical,	
imaging	and	biochemical	indices.	Moeover	they	suggest	that	ambroxol	has	potential	as	a	
neuroprotective	agent	in	Parkinson	disease.
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Chapter	1	-	Introduction	
	
1.0	The	glycosphingolipid	pathway	
	
Glycosphingolipids	are	a	class	lipids	found	in	eukaryotic	organisms.		They	share	a	common	
two	tailed	lipid,	ceramide,	which	anchors	the	molecule	in	the	cell	membrane.	The	addition	
in	most	cases	of	a	lactosylceramide	forms	the	basic	disaccharide	whilst	a	number	of	other	
carbohydates	can	be	attached	to	the	galactose	group	by	glycosidic	linkage.	Their	
concentration	on	cell	membranes	varies	dramatically	on	the	basis	of	cellular	function.1	
	
Genetically	derived	enzyme	deficiencies	at	different	stages	of	the	glycosphingolipid	
catabolic	pathway	give	rise	to	highly	stereotyped	diseases	with	varying	severity	and	clinical	
presentations,	reflecting	accumulation	of	the	respective	sphingolipid	substrates	in	various	
visceral	organs	2,3.	The	GM1	and	GM2	gangliosidoses	for	instance,	caused	respectively	by	
deficiencies	in	the	Beta	hexaminidase	and	Beta	galctosidase,	are	severe	and	progressive	
diseases	of	childhood	onset	neurodegeneration	4.	Fabry	disease,	a	deficit	of	alpha	
galactosidase,	leads	to	accumulation	of	globotriaosylceramide	through	an	as	yet	
unidentified	mechanism,	and	a	variety	of	clinical	phenotypes	including	cornea	verticillata,	
peripheral	neuropathy,	cardiomyopathy,	stroke,	chronic	renal	failure	and	cutaneous	
angiokeratoma	formation	5.	
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1.1 Glucocerebrosidase	and	Gaucher	disease	
	
	Glucocerebrosidase	(also	called	glucosylceramidase)	is	a	lysosomal	hydrolase	enzyme	which	
catalyses	the	breakdown	of	the	sphingolipid	glucosylceramide	(Gb1)	into	ceramide	and	
water.	It	is	a	particularly	important	component	of	this	pathway	because	it	lies	downstream	
of	the	glycosphingolipids	GM1	and	globoside,	meaning	that	it	is	implicit	in	the	breakdown	of	
these	molecules	and	their	catabolites	3.	In	Gaucher	disease,	homozygous	carriers	of	
mutations	in	the	glucocerebrosidase	gene	(GBA)	cause	an	accumulation	of	
Glucosylceramide,	which	is	deposited	in	the	spleen,	liver	and	bones.	A	number	of	more	
“severe”	GBA	mutations	are	variably	associated	with	symptoms	of	central	nervous	system	
involvement.	Characteristically	these	neuronopathic	forms	of	Gaucher	disease,	which	are	
subdivided	in	an	acute	onset	(invariably	fatal)	presentation	(type	2)	and	a	more	chronic	
progressive	form	(type	3),	give	rise	to	supranuclear	gaze	palsy	accompanying	other	features	
such	as	cognitive	impairment,	epilepsy	and	tremor	6-9.	In	practice	the	demarcation	between	
types	2	and	3	is	more	fluid		and	the	presence	of	neuronopathic	features	is	highly	variable,	
even	amongst	those	with	identical	genetic	mutations	of	the	GBA	gene	10.		
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Fig	1.	The	sphingolipid	pathway.	Adapted	from:	Jeyakumar,	M.,	Butters,	T.	D.,	Dwek,	R.	a,	&	Platt,	F.	
M.	(2002).	Glycosphingolipid	lysosomal	storage	diseases:	therapy	and	pathogenesis.	
Neuropathology	and	applied	neurobiology,	28(5),	343-57.		
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1.2		Glucocerebrosidase	and	Parkinson	disease	
	
In	the	1990s	it	was	noticed	that	there	appeared	to	be	a	higher	incidence	of	Parkinson	
disease	amongst	those	with	Gaucher	disease	and	their	kindred.	Longitudinal	studies	
amongst	Gaucher	disease	cohorts	suggest	a	conversion	to	Parkinson	disease	of	
approximately	10%	by	the	age	of	80	11-13.	For	heterozygous	GBA	carriers	penetrance	has	
been	quoted	as	high	as	30%,	although	this	figure	is	controversial	14,15.	That	said	it	is	clear	
that	the	true	penetrance	is	substantially	lower	than	50%,	making	GBA	a	genetic	risk	factor	as	
opposed	to	an	autosomal	dominant	allele	in	the	traditional	Mendelian	sense.	There	are	to	
date	in	excess	of	300	known	Gaucher	causing	GBA	mutations	and	their	prevalence	
(quantified	using	exon	sequencing)	has	been	demonstrated	in	the	UK	to	be	as	high	as	3%	16,	
although	more	usually	this	is	reported	around	1%	17-19.	Amongst	Ashkenazi	Jewish	enriched	
population,	where	these	mutations	are	more	common,	this	can	rise	to	around	6%	20,21.					
	
There	is	substantial	variation	in	the	effect	size	(in	terms	of	conversion	to	Parkinson	disease	
and	GD)	of	individual	mutations.	Strikingly	those	alleles	which	are	associated	with	
neuronopathic	forms	of	Gaucher	disease	also	appear	to	be	those	which	carry	a	higher	risk	of	
Parkinson	disease	conversion	22.	Conversely	there	are	a	number	of	GBA	gene	variants	which	
cause	Gaucher	disease	only	in	combination	with	a	‘severe’	Gaucher	disease	allele.	These	
variants	have	been	suggested	to	be	associated	with	Parkinson	disease	with	marginal	odd	
ratios	23,24.	Some	of	these	individual	alleles	have	been	demonstrated	with	allele	frequencies	
within	the	general	population	as	high	as	2%	and	up	to	7%	in	idiopathic	Parkinson	disease	
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populations	16.	This	makes	GBA	comfortably	the	most	numerically	significant	genetic	risk	
factor	for	Parkinson	disease	identified	to	date	25.	
	
It	appears	that	there	are	some	clinical	differences	between	the	phenotype	of	GBA	and	
idiopathic	PD.	Most	prominently	there	is	a	striking	cognitive	phenotype	which	appears	to	be	
proportionate	to	the	severity	of	the	GBA	mutation	in	question	26-30.	Interestingly	GBA	
appears	also	to	be	a	genetic	risk	factor	for	Lewy	body	dementia	31,32.	Some	evidence	
suggests	there	is	a	more	pronounced	visuospatial	deficit	to	this	cognitive	impairment	33.	
Moreover	age	of	onset	of	GBA	Parkinson	disease	cases	is	approximately	4	years	earlier	and	
there	appears	to	be	a	more	symmetrical	presentation	with	less	evidence	of	unilateral	
tremor	or	rigidity	30.	Anecdotally	there	is	evidence	of	more	neuropsychiatric	features	and	a	
faster	disease	progression,	although	there	is	a	lack	of	high	quality	data	to	support	these	
findings	at	present.	
	
1.3	GBA	and	alpha	synuclein	
	
Alpha	synuclein	is	a	cystolic	protein	of	unknown	physiological	function	which	is	the	
substantive	component	of	Lewy	bodies,	the	pathological	stigmata	of	Parkinson	disease.	
There	is	compelling	data	to	suggest	a	direct	and	reciprocal	relationship	between	GCase	
activity	and	alpha	synuclein.	Biochemical	inhibition	of	GCase	activity	with	conduritol-B-
epoxide	(CBE)	leads	to	an	an	increase	in	alpha	synuclein	levels	34.	In	fibroblasts,	mouse	
primary	cultures,	neural	crest	cells	and	induced	pluripotent	stem	cells	carrying	GBA	
mutations,	alpha	synuclein	is	upregulated	35-37.		
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1.4	Putative	pathogenic	mechanisms	of	the	contribution	of	GBA	mutation’s	to	Parkinson	
disease	
	
The	mechanism	of	the	contribution	of	the	mutant	GBA	gene	to	Parkinson	disease	is	
uncertain.	A	number	of	mechanisms	have	been	proposed.	Broadly	these	can	be	grouped	
into	those	which	postulate	that	the	loss	on	function	of	the	catalytic	activity	of	the	GCase	
enzyme	is	the	primary	driver	of	disease	and	those	which	believe	mutations	lead	to	
secondary	biochemical	consequences	and	Parkinson	disease	(gain	of	function).			
	
1.5	Loss	of	function	
	
There	is	evidence	to	suggest	that	dysfunction	of	GCase	catalytic	activity	is	associated	with	
increased	Parkinson’s	risk.	Peripheral	blood	leucocyte	GCase	activity	is	reduced	amongst	
idiopathic	Parkinson	disease	patients	and	in	the	brains	of	idiopathic	Parkinson	disease	
subjects	compared	to	controls	38,39.	Studies	in	cerebrospinal	fluid	of	idiopathic	Parkinson	
disease	cases	show	lower	GCase	activity	levels	compared	to	controls	40.		
	
That	said	there	are	major	inconsistencies	to	this	argument.	In	particular	there	is	a	relatively	
poor	correlation	between	GCase	activity	levels	and	disease	risk	in	Parkinson	disease	and	
indeed	GD.		For	instance,	one	study	showed	that	GCase	activity	from	peripheral	blood	spots	
categorised	by	mutation	did	not	correlate	with	the	severity	of	those	individual	mutations	in	
terms	of	Parkinson	disease.	L444P	Parkinson	disease	cases	for	instance	appear	to	have	
higher	GCase	activity	than	those	with	N370S,	even	though	L444P	mutations	convey	between	
2-3	times	the	risk	of	Parkinson	disease	compared	to	N370S	30,38,41,42.	Equally	heterozygous	
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carriers	of	the	84GG	mutation,	which	is	a	frameshift		mutation	and	would	be	expected	to	be	
null	in	terms	of	GCase	activity,	had	comparable	enzyme	activity	with	other	missense	GBA	
mutations	38.	
	
	It	may	be	that	this	disparity	is	a	reflection	of	the	limitations	of	the	GCase	activity	assay.	
Typically	in	leucocyte	GCase	is	normalised	to	the	protein	concentration	of	the	lysate	
produced	and	in	cerebrospinal	fluid	there	is	no	normalisation	to	protein	concentration	at	all	
43-45.	Differences	in	the	expression	levels	of	the	mutant	and	wild	type	GCase	protein	(from	
the	remaining	non	mutated	allele)	will	substantially	influence	what	is	effectively	an	assay	
which	measures	the	rate	of	substrate	catalysis,	yet	to	date	there	is	no	mechanism	to	
normalise	for	GCase	protein	expression.				
			
1.5a	Substrate	accumulation	
	
Glycosylceramide	accumulation	has	been	demonstrated	in	both	neuronopathic	and	non	
neuronopathic	forms	of	Gaucher	disease	and	has	been	shown	to	cause	significant	microglial	
activation	in	human	brains	and	a	number	of	mouse	models	in	the	former	46-48.	This	
mechanism	(and	central	nervous	system		immune	dysregulation	more	generally),	has	been	
postulated	as	a	pathogenic	mechanism	is	Parkinson	disease	48-55,	although	of	course	it	is	
highly	non	specific	and	could	be	caused	by	a	wide	variety	of	processes.	Substrate	
accumulation	has	been	suggested	as	a	pathogenic	mechanism	of	Parkinson	disease	in	GCase	
mutation	carriers	56.	To	date	substrate	accumulation	has	not	been	demonstrated	in	
Parkinson’s	brains,	although	one	study	did	show	a	reduction	in	ceramide,	the	product	of	
GCase	catalysis	57,58.					
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1.5b	Direct	disposal	of	alpha	synuclein	by	GCase	
	
Nuclear	magnetic	resonance	spectroscopy	provides	direct	evidence	of	a	pH	dependent	
interaction	between	GCase	and	alpha	synuclein	59-61.	Equally,	as	described	previously,	a	
reciprocal	relationship	has	been	reproducibly	demonstrated	between	alpha	synuclein	levels	
and	GCase	activity	34,36.	Such	a	direct	interaction	implies	a	direct	role	of	GCase	in	alpha	
synuclein	breakdown.		
	
Autophagic	dysfunction	is	a	well	established	paradigm	within	the	field	of	neurodegeneration	
and	in	particular	within	Parkinson	disease	62-65.	Chaperone	mediated	autophagy	(CMA)	
dysfunction,	by	which	transit	of	the	substrate	into	the	lysosome,	aided	by	the	a	complex	of	
the	LAMP2A	protein	isoform	and	heat	shock	protein	70	(HSP	70),	has	been	heavily	
implicated	with	Parkinson	disease	66-68.	Interruption	of	this	mechanism	has	been	found	in	a	
variety	of	cell	models	as	well	as	Parkinson	disease	brains.	Alpha	synuclein	has	been	
demonstrated	to	be	degraded	via	CMA	and	some	models	additionally	indicate	direct	
inhibition	of	CMA	by	alpha	synuclein	63,65,69,70;	in	turn	creating	a	vicious	cycle	of	impaired	
CMA	mediated	disposal	of	the	protein.	It	is	tempting	to	speculate	that	a	generalised	
interruption	of	physiological	autophagic	homeostasis	-	with	GCase	being	a	component	of	
this	pathway	-	may	account	for	this	association,	however	to	date	other	lysosomal	storage	
diseases	have	not	been	shown	to	be	associated	with	Parkinson	disease	71,72.	Further	efforts	
to	qualify	the	relationship	between	GCase	and	alpha	synuclein	are	little	more	than	
speculative	and	have	failed	to	reliably	account	for	it.		
	
	
Stephen	Mullin	–	PhD	thesis	
	
	
29	
	
1.6	Toxic	gain	of	function	
1.6a	Endoplasmic	reticulum	GCase	sequestration	
	
Perhaps	the	most	plausible	hypothesis	for	mutant	GCase	mediated	toxic	gain	of	function	
comes	from	the	lysosomal	storage	disease	field.	A	series	of	elegant	experiments	has	
demonstrated	that	GBA	mutations	interrupt	the	physiological	mechanism	of	post	
translational	modification	of	the	GCase	protein	73,74.			This	in	turn	results	in	a	failure	of	
trafficking	of	the	protein	from	the	endoplasmic	reticulum.	Consequently	it	not	only	may	
interrupt	any	putative	interaction	between	alpha	synuclein	and	GCase	within	the	lysosome,	
but	has	been	shown	to	result	in	an	“unfolded	protein	response”,	whereby	reactive	oxygen	
species	are	produced	in	response	to	the	sequestered	protein,	leading	to	cellular	toxicity	and	
ultimately	death	75.	In	terms	of	Gaucher	disease,	the	degree	of	GCase	sequestration	has	
been	shown	to	be	a	correlate	of	the	clinical	severity	of	the	phenotype	76.			
	
This	hypothesis	chimes	with	concurrent	theories	underlying	the	basis	for	the	selective	
vulnerability	of	nigral	neurons.	Surmeier	et	al.	have	produced		evidence	to	show	that	that	
the	intracellular	calcium	homeostasis	and	specifically	the		rapid	and	characteristic	
oscillations	of	calcium	which	characterises	“pacemaking”	nigral	neurons,	is	responsible	for	
the	overload	of	michondrial	calcium	buffering	capacity	77.		Sequestration	of	protein	within	
the	ER	has	been	shown	to	substantially	upregulate	calcium	release	78	and	hence	provides	a	
plausible	explanation	for	the	particular	predilection	of	GBA	mutations	for	the	Parkinson	
disease	phenotype.				
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1.6b	Alpha	synuclein	aggregation	dynamics	and	Impaired	GCase	
	
Alpha	synuclein	aggregation	is	thought	to	be	pathogenic	mechanism	of	neuronal	death	in	
Parkinson	disease.	In	the	native	state	alpha	synuclein	is	monomeric.	In	the	presence	of	a	
variety	of	factors	such	as	oxidative	stress,	shaking,	contact	with	lipid	membranes	and	certain	
inorganic	ions	such	as	copper	or	iron,	it	defers	to	beta	sheet	rich	fibrillar,	oligomeric	or	
aggregated	forms	79-84.	It	is	these	aggregated	species	that	make	up	Lewy	bodies.	Monogenic	
forms	of	Parkinson	disease	caused	by	alpha	synuclein	mutations	have	been	shown	to	have	
enhanced	aggregation	dynamics	85-88.	Morever	increased	cytosolic	synuclein	concentrations	
upregulate	aggregation	propensity	89,90.	Although	the	subject	is	controversial	it	is	thought	
that	oligomeric	species	are	the	predominant	pathogenic	form	of	the	protein	91-96.	Moreover	
it	appears	that	these	aggregated	species	are	able	in	the	presence	of	monomeric	synuclein,	
to	cause	it	to	defer	to	an	aggregated	form,	as	was	shown	initially	in	neuronal	grafts	
transplanted	into	Parkinson	disease	cases	which	developed	Lewy	pathology	97.	These	
findings	were	subsequently	replicated	in	a	variety	of	models	in	which	pre	formed	fibrils	of	
alpha	synuclein	where	injected	into	the	brains	of	a	variety	of	mammals	98-102.		
	
To	the	knowledge	of	the	author	there	has	to	date	been	little	work	looking	at	the	direct	
effect	of	GCase	or	mutant	GCase	on	alpha	synuclein	aggregation	dynamics,	short	of	the	
finding	that	alpha	synuclein	binds	directly	to	the	GCase	active	site	59.	It	may	be	that	an	
interruption	of	the	GCase	mediated	physiological	disposal	of	one	or	all	of	the	synuclein	
species	may	increase	aggregation	propensity	either	by	the	failure	to	remove	seeding	
fibrillary	species	or	simply	by	increasing	cystolic	synuclein	concentrations.	
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1.7	Toxic	gain	of	function	as	a	consequence	of	loss	of	function	or	loss	of	function	as	a	
consequence	of	toxic	gain	of	function?		chicken	or	egg?	
	
There	may	of	course	be	the	potential	for	both	loss	of	function	and	a	toxic	gain	of	function	to	
be	coexistent	or	perhaps	more	plausibly	a	product	of	one	another.	For	instance	any	
structural	alteration	to	the	GCase	protein	may	give	rise	to	gain	in	function	but	may	
incidentally	reduce	enzyme	activity.	Conversely	a	loss	of	enzyme	activity	may	result	
downstream	in	an	added	gain	of	function	as	a	result	of	disruption	of	the	balance	of	
substrate/product.			As	such	the	distinction	between	the	two	may	well	be	no	more	than	an	
exercise	in	semantics.		
	
1.8	Understanding	which	GBA	mutation	carriers	will	convert	to	Parkinson	disease	
	
It	is	crucial	that	the	distinction	is	made	between	GBA	mutations,	which	(along	with	LRRK2	
mutations)	are	a	genetic	risk	factor	for	Parkinson	disease	and	other	Mendelian	forms	of	
genetic	Parkinson	disease	such	as	mutations	in	the	alpha	synuclein,	PINK	or	PARKIN	genes	
25.	Crucially,	on	balance	of	probabilities,	GBA	mutations	carriers	are	more	likely	not	to	
develop	Parkinson’s	13,14,103.		The	question	of	the	variable	penetrance	of	GBA	Parkinson	
disease	accordingly	remains	a	major	unanswered	point	in	our	understanding	of	Parkinson	
disease	and	is	of	particular	interest	because	it	mimics	the	inheritance	of	idiopathic	
Parkinson	disease.	More	specifically,	a	family	history	of	Parkinson	disease	is	the	single	
greatest	risk	factor	for	developing	Parkinson	disease,	although	only	a	small	minority	of	cases	
develop	Parkinson’s	in	a	Mendelian	manner	25,104.	One	can	speculate	that	untangling	the	
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factors	which	contribute	to	the	conversion	of	GBA	carriers	to	Parkinson’s	may	also	allow	us	
to	reveal	those	who	will	develop	idiopathic	Parkinson	disease.	
	
One	aspect	is	of	course	the	“potency”	of	the	GBA	mutations.	There	are	to	date	over	300	
Gaucher	disease	causing	GBA	mutations	and	many	more	polymorphisms,	associated	only	
with	Gaucher	disease	in	the	conjunction	only	with	a	‘severe’/’neuronopathic’	GBA	allele	
105,106.		It	is	now	abundantly	clear	that	so	called	severe	Gaucher	diseasecausing	mutations	
are	associated	with	a	much	greater	risk	of	Parkinson	disease	than	mild	ones	22.	In	the	case	
of	the	most	common	mutations	(N370S	and	L444P)	it	is	even	possible	to	quantify	the	risk	
individually,	with	each	mutation	respectively	conveying	an	odds	ratio	of	3-4	of	developing	
Parkinson	disease	30,42		and	6-12	30,41,42	respectively.				
	
Even	with	this	taken	into	account	the	cause	of	the	variable	penetrance	of	Parkinson’s	
caused	by	GBA	alleles	remains	unclear.		The	three	most	likely	candidates	would	seem	to	be	
genetic,	epigenetic	and	environmental	cofactors	25,	although	to	date	a	series	of	
environmental	exposures	(such	as	smoking,	NSAID	exposure,	coffee,	outdoor	lifestyle	and	
head	trauma	104)	have	been	implicated	as	protective	or	risk	factors	in	Parkinson	disease,	
none	have	been	proven	to	be	relevant	in	the	context	of	GBA	Parkinson	disease,	whilst	
evidence	for	specific	genetic	or	epigenetic	cofactors		is	scant.		
	
1.9	Early	detection	of	conversion	in	GBA	Parkinson	disease	
	
It	has	been	known	for	some	years	that	a	clinical	prodrome	which	includes	hyposmia,	
constipation,	cognitive	impairment	and	REM	sleep	disorder	preceeds	the	onset	of	motor	
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Parkinson	disease	by	up	to	20	years	107-110.	Our	own	analyses	of	our	longitudinal	cohort	has	
established	some	of	these	features	are	prominent	amongst	GBA	carriers	111,112.		Equally	
genotyping	of	those	with	electrophysiologically	proven	REM	sleep	disorder		dysfunction	
shows	a	higher	prevalence	of	GBA	mutation	carriers	compared	to	age	matched	controls	113.	
It	may	be	that	by	using	a	combination	of	genetic,	clinical,	biochemical	and	imaging	
biomarkers	we	are	able	to	stratify	the	risk	of	developing	Parkinson	disease	amongst	GBA	
mutation	carriers.		
	
1.10	GCase	targeted	neuroprotection	in	Parkinson	disease		
	
Clearly	the	major	draw	of	research	looking	at	monogenetic	risk	factors	for	Parkinson’s	is	that	
it	offers	the	possibility	of	targeted	neuroprotective	interventions.	It	has	been	proposed	that	
the	GCase	pathway	is	amenable	to	such	modification	through	five	predominant	
mechanisms.		
	
1.10a	Gene	therapy		
	
Gene	therapy	refers	to	the	modification	of	specific	genes	within	a	subset	of	cells	using	a	
targeted	vector	such	as	a	virus.		Interest	in	gene	therapy	targeting	the	GBA	gene	has	mostly	
been	in	the	context	of	Gaucher	disease	and	has	been	longstanding	114.	Of	particular	interest	
has	been	the	realistic	prospect	of	such	therapy	crossing	the	blood	brain	barrier	and	hence	
being	a	viable	treatment	for	the	neuronopathic	form	of	the	disease.	Using	invariant	natural	
T	killer	cells	it	was	shown	in	2011	Gaucher	fibroblasts	could	be	transfected	using	a	high-titer,	
amphotropic	retroviral	vector	in	which	human	GBA1	was	driven	by	the	mutant	polyoma	
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virus	enhancer/herpesvirus	thymidine	kinase	gene	promoter	115,116.		Unfortunately	the	
clinical	protocol	that	resulted	achieved	only	a	transfection	efficiency	of	1-10%	which	was	
insufficient	to	cause	a	clinically	significant	improvement	in	substrate	levels	117.	Finding	
stable	and	safe	means	of	efficient	transfection	remains	the	principle	obstacle	to	the	
successful	clinical	application	of	this	technology	118.	Using	a	murine	GBA	knockout	model	an	
intravenously	injected	lentiviral	vector	was	shown	to	be	able	to	deliver	improved	GCase	
activity,	reduced	substrate	accumulation	and	improvements	in	a	number	of	clinical	
outcomes	119,	however,	whether	such	outcomes	can	be	replicated	in	human	subjects	is	
uncertain.	In	the	context	of	Parkinson	disease	moreover	it	is	unclear	whether	affected	brain	
regions	(e.g	substantia	nigra	and	striatum)	could	be	reached	by	such	vector	technologies.			
	
1.10b	GCase	replacement	therapy	
	
Direct	supplementation	of	recombinant	GCase	enzyme	has	been	a	highly	successful	
treatment	in	Gaucher	disease	and	has	extended	the	life	expectancy	of	these	patients	by	
decades	120,121.	Systematically	recombinant	GCase	has	been	shown	to	localise	to	the	
lysosome	and	upregulate	enzyme	activity.	The	limitation	of	this	approach	in	the	context	of	
Parkinson	disease	is	that	GCase,	as	a	60	kd	protein,	is	too	large	to	cross	the	blood	brain	
barrier	in	sufficient	quantities	to	modify	central	nervous	system	GCase	activity	122,123:	A	
variety	approaches	such	as	co	therapy	with	pharmacological	agents	and	inducing	blood	
vessel	inflammation	have	been	suggested	as	mechanism	to	enhance	central	nervous	system		
GCase	uptake	124,	although	there	is	currently	no	evidence	of	their	relevance	to	clinical	
practice.	An	alternative	approach	might	be	direct	intrathecal	administration	of	recombinant	
GCase	123,125.	A	prototype	for	this	approach	exists	in	treatment	of	the	lysosomal	storage	
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disorders	Hunter’s	and	Hurler’s	diseases	(Mucopolysaccharidosis	type	I	and	II)	126	although	
doubt	remains	about	the	ability	of	a	intrathecally	administered	ERT	to	provide	a	sufficient	
concentration	gradient	to	breach	the	parenchymal	cells	of	the	brain	and	hence	penetrate	
neuronal	tissues.	
	
1.10c	Substrate	reduction	
	
I	have	already	discussed	the	paucity	of	evidence	for	the	presence	of	substrate	accumulation	
in	Parkinson	disease.	None	the	less,	there	is	significant	interest	in	its	use	as	a	
neuroprotective	agent	in	Parkinson	disease.	This	has	primarily	been	driven	by	the	finding	
that	in	synuclein	overexpression	cell	lines	GCase	substrate	inhibition	appears	to	reduce	
alpha	synuclein	levels	56	Miglustat,	a	reversible	inhibitor	of	glucosylceramide	synthase	has	
been	used	in	the	context	of	type	3	Gaucher	disease,	although	concerns	exist	over	the	side	
effect	profile	and	in	particular	the	incidence	of	peripheral	neuropathy	127-129.	A	new	agent	
(eliglustat)	which	also	inhibits	glucosylceramide	synthase,	is	currently	undergoing	evaluation	
in	clinical	trials	in	Gaucher	disease	130	and	Parkinson	disease	131.		
	
1.10d	Small	molecular	chaperones	
	
Relying	on	the	observation	that	mutant	GCase	is	sequestered	within	the	endoplasmic	
reticulum,	small	molecular	chaperones	act	as	molecular	cofactors	which	aid	physiological	
post	translational	folding	and	in	turn,	upregulate	trafficking	of	mutant	GCase	to	the	
lysosomal	compartment	of	the	cell	132-134.	Two	types	of	chaperone	exist,	the	prototype	
inhibitory	chaperone	(which	binds	to	the	active	site	of	the	GCase	protein)	and	non	inhibitory	
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chaperones,	which	bind	to	alternate	parts	of	the	structure	yet	are	still	able	to	modulate	
folding	sufficiently	to	restore	or	partially	restore	post	translational	folding	135.		In	both	cases	
the	change	in	the	pH	environment	causes	partial	elution	of	the	chaperone	upon	entry	into	
the	lysosomal	compartment,	although	as	we	shall	discuss	later	the	degree	of	this	elution	is	
variable.	
	
1.10e	Inhibition	of	the	proteosomal	system	
	
Misfolded	GCase	is	removed	from	cytosol	predominately	by	the	proteosomal	system.	This	
mechanism	is	heavily	reliant	on	heat	shock	protein	90,	a	chaperone	which	amongst	a	huge	
variety	of	other	functions,	removes	misfolded	GCase	via	the	proteosomal	system	136.		This	
occurs	through	the	LAMP2A	protein,	which	mediates	recognition	of	defective	proteins	for	
translocation	to	the	lysosome	137.	A	mooted	therapeutic	strategy	has	been	the	interruption	
of	the	recognition	of	the	GCase	protein	by	the	HSP	90	protein,	in	turn	reducing	the	amount	
of	GCase	degraded	via	chaperone	mediated	autophagy	(CMA)	and	increasing	cytosolic	
concentrations	of	the	protein	123.	Histone	deacetylase	inhibitors	have	been	shown	in	vitro	to	
reduce	GCase	degredation	136.	Given	the	wealth	of	evidence	linking	alpha	synuclein	to	
impaired	degredation	within	the	proteosomal	system	137	it	seems	some	what	
counterintuitive	to	impair	this	mechanism	as	a	potential	therapeutic	strategy	in	Parkinson	
disease.	
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1.11	Outline	of	thesis	
	
The	focus	of	this	thesis	is	to	discern	tools	to	construct	and	ascertain	genetic,	chemical,	
clinical	and	imaging	biomarkers	of	conversion	of	Parkinson	disease	amongst	GBA	carriers.	It	
will	attempt	to	understand	the	basis	for	the	variable	phenotypic	penetrance	of	GBA	
Parkinson	disease	and	of	the	selective	vulnerability	of	certain	parts	of	the	brain	to	GBA.	
Finally,	I	will	detail	the	validation	work	and	preliminary	findings	of	clinical	trial	utilising	a	
targeted	neuroprotective	strategy,	namely	small	molecular	chaperones	of	the	GCase	
enzyme.	
	
In	chapter	2	I	will	outline	the	basis	of	the	genetic	risk	of	Parkinson’s	caused	by	GBA	alleles.	
There	is	already	an	established	literature,	based	largely	on	genetic	case	control	studies,	
which	correlates	the	severity	of	the	Gaucher	phenotype	of	known	GBA	mutations	and	the	
risk	of	Parkinson	disease.	I	develop	this	analysis	further	to	attempt	to	quantify	the	disease	
risk	of	individual	mutations,	including	the	so	called	Parkinson	disease	associated	Gaucher	
polymorphisms.	
	
In	Chapter	3	I	will	present	the	prospective	analysis	of	some	100	GBA	mutations	carriers	
without	Parkinson	disease	for	prodromal	features	of	Parkinson	disease.	We	will	show	
globally	that	there	is	an	increased	prevalence	of	a	number	of	these	features	and	
furthermore	there	is	clustering	of	them	amongst	a	‘high	risk’	group	of	patients	who	may	be	
at	increased	risk	of	Parkinson	disease.		
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In	Chapter	4	I	will	describe	the	development	of	rapsodi,	an	internet	based	platform	for	
assessment	of	prodromal	Parkinson	disease	features.	The	portal	aims	to	increase	the	power	
of	these	analyses	and,	in	turn,	provide	a	means	for	the	prediction	of	future	Parkinson	
disease	conversion.	I	will	also	outline	preliminary	validation	data	for	the	portal	which	will	
show	its	utility	in	terms	of	remotely	assessing	GBA	carriers.	
	
Chapter	5	will	show	work	looking	for	prospective	chemical	biomarkers	of	Parkinson	disease	
conversion	amongst	GBA	carriers	.	It	will	also	detail	the	results	of	PET	imaging	scans	using	
the	dopamine	active	transporter	(DAT)	and	the	PK11195	ligands,	which	provide	preliminary	
evidence	of	nigral	glial	activation	and	inflammation	amongst	non	Parkinson	disease	GBA	
carriers.	Additionally	I	shall	describe	work	carried	out	within	the	same	cohort	looking	for	
urine	and	serum	biomarkers,	which	implies	a	role	for	systemic	inflammation	in	the	
pathogenesis	of	GBA	Parkinson	disease	in	addition	to	some	more	established	
neurodegenerative	pathways.				
	 	
Drawing	heavily	on	the	work	of	Mia	Horowitz	and	James	Surmeier,	in	chapter	6	I	will	
postulate	a	theoretical	basis	for	both	the	incomplete	penetrance	of	GBA	Parkinson	disease	
and	the	selective	vulnerability	of	dopaminergic	(and	other)	neuronal	subtypes	in	chapter	3.	I	
will	suggest	that	the	unfolded	protein	response	brought	about	by	mutant	GCase	
sequestration	gives	rise	to	a	chain	of	intracellular	calcium	evoked	calcium	release	which	
overwhelms	mitochondrial	buffering	capacity	and	ultimately	leads	to	neuronal	death.	
Unfortunately	this	work	did	not	produce	results	which	corroborate	this	hypothesis.			
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In	chapter	7	I	shall	outline	the	design	and	validation	studies	for	the	AiM	PD	trial,	a	phase	II,	
open	label,	non	placebo	controlled	clinical	trial	of	the	the	inhibitory	small	molecular	
chaperone	ambroxol	amongst	GBA	and	idiopathic	Parkinson	disease	subjects.	I	shall	detail	
work	necessary	to	validate	reproducibly	the	GCase	activity	assay	in	cerebrospinal	fluid	and	
blood	leucocytes,	assays	to	detect	ambroxol	in	serum	and	cerebrospinal	fluid	and	mass	
spectrometry	assays	to	detect	and	quantify	GCase	and		glucosylceramide	in	cerebrospinal	
fluid.	
	
In	Chapter	8	I	will	describe	the	preliminary	data	from	the	Aim	PD	study.		We	will	present	
blood	GCase	activity	pre	and	post	commencement	of	ambroxol	and	baseline	cerebrospinal	
fluid	GCase	data.	These	data	will	show	an	upregulation	of	leucocyte	GCase,	supporting	the	
putative	action	of	ambroxol.	The	cerebrospinal	fluid	data	will	be	discussed	in	terms	of	its	
relevance	to	prevailing	debates	and	controversies	within	the	field,	with	particular	focus	on	
the	role	of	GCase	activity	in	the	pathogenesis	of	GBA	Parkinson	disease.	
	
In	chapter	9	I	shall	conclude	by	suggesting	that	GBA	Parkinson	disease	provides	a	prototype	
for	the	targeting	of	“bespoke”	neuroprotection.	I	will	suggest	that	using	the	presence	of	
GBA	mutation	as	a	baseline	screening	assessment	it	may	be	possible	to	identify	and	treat	
high	risk	individuals	with	neuroprotective	agents	targeted	at	the	GCase	pathway.	More	
broadly,	given	that	an	estimated	70%	of	the	heritability	of	Parkinson	disease	remains	
unaccounted	for,	I	shall	suggest	that	such	an	approach	may	have	wider	applications	to	
idiopathic	Parkinson	disease	as	a	whole.	
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Chapter	2	-	Characterising	the	mutation	specific	genetics	of	GBA	Parkinson’s	
	
2.0	Introduction	
	
The	mutations	spectrum	within	the	GBA	gene	has	been	ably	defined	over	the	last	two	
decades	by	research	into	the	Gaucher	disease.	Over	300	Gaucher	causing	mutations	have	
been	defined	and	a	crude	measure	of	their	potency	has	been	produced	on	the	basis	of	
whether	they	have	been	described	in	subjects	with	neuronopathic	forms	of	the	disease	
105,106.	The	relevance	of	this	classification	has	been	highlighted	by	work	which		has	revealed	
that	‘severe’	Gaucher	causing	mutations	are	collectively	associated	with	an	odds	ratio	of	
Parkinson’s	≈	16	as	opposed	to	‘mild’	mutations	which	are	associated	with	an	odds	ratio	≈	3	
22.	These	data	are	based	on	genetic	case	control	studies,	in	which	an	odds	ratio	and	
confidence	intervals	are	constructed	from		the	allele	frequency	of	carriers	of	the	mutation	in	
question	with	and	without	Parkinson	disease	138.	Moreover	in	a	small	cross	sectional	survey	
a	significant	majority	of	the	Parkinson	disease	affected	offspring	of	Gaucher	patients	
carrying	one	severe	and	one	mild	mutations	had	a	severe	Gaucher	disease	causing	mutation	
139.			
	
Conversely	Gaucher	associated	polymorphisms,	which	cause	Gaucher	disease	but	only	in	
conjunction	with	a	severe	disease	causing	allele,	have	been	associated	with	Parkinson	
disease,	although	the	subject	is	controversial.		The	two	most	prominent	of	these,	T369M	
and	E326K	have	been	variously	shown	to	be	both	pathogenic	and	non	pathogenic	in	a	
number	of	studies	16,23,24.	These	contradictory	findings	may	be	a	reflection	of	the	low	odds	
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ratios	of	the	effect	size	(which	on	the	whole	are	within	the	range	of	1-2)	and	which	will	
accordingly	require	large	sample	sizes	to	reach	the	threshold	for	significance.		
	
These	rudimentary	studies	have	established	stark	variability	in	the	‘potency’	of	GBA	
mutations	in	terms	of	Parkinson	disease.	Such	variation	is	of	key	importance	as	the	
penetrance	of	GBA	Parkinson	disease	has	collectively	been	estimated	between	10-30%	13,14,	
but	it	becomes	less	perplexing	if	one	infers	that	the	type	(and	potency)	of	mutations	that	
make	up	the	cohorts	upon	which	these	estimates	are	based	may	vary	substantially.	Taking	
this	line	of	argument	to	its	logical	end,	it	may	be	feasible	to	stratify	the	risk	of	development	
of	Parkinson	disease	based	on	the	specific	individual	mutations	in	question.					
	
2.1	Methods	
	
A	full	outline	of	the	methods	of	this	study	is	detailed	in	the	appendices.	(section	10.0).	
	
In	order	to	attempt	to	derive	assessments	of	the	risk	of	Parkinson	disease	associated	with	
individual	GBA	mutations	a	comprehensive	literature	search	was	carried	out	using	the	
following	terms:	“glucocerebrosidase”	(or	“GBA”),	risk	(or	“odds	ratio”	or	“OR”	or	“risk	
ratio”	or	“RR”)	and	”Parkinson’s”	(or	“Parkinson”	or	“Parkinson	disease”).	High	quality	case-
control	genetics	studies	were	selected	according	to	the	following	criteria:	
	
• Estimated	the	odds	ratio	or	risk	ratio	of	developing	Parkinson	disease	due	to	a	GBA	
mutation	
• Appropriately	matched	control	groups		
Stephen	Mullin	–	PhD	thesis	
	
	
43	
• GBA	genotyping	using	a	recognised	and	validated	method	that	prevented	
amplification	of	the	pseudogene	GBAP1	(either	whole/partial	gene	Sanger	
sequencing	or	mutation/variant	specific	microarray	screening)	
• No	duplication/sharing	of	datasets	in	studies	included	in	the	analysis		
	
Articles	were	short	listed	in	November	2016	on	the	basis	of	abstracts	and	rejected/selected	
following	review	of	the	full	text.	The	selected	articles	were	supplemented	by	articles	
identified	by	reviewing	the	references	of	established	meta-analyses	22,30,42,140,141	or	from	
the	private	databases	of	the	authors	(SM	and	AHVS).	A	flow	diagram	of	the	selection	
process	is	shown	in	Fig.	1	and	a	complete	list	of	studies	from	which	data	was	taken	is	
available	in	the	appendix	(sup.	table	1)	
	
Each	study	was	individually	reviewed	by	a	single	reviewer	(SM)	and	variant	alleles	detected	
amongst	the	case	and	control	groups	were	recorded.	Any	variant	detected	in	two	or	more	
separate	studies	was	included	in	the	final	analysis.		Where	applicable,	the	microarray	design	
was	reviewed	and	if	unable	to	differentiate	between	individual	mutations	which	also	appear	
as	part	of	a	haplotype	(e.g.	L444P	and	L444P;A456P;V460V),	the	study	was	excluded	from	
relevant	analyses.	The	total	number	of	cases	and	controls	from	all	studies	in	which	
genotyping	covered	the	variant	in	question	(i.e.	full	exon	Sanger	sequencing,	partial	exon	
Sanger	sequencing	covering	region	of	variant,	or	variant	specific	microarray	screening)	was	
calculated	as	were	the	total	number	of	case	and	control	subjects	who	were	
mutation/variant	carriers.		
	
We	initially	carried	out	meta-analysis	to	determine	the	risk	associated	with	developing	
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Parkinson	disease	for	each	mutation.	A	fixed	effects	model	was	employed	in	all	cases	to	
calculate	an	OR	of	the	risk	of	developing	Parkinson	disease.	A	pooled	OR	was	calculated	
using	the	Mantel-Haenszel	test	142.		Homogeneity	of	the	sample	was	assessed	using	Woolf’s	
test	for	heterogeneity	143.	To	assess	for	publication	bias	we	carried	out	Begg’s	test	144.		
	
We	then	carried	out	further	joint	analyses,	one	which	used	the	pooled	count	data	for	that	
mutation	and	a	second	where	this	dataset	was	augmented	with	ethnically	matched	control	
count	data	derived	from	the	The	Exome	Aggregation	Consortium	(ExAc)	database	
(ExAc.broadinstitute.org)	145,146.	Where	mutations/variants	appeared	to	be	specific	to	one	
ethnicity	we	excluded	all	studies	not	drawn	from	that	ethnicity	for	the	joint	analysis	(full	
details	in	individual	mutations	section	within	appendicies)	.	We	then	used	Firth	logistic	
regression	(which	has	been	shown	to	minimise	type	1	errors	in	both	balanced	and	
unbalanced	case-control	datasets)	to	calculate	the	risk	of	Parkinson	disease	associated	in	
these	amalgamated	datasets	147.	In	all	cases	we	applied	a	Holm-Bonferroni	correction	for	
multiple	comparisons	148.	The	details	of	the	exact	methods	used	for	each	mutation	are	
shown	in	the	supplementary	materials	(section	10.0).	
	
Selection	of	articles,	compilation	of	count	data	and	primary	data	analysis	was	carried	out	by	
myself.	Dr	Steven	Lubbe	advised	on	aspects	of	data	analysis.	
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248	search	results	
74	studies	following	abstract	review
23	studies	following	full	review
7 additional	articles	added	from	authors’	
private	collections
11		additional	articles	added	from	
references	of	meta	analyses41	studies	in	total
30	studies
Fig	1.	Process	of	study	selection	for	
analyses
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2.2	Results	
	
A	more	detailed	summary	of	the	findings	for	each	individual	mutations	are	detailed	in	the	
appendices	together	with	forest	plots	and	Begg	plots	(section	10.0).	A	breakdown	allele	
frequency/counts	by	ethnicity	is	shown	in	Table	1.	Summary	effect	sizes	of	significant	
mutations	are	shown	in	Fig	2.		
	
2.2a	Major	variations	in	mutation	composition	with	ethnicity	
	
Its	has	been	previously	reported	that	N370S	is	almost	exclusively	found	amongst	Caucasian	
and	Ashkenazi	cohorts	and	this	was	indeed	replicated	in	our	study	41,42,149.	Disproportionally	
the	severe	Gaucher	causing	mutations	R120W,	L444P	and	RecNcil	(a	haplotype	combining	
L444P,	A456P	and	the	silent	mutant	V460V)	were	found	amongst	East	Asian	populations.	
This	may	provide	an	explanation	for	the	consistently	high	odds	ratios	encountered	in	meta	
analyses	of	the	effect	sizes	of	GBA	mutations	amongst	these	populations	41	R463C,	E326K	
and	T369M	were	almost	exclusively	found	amongst	Caucasian	populations	while	84GG	was	
disproportionately	found	amongst	Ashkenazi	(and	to	a	lesser	extent	east	Asian)	populations.	
	
We	chose	the	ethnic	classifications	of	the	cohort	on	the	basis	of	definitions	used	in	the	ExaC	
database,	however,	it	was	clear	that	within	these	regions	(Caucasian,	Hispanic,	African,	East	
Asian)	substantial	country	by	country	variation	also	exists.		One	hundred	percent	of	H255Q	
mutations	were	found	amongst	the	two	Greek	cohorts	whilst	24/28	R120W	mutations	were	
from	the	two	Japanese	cohorts	included	in	the	study.	
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ALL GBA MUTATIONS/VARIANTS**
L444P;A456P;v460V (RecNcil)
L444P
D409H
N370S
R120W
84GG
Mutation
Joint Analysis
Meta Analysis
Joint Analysis
Meta Analysis
Joint Analysis
Meta Analysis
Joint Analysis + Exac
Joint Analysis
Meta Analysis
Joint Analysis + Exac
Joint Analysis
Meta Analysis
Joint Analysis
Meta Analysis
Joint Analysis
Meta Analysis
Effect (95% CI)
2.44 (2.18, 2.73)
3.53 (3.13, 3.61)
3.63 (1.68, 7.87)
3.08 (1.65, 5.76)
13.91 (8.58, 22.54)
8.75 (6.01, 12.75)
10.47 (4.71, 23.30)
6.89 (1.30, 36.60)
2.58 (1.04, 6.39)
4.24 (3.52, 5.11)
3.85 (2.63, 5.63)
3.11 (2.60, 3.72)
51.92 (3.15, 853.30)
8.85 (2.52, 31.12)
14.42 (6.96, 29.88)
13.47 (7.75, 23.44)
p_value
3.64x10-56
3.61x10-99
2.0x10-3
8.0x10-4
1.0x10-26
1.2x10-29
5.3x10-10
.044
.039
7.2x10-52
5.12x10-12
1.84x10-35
.016
4.0x10-4
1.94x10-12
2.26x10-20
Favours protective for PD Favours causative of PD
0 1 5 10 15 20 25
Fig	2.	Effect	size	(OR)	with	95%	CI	of	PD	risk	associated	with	84GG,	R120W,	N370S,	D409H,	
L444P	and	L444P;A456P:V460V	(RecNcil)	and	all	GD	causing	mutations.	**	all	GBA	
mutations	estimate	is	significantly	heterogenous.	It	is	displayed	for	illustrative	comparative	
purposes	and	should	not	be	considered	a	reliable	risk	estimate	(see	text	for	details)
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Table	1.	Distribution	of	Mutation/Variant	count	data	by	ethnicity	
	 Caucasian	
n	Parkinson	
disease(%)/	
n	CTL	(%)	
East	Asian	
n	Parkinson	
disease(%)/	
n	CTL	(%)	
Hispanic	
n	Parkinson	
disease(%)/	
n	CTL	(%)	
North	
African	
n	Parkinson	
disease(%)/	
n	CTL	(%)	
Ashkenazi	
n	Parkinson	disease	
(%)/	
n	CTL	(%)	
Total	
n	
Parkinson	
disease/n	
CTL	
84GG	 0(0.0)/0(0.0)*	 8(21.0)/1(10.0)	 -	 0(0.0)/0(0.0)	 30(79.0)/9(90.0)*	 38/10	
R120W	 3(10.7)/0(0.0)	 25(89.3)/0(0.0)	 -	 0(0.0)/0(0.0)	 0(0.0)/	0(0.0)	 28/0	
H255Q	 8	(100.0)/	0(0.0)	 0	(0.0)/	0(0.0)	 -	 0(0.0)/0(0.0)	 -	 8/0	
H255Q;D409H	 12(100.0)/3(100.0)	 0(0.0)/0(0.0)	 -	 0(0.0)/0(0.0)	 -	 12/3	
E326K	 165(98.8)/76(98.8)*	 1(0.6)/0(0.0)	 -	 1(0.6)/1(1.2)	 -	 167/77	
T369M	 75(96.7)/23(95.8)*	 1(0.0)/0(0.0)	 -	 2(3.3)/1(4.2)	 -	 78/24	
N370S	 179(48.8)/28(7.8)*	 6(1.6)/2(0.6)	 2(0.5)/1/(0.3)	 2(0.5)/0(0)	 178(48.5)/320(91.1)*	 367/351	
D409H	 8	(57.1)/0(0.0)	 6	(42.9)/0(0.0)	 -	 0(0.0)/0(0.0)	 0	(0.0)/0(0.0)*	 14/0	
L444P	 173()/12()*	 104(34.3)/5(15.7)	 21(4.1)/0(0.0)	 2(0.9)/0(0.0)	 5(1.8)/4(21.1)*	 305/21	
L444P;A456P;	
V460V(RecNcil)	
15(33.3)/1/(14.2)	 27(60.0)/6(85.7)	 1(2.2)/0(0.0)	 2(4.4)/0(0.0)	 -	 45/7	
R463C	 11(100.0)/0(0.0)	 0(0.0)/0(0.0)	 0(0.0)/0(0.0)	 0(0.0)/0(0.0)	 -	 11/0	
CTL-	control,	n	–	number	of	samples,	Parkinson	disease	–	Parkinson	disease	*.	Excludes	Alcalay	et	al.	As	distribution	of	
mutations	within	Ashekenazi/non	Ashkenazi	subjects	unclear	
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Fig.	3.	Forest	plot	of	risk	of	PD	(with	95%CI)	associated	with	all	GD	causing	
mutations.	Please	note	sample	significantly	heterogenous and	is	displayed	
for	illustrative	comparative	purposes	and	should	not	be	considered	a	
reliable	risk	estimate	(see	text	for	details)
All Gaucher causing GBA mutations and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 2.84 (1.65,4.88) Alcalay et al.   5.5
 6.90 (3.21,14.85) Asselta et al.   2.8
 2.14 (1.33,3.46) Benitez et al.   7.2
 7.15 (1.97,25.89) Bras et al   0.6
 7.43 (0.38,144.57) Choi et al.   0.1
 3.62 (1.48,8.86) Clark et al   1.9
 13.81 (1.77,107.41) De Marco et al.   0.3
 12.33 (5.10,29.81) Duran et al   1.1
 6.70 (0.84,53.25) Emelyanov et al.   0.3
 3.66 (2.99,4.49) Gan-or et al  23.4
 5.03 (2.79,9.08) Gan-or et al   3.7
 26.75 (3.62,197.51) Guo et al   0.3
 2.56 (1.15,5.71) Han et al   2.5
 2.78 (0.56,13.86) Hu et al.   0.6
 15.04 (3.61,62.67) Huang et al   0.6
 5.56 (0.68,45.74) Kalinderi et al   0.3
 10.94 (1.40,85.17) Kumar et al   0.3
 3.77 (2.02,7.05) Lesage et al.   4.5
 5.26 (1.15,24.07) Lesage et al.   0.6
 52.17 (3.15,864.10) Li et al   0.1
 13.76 (1.84,102.92) Mao et al.   0.3
 5.51 (1.64,18.57) Mata et al.   1.0
 43.39 (2.62,719.27) Mitsui et al   0.1
 2.72 (0.95,7.78) Moritau et al   1.4
 4.86 (1.15,20.51) Neumann   0.8
 0.88 (0.52,1.49) Nichols et al.   8.3
 4.67 (0.19,115.01) Nishioka et al.   0.1
 0.78 (0.36,1.69) Noreau et al.   4.0
 6.95 (4.33,11.15) Peretz et al.   2.3
 1.53 (1.14,2.06) Ran et a.  21.2
 31.17 (1.77,550.28) Rincon et al   0.1
 5.76 (0.63,52.47) Sato et al.   0.2
 28.92 (3.91,214.05) Seto Salvia et al.   0.3
 21.06 (1.00,444.16) Spitz et al.   0.1
 18.26 (1.05,317.65) Tan et al   0.1
 1.34 (0.48,3.74) Toft et al   1.8
 13.14 (0.70,246.62) Vaz dos Santos   0.1
 5.37 (1.23,23.51) Wu et al.   0.7
 4.35 (0.52,36.56) Yu et al.   0.3
 26.80 (1.50,479.51) Zhang et al.   0.1
 3.53 (3.14,3.97) Overall (95% CI)
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2.2b	Wide	variations	exist	amongst	the	odds	ratios	of	Parkinson	disease	risk	amongst	
individual	Gaucher	causing	mutations		
	
Fig.	2	shows	the	odds	ratios	of	all	those	Gaucher	disease	causing	mutations	found	to	be	
causative	of	Parkinson	disease	in	all	analyses	undertaken.	Reassuringly	there	is	substantial	
concordance	between	the	estimates	obtained	for	N370S,	L444P	and	all	GBA	variants	in	the	
analysis	and	those	derived	from	established	meta	analyses	30,41,42.	Forest	ands	Begg	plots	of	
these	two	mutations	and	all	Gaucher	disease	causing	mutations	are	available	in	the	
appendices	(Supplementary	Fig	1,2	&	6,		section	10.0).		The	latter	is	however	of	dubious	
significance	because	the	heterogeneity	test	failed	to	confirm	the	sample	was	homogenous	
(I2=71.1	p=1.6x10-12),	suggesting	that	the	constituent	studies	that	make	up	the	estimate	are	
not	sufficiently	similar	in	terms	of	their	findings	to	be	able	to	derive	an	accurate	estimate	of	
the	cumulative	effect	size.	The	forest	plot	of	the	meta	analysis	is	shown	in	Fig	3.		This	has	
been	an	issue	which	has	been	encountered	previously	in	this	context	30	(i.e	meta	analyses	of	
GBA	mutations)	and	highlights	the	difficulty	of	deriving	risk	estimates	cumulatively	from	
mutations	with	substantially	different	odds	ratios	associated	with	them.			
	
Amongst	the	highest	odds	ratios	derived	are	those	derived	from	the	84GG	mutation	(sup.	
Figures	3	&	7,	section	10.0),	a	severe	frameshift	caused	by	a	Guanine	duplication	at	position	
84	of	the	DNA	sequence	150.	This	gives	rise	to	a	null	protein	with	an	entirely	distinct	protein	
sequence	compared	to	wild	type.		It	is	unclear	whether	this	provides	evidence	that	GCase	
activity	is	the	presiding	mechanism	of	pathogenicity	or	whether	there	is	broader	disruption	
of	the	GCase	structure	leading	a	secondary	loss/gain	of	function.		
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RecNcil	(supp.	figures	3	&	6,	section	10.0)	is	a	complex	haplotype	comprising	substitutions	at	
L444P,	A456P	and	the	silent	mutation	V460V.	In	common	with	L444P	it	gives	rise	to	a	severe	
neuronopathic	Gaucher	disease	phenotype,	although	in	both	the	joint	and	meta	analyses	
undertaken	the	odds	ratio	of	the	haplotype	was	significantly	lower	than	the	L444P	mutation	
in	isolation.	This	result	is	puzzling	and	implies	that	the	additional	structural	modifications	
produced	by	these	three	mutations	may	lessen	the	pathogenicity	of	the	L444P	mutation.	
There	are	precedents	for	such	a	reduction	in	pathogenicity.	The	RecTL	mutation,	a	
haplotype	of	L444P,	A456P,	V460V		and	D409H	has	been	described	as	having	a	significantly	
milder	clinical	Gaucher	disease	phenotype	than	either	the	L444P	or	D409H	mutations	in	
isolation,	both	of	which	are	severe	neuronopathic	mutations	151.		
	
The	odds	ratios	and	confidence	intervals	for	all	those	mutations	which	failed	consistently	
across	all	analyses	undertaken	to	reach	significance	are	shown	in	sup.	Fig	1.	
	
2.2c	The	E326K	polymorphism	is	a	genetic	risk	factor	for	Parkinson	disease,	however	T369M	
is	not.		
	
In	all	three	analyses	we	were	able	to	demonstrate	the	E326K	polymorphism	(supp.	figures	4	
and	7,	section	10.0)	as	a	genetic	risk	factor	for	Parkinson	disease.	To	our	knowledge	is	the	
first	time	this	has	been	shown.	Conversely,		in	contrast	to	a	recent	meta-analysis	24,	our	
analyses	of	T369M	(sup.	figures	4	and	7,	section	10.0)	did	not	(although	trends	were	
demonstrated	across	all	analyses	and	the	meta	analysis	narrowly		
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Fig	4.	Effect	size	(OR)	with	95%	CI	of	PD	risk	associated	with	E326K	and	T369M	variants
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Fig.	5.	Blood	leucocyte	GCase activity	(Alcalay et	al.	2016)	plotted	against	the	odds	ratios	of	individual	GBA	mutations)	
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Fig	6.	The	X-ray	structure	of	glucocerebrosidase	(PDB	code	3GXI).	Domain	I	is	shown	in	green.	The	glycosylation	site	at	N19	is	
shown	as	a	ball-and-stick	model.	Domain	II	is	shown	in	pink.	Domain	III,	the	catalytic	domain,	is	shown	in	blue	and	contains	the
active-site	residues	E253	and	E340	which	are	shown	as	ball-and-stick	models.	The	six	significant	glucocerebrosidase	mutations	
(R120W,	L444P,	E326K,	N370S,	D409H	and	RecNcil)	are	shown	with	spheres.	The	colour	of	the	spheres	corresponds	with	the	odds	
ratio	associated	with	the	mutation:	green	(<5);	yellow	(5-10)	and	red	(10<)	from	the	meta	analyses	(A)	and	joint	analyses	(B).
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missed	significance	(p=0.051)	following	correction	for	multiple	comparisons.	This	may	be	
because	the	aforementioned	meta	analysis	contained	unpublished	data	to	which	we	did	not	
have	access.	Effect	sizes	of	these	two	mutations/variants	are	shown	in	Fig	4.	
	
2.2d	No	clear	structural	correlations	with	the	odds	ratios	of	individual	GBA	mutations	or	with	
GCase	activity	in	peripheral	blood.	
	
We	explored	whether	our	results	could	be	used	to	provide	insights	into	the	mode	of	
pathogenicity	of	the	GCase	protein	by	comparing	these	odds	ratios	with	measured	
peripheral	blood	GCase	activity	in	GBA	Parkinson	disease	heterozygotes	38	(Fig	5).	We	also	
mapped	the	mutations	on	the	crystal	structure	of	the	GCase	protein	152,153	to	crudely	
understand	whether	any	commonalities	exist	between	the	structural	locations/disruptions	
caused	by	individual	mutations	and	their	severity	(Fig	6).	In	both	cases	were	were	unable	
show	a	clear	pattern/correlation	between	the	scale	of	the	odds	ratio	and	the	parameter	is	
question.					
	
It	may	be	that	these	approaches	are	too	rudimentary	to	tackle	adequately	this	question.	As	
discussed	previously	there	is	enormous	variation	in	peripheral	blood	GCase	activity,	even	
between	subjects	with	the	same	mutation.	It	is	also	unclear	whether	peripheral	blood	GCase	
activity	is	an	adequate	reflection	of	central	nervous	system	activity,	(although	experiments	
carried	out	in	chapter	5	on	Parkinson	disease	leucocytes	and	cerebrospinal	fluid	do	provide	
some	clarity	on	this	point).	In	heterozygotes	the	expression	levels	and	relative	activity	of	
GCase	derived	from	the	remaining	wildtype	allele	have	a	substantial	impact.	That	said,	it	is	
revealing	that	in	a	relatively	substantial	sample	of	40	N370S	and	8	L444P	carriers	N370S	
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activity	is	lower	than	that	of	L444P	even	though	the	odds	ratio	is	3-4	times	greater	in	the	
latter	38.			
	
In	terms	of	the	structural	characterisation	of	these	mutations,	this	model	is	of	course	static	
and	so	gives	only	a	broad	indication	of	the	modification	produced	.	It	may	be	that	these	
mutations	give	rise	to	common	or	dynamic	structural	modifications	which	are	beyond	the	
scope	of	this	approach.	Of	these	mutations,	only	N370S	has	had	it’s	crystal	structure	
described	154.	The	structure	of	wild-type	and	mutant	GCase	are	virtually	indistinguishable	at	
both	acidic	and	neutral	pH,	however	N370S	GCase	was	more	stable	at	neutral	pH	in	both	
analyses	supporting	the	hypothesis	that	in	N370S	mutant	protein	the	pH	optima	shifts	from	
4.5	to	6.4	155.	Analysis	of	both	the	x-ray	structure	154		and	molecular	dynamic	simulations	156		
suggest	that	the	biggest	change	is	the	orientation	of	loop	3.	At	neutral	pH	loop	3	adopts	an	
extended	conformation	which	transitions	to	a	helical	conformation	in	acidic	conditions	for	
catalysis.	However,	just	one	conformation	for	loop	3	is	observed	in	N370S	GCase,	presenting	
only	in	the	extended	conformation	across	the	pH	range	154,156		again	providing	evidence	that	
the	Asn	370	residue	is	important	in	stabilising	the	helical	turn	of	loop	3.	This,	it	is	suggested,	
results	in	a	rigid	structure,	potentially	reducing	substrate	binding,	access	to	the	active	site	
and	catalytic	dyad	integrity.		
	
In	terms	of	the	other	mutations	analysed,	a	number	of	mechanisms	for	structural	
dysfunction	can	and	have	been	postulated,	although	it	is	hard	to	identify	a	common	theme	
relating	them	to	the	pathogenicity	identified.		R120W	for	instance	(which	lies	immediately	
adjacent	to	the	active	site	–	Fig	6)	may	directly	reduce	enzyme	kinetics	157.	The	Arg120	
residue	has	a	crucial	role	in	the	stability	and	polarity	of	the	cavity	of	the	active	site	of	the	
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enzyme	and	through	the	guanidine	center	supports	an	array	of	hydrogen	bonds	with	Asp	
282,	Asn	234,	Ser	177	and	a	salt	bridge	with	340.	This	role	is	dramatically	subverted	by	the	
replacement	of	the	bulky	hydrophobic	structure	of	the	tryptophan.	Other	mutations	may	
more	drastically	interfere	with	the	protein	structure	leading	to	sequestration.	The	
replacement	of	L444	by	a	Pro,	just	at	the	edge	of	two	beta	strands	is	likely	to	likely	perturb	
the	kinetics	of	formation	of	the	hydrogen	bonds	between	the	main	chains	of	Asp	445	and	
Leu	461.	It	has	been	shown	that	this	proline	substitution	causes	rigidity	in	the	protein	
backbone,	disrupting	the	hydrophobicity	of	domain	II	and	in	turn	improper	domain	folding	
and	impaired	enzyme	function	158,	Likewise,	D409H	causes	a	destabilised	protein	through	
prevention	of	proper	hydrogen	bond	networks	158.	For	E326K	the	kinetics	of	protein	folding	
and	stability	of	the	tertiary	structure	should	be	expected	to	be	disrupted	by	the	
replacement	of	Glu	326	by	a	Lys.	The	Glu	326,	in	fact,	is	engaged	in	the	formation	of	highly	
stabilizing	bonds	with	the	guanidine	group	of	Arg	329.	A	Lys	in	position	326	introduces	a	
repulsive	force	toward	Arg	329	thus	generating	a	negative	tension	on	the	polypeptide	which	
disfavors	the	helix	formation.		
	
2.3	The	principle	of	quantifiable	risk	stratification	of	individual	GBA	mutation	for	Parkinson	
disease	risk	is	feasible	and	realistic	
	
The	analyses	carried	out	here	show	that	is	possible	on	the	basis	of	existing	case	control	data	
to	quantify	the	risk	of	Parkinson’s	associated	with	individual	GBA	mutations.	The	stark	
variation	in	risk	associated	with	each	mutation	is	emphasised.	Some	are	more	useful	than	
others.	The	broad	confidence	intervals	of	a	number	of	the	estimates	are	a	reflection	of	the	
relatively	small	numbers	of	individuals	with	some	of	the	less	common	mutations,	however	
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the	example	of	E326K	shows,	quantification	is	feasible	even	in	the	case	of	comparatively	
weak	mutations	when	the	mutation	is	sufficiently	common.		
	
This	approach	may	be	able	to	provide	precise	estimates	(i.e	odds	ratios	with	narrow	
confidence	intervals)	for	the	more	common	mutations.	For	RecNcil	for	instance	a	power	
calculation	(Firth	logistic	regression	147	and	assuming	equal	Parkinson	disease	and	control	
groups)	shows	that	to	produce	an	odds	ratio	with	confidence	intervals	with	a	range	of	3.0	
would	require	a	sample	of	≈100,000	Parkinson	disease	cases	which	although	ambitious	is	a	
plausible	cohort	size	across	a	number	of	centres	nationally	or	internationally.	Conversely	
equivalent	estimates	are	probably	unrealistic	in	the	case	of	less	common	mutations	such	as	
D409H,	where	the	same	calculation	estimates	a	sample	size	of	30	million	Parkinson	disease	
cases.	That	said	the	scale	of	these	estimates	will	still	be	useful	in	stratification	of	Parkinson	
disease	risk	even	if	they	are	crude	and	unsuitable	for	genetic	counselling.	For	instance	it	is	
clear	that	84GG	is	associated	with	a	very	high	Parkinson	disease	risk	even	if	exact	
quantification	is	hindered	by	the	scale	of	the	confidence	intervals.	This	information	could	be	
used	as	a	flag	for	‘enhanced	scrutiny	and	screening’	for	prodromal	Parkinson	disease	signs	in	
carriers.	Finally,	in	the	case	of	very	rare	variants	in	the	GBA	gene,	larger	cohort	sizes	would	
allow	confirmation	or	refutation	of	pathogenicity	and	decision	making	as	to	whether	
screening	for	prodromal	Parkinson	disease	signs	is	necessary.		
	
2.4	Concluding	remarks	
	
These	data	provide	considerable	information	as	to	the	ethnic	variability	of	GBA	mutants,	the	
widespread	disparity	of	Parkinson	disease	risk	associated	with	them	and	in	some	cases	
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precise	quantification	of	these	risks.	They	give	an	invaluable	insight	as	to	how	a	future	
screening	strategy	for	GBA	variants,	in	order	to	select	subjects	for	early	neuroprotection,	
might	operate	and	are	an	indication	of	its	potential	utility.	
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Chapter	3	-	Prodromal	Parkinson	disease	features	amongst	GBA	carriers	as	a	tool	for	
stratification	of	Parkinson	disease	conversion		
	
3.0	Introduction	
	
GBA	is	distinct	from	the	Mendelian	forms	of	genetic	Parkinson’s	which	preceeded	it	in	that	
has	an	autosomal	dominant	inheritance.	It	has	an	incomplete	penetrance	of	between	10-
30%	11,13,14.	This	figure	is	calculated	on	the	basis	of	all	GBA	mutations	with	all	the	limitations	
discussed	previously	which	accompany	this	approach.	None	the	less,	it	is	clear	that	GBA	
carriers	are	substantially	more	likely	not	to	develop	Parkinson’s.	The	estimates	quoted	
above	refer	only	to	Gaucher	causing	mutations	and	do	not	take	into	account	polymorphisms	
such	as	E326K	and	T369M.	On	the	basis	of	the	approximate	odds	ratios	calculated	in	the	
previous	chapter	and	estimated	Parkinson’s	prevalence	at	age	80	159	(which	produces	the	
highest	estimate	of	this	figure)	this	would	mean	that	between	1.9-3.9%	of	carriers	of	the	
E326K	mutations	will	develop	Parkinson	disease	assuming	they	lived	to	age	80.		In	this	case,	
given	an	allele	frequency	of	0.02	(2%)	in	western	European	populations	159,	blanket	
administration	of	a	neuroprotective	agent	would	be	at	best	uneconomical	and	at	worst	
potentially	dangerous	depending	on	the	side	effect	profile	of	the	compound	in	question.		
	
The	clinical	prodrome	of	Parkinson	disease	includes		constipation	104,107,	hyposmia	160,	
anxiety	,	depression	160,	rapid	eye	movement	sleep	disorder	161).	These	features	are	
postulated	to	correlate	with	the	spread	of	alpha	synuclein	from	the	enteric	nervous	system	
(constipation)	to	various	autonomic	ganglions,	the	vagus	nerve,	midbrain	(dysautonomia	
and	other	motor	features),	olfactory	bulb	(hyposmia)	and	eventually	the	cortex	and	
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neocortex	(cognitive	impairment,	anxiety	and	depression),	mimicking	the	pattern	of	lewy	
pathology	development	postulated	by	Braak	162.The	neuroanatomical	correlates	of	REM	
sleep	disorder	are	unclear	although	it	seems	likely	to	invlove	a	variety	of	brainstem	
(predominately	pontine)	structures	163.	
	
The	difficulty	in	terms	of	broader	screening	strategies	for	Parkinson	disease	is	that	these	
symptoms	are	common	amongst	the	general	population.	All	age	self	reported	rates	of	
constipation	are	estimated	to	be	as	high	as	≈	40%	in	some	studies	whilst	those	with	clinically	
diagnostic	features	of	constipation	number	some	15%	164.	From	the	age	of	30	onwards	20-
30%	of	subjects	have	been	shown	to	have	clinically	defined	hyposmia	with	a	similar	number	
being	defined	as	anosmic		from	the	age	of	50	165.	Mild	cognitive	impairment	has	been	
reported	as	high	as	28%	amongst	over	60s	and	39%	in	over	70s.166	Up	to	7%	167	and	17%	of	
the	population	respectively	have	been	reported	to	have	anxiety	disorder	or	a	diagnosis	of	
depression	in	western	Europe	and	the	United	States.	REM	sleep	disorder	is	an	exception	to	
this,	because	true	electrophysiologically	proven	REM	sleep	disorder	is	present	amongst	
≈0.5%	of	the	population	(and	these	studies	were	carried	out	in	elderly	populations)	168,	
although	all	age	prevalence	of	so	called	subclinical	REM	sleep	disorder	(i.e	reported	
predominately	on	the	basis	of	validated	questionnaires	without	electrophysiological	
confirmation)	may	be	as	high	as	5%	168.	
	
The	possibility	of	using	a	tandem	population	based	screening	for	GBA	mutation	carriers	(and	
then	assessing	for	prodromal	features	of	Parkinson	disease)	as	a	means	to	target	
neuroprotective	therapies	is	attractive,	as	it	can	be	presumed	to	substantially	increase	the	
specificity	of	the	approach.	This	would	in	turn	avoid	unwarranted	expense	and	side	effects.	
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As	such,	we	carried	out	a	five	year	extended	follow	up	of	GBA	mutation	carriers,	assessing	
them	for	prodromal	Parkinson	disease	features	and	comparing	them	with	a	control	group.	
	
3.1	Methods	
	
A	more	detailed	summary	of	the	assessment	and	analysis	procedure	is	included	in	the	
appendices	(section	10.2).	
	
	Briefly	117	(35	controls,	39	heterozygote	GBA	carrier	and	43	biallelic	GBA	carriers)	were	
assessed	over	a	5	year	period	at	three	timepoints	for	prodromal	Parkinson	disease	features.	
Hyposmia,	cognitive	impairment,	depression,	REM	sleep	disorder,	autonomic	features,	
motor	symptoms	and	signs	of	Parkinson	disease	were	assessed	respectively	using	the	
University	of	Pennsylvania	smell	identification	test	(UPSIT)	169,	the	Montreal	cognitive	
assessment	(MoCa)	170,	the	Beck	depression	inventory	(BDI)	171,	the	Rapid	eye	movement	
sleep	behaviour	disorder	questionnaire	(RBDSQ)	172,	a	subscale	of	the	unified	multi	system	
atrophy	rating	scale	(UMSARS)	173	and	the	unified	Parkinson	disease	rating	scale	parts	II	and	
III.	For	the	latter	we	performed	comparisons	of	assessments	between	assessors	to	minimise	
inter	assessor	variability	and	found	minimal	varance	(range	0-4	points,	section	1.2c	
Appendices).			We	compensated	for	the	effect	of	missing	data	using	multiple	imputation	174	
(details	Appendices	section	10.3b).		The	demographics	of	the	study	groups	together	with	
significance	testing	of	differences	in	the	three	study	groups	(Mann-Whitney	U	test	for	
het/bia/ctl	or	Fishers	exact	test	for	GBA/ctl)	are	shown	in	table	1.		SM	collected	data	for	the	
2014/15	(75%)	in	conjunction	with	Dr	Michelle	Beavan	(25%).	Analysis	was	carried	out	by	
SM.		
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Table	1.	Demographic	and	significance	testing	amongst	participants	
	 baseline	 timepoint		1	 timepoint		2	
control	median	age		 61	 59	 59	
bia	median	age		 51	 52	 52.5	
het	median	age		 60	 63	 61.5	
Significance	level		 P=0.002	 p=0.017	 p=0.031	
GBA	median	age		 55	 56	 56	
Significance	level	
(vs	ctl)	
p=0.142	 p=0.505	 p=0.748	
ctl	%	male	(n)	 47		 57	 56	
bia	%	male	(n)	 58	 61	 55	
het	%	male	(n)		 45	 40	 35	
Significance	level	 p=0.537	 p=0.282	 p=0.221	
GBA	%	male	(n)	 51		 50	 49	
Significance	level	
(vs	ctl)	
p=0.396	 p=0.404	 p=0.350	
ctl	%	Fhx	Parkinson	
disease/dementia	
(n)	
6	 8	 11	
bia	%	Fhx	Parkinson	
disease/dementia	
(n)	
23	 21	 22	
het	%	Fhx	Parkinson	
disease/dementia	
(n)	
10	 15	 19	
Significance	level	 p=0.062	 p=0.308	 p=0.315	
GBA	%	Fhx	
Parkinson	
disease/dementia	
(n)	
17	 17	 22	
Significance	level	
(vs	ctl)	
p=0.084	 p=0.253	 p=0.226	
ctl	%	university	
educated	(n)	
68	 63	 74	
bia	%	university	
educated	(n)	
48	 49	 43	
het	%	university	
educated	(n)	
50	 53	 50	
Significance	level	
(vs	ctl)	
p=0.247	 p=0.625	 p=0.100	
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GBA	%	university	
educated	(n)	
49	 50	 48	
Significance	level	
(vs	ctl)	
p=0.075	 p=0.199	 p=0.030	
ctl	%	smoker	(n)	 31	 33	 42	
bia	%	smoker	(n)	 30	 29	 29	
het	%	smoker	(n)	 36	 33	 42	
Significance	level	 p=0.851	 0.904	 p=0.459	
GBA	%	smoker	(n)	 27	 31	 34	
Significance	level	
(vs	ctl)	
p=0.527	 p=0.510	 p=0.361	
	
Table	2.	Summary	table	of	results		
Comparison	of	prevalence	of	Parkinson	disease	prodromal	features	all	GBA	
carriers	vs	controls	
baseline	(2010/11)	 p	value,	OR	[95%CI]		
UPSIT	 p=0.003,	4.0	[1.6-10.4]	
MOCA	 p<0.001,	6.0	[2.3-15.2]	
timepoint	1	(2012/13)	 p	value,	OR	[95%CI]		
UPSIT	 p<0.001,	7.6	[2.7-21.8]	
MOCA	 p=0.002,	7.3	[2.1-24.9]	
timepoint	2	(2014/15)	 p	value,	OR	[95%CI]		
UPSIT	 p=0.002,	6.8	[2.0-23.1]	
MOCA	 p=0.024,	4.0	[1.2-13.6]	
BDI	 p=0.029,	10.6	[1.3-90.0]	
Repeated	measures	model	for	prodromal	Parkinson	disease	features	in	
GBA	carriers	vs	controls	
	 p	value,	OR	[95%CI]		
UPSIT	 p=0.006,	5.0	[1.6-16.1]	
MOCA	 p=0.007,	5.7	[1.5-20.0]	
BDI	 p=0.158,	2.3	[0.7	-	7.4]	
RBDSQ	 p=0.120,	3.2	[0.7-13.4]	
Correlation	of	prodromal	feature	risk	scores	with	UPSIT	risk	score	in	all	
GBA	carriers	
	 p	value,	OR	[95%CI]		
MOCA	 p=0.033,	1.5	[1.03-2.3]	
BDI	 p=0.030,	1.3	[1.02-1.8]		
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3.2	Results	
	
A	summary	table	of	results	are	presented	in	Table	2.	A	more	detailed	presentation	of	
descriptive	statistics	and	analyses	undertaken	is	presented	in	supplementary	tables	3	and	4	
(section	10.2),	
	
3.2a	Hyposmia	and	cognition	are	globally	worse	amongst	heterozygous	and	bi-allelic	GBA	
mutation	carriers	compared	to	controls.	
	
At	all	three	timepoints	for	GBA	mutation	carriers	compared	to	controls,	UPSIT	and	MOCA	
scores	were	worse	(UPSIT	baseline	OR	4.0	p=0.003,	timepoint	1	OR	7.6	p<0.001,	timepoint	2	
OR	6.8	p=0.002,	MOCA	baseline	OR	6.0	p<0.001,	timepoint	1	OR	7.3	p=0.002,	timepoint	2	
OR	4.0	p=0.024).	Subset	analyses	showed	that	for	the	UPSIT	both	bi-allelic	(baseline	OR	4.2	
p=0.006,	timepoint	1	OR	6.3	p=0.002	and	timepoint	2	OR	6.8	p=0.005)	and	heterozygous	
groups	(baseline	OR	4.3	p=0.011,	timepoint	1	OR	9.0	p<0.001,	timepoint	2	OR	7.2	p=0.004)	
also	had	worse	scores	at	all	timepoints.	MOCA	scores	were	worse	amongst	bi	allelic	and	
heterozygous	groups	at	baseline	(bia	OR	5.0	p=0.003,	het	OR	6.8	p<0.001)	and	at	timepoint	
3	for	the	bi-allelic	group	(OR	5.9	p=0.011).	Strong	trends	were	exhibited	at	timepoint	2	for	
both	bi-allelic	(p=0.069)	and	heterozygous	groups	(p=0.072).	BDI	scores	were	significantly	
worse	at	timepoint	2	only	(OR	10.6	p=0.029)	which	was	mirrored	in	subset	analysis	in	the	
biallelic	group	(OR	6.3	p<0.001)	but	not	the	heterozygous	groups	(p=0.069).	There	were	no	
significant	differences	cross	sectionally	for	RBDSQ	scores.	
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Although	there	were	clear	trends	showing	worse	autonomic	dysfunction,	REM	sleep	
disorder,	and	UPDRS	II	and	III	scores	in	GBA	mutation	carriers	compared	to	controls	(see	
Figures	1	and	2),	these	only	reached	statistical	significance	in	the	case	of	UPDRS	III	at	
timepoint	2	(p=0.020),	UPDRS	II	at	timepoint	3	(p=0.022)	and	UMSARS	at	baseline	(p=0.040)	
with	some	subset	analyses	in	bi	allelic	and	heterozygous	groups	mirroring	these	finding.	(see	
supplementary	Table	4	for	further	details).		
	
Deterioration	of	UPSIT	and	MOCA	was	worse	amongst	the	combined	group	of	GBA	carriers	
compared	to	controls	with	the	steepest	deterioration	seen	for	UPSIT	(OR	21.3	p<0.001)	then	
MOCA	(OR	5.7	p=0.007).	This	was	replicated	amongst	both	bi-allelic	and	heterozygous	
carriers	compared	to	controls	(supplementry	Table	2).	Although	trends	were	exhibited	there	
was	no	significant	difference	in	the	rate	of	decline	of	RBDSQ	(p=	0.120)	or	BDI	scores	
(p=0.158)	compared	to	controls	(supp.	Table	4).		
	
3.2b	‘High	risk’	GBA	mutation	carriers	develop	a	combination	of	impaired	cognition,	
hyposmia	and	depression	
	
We	hypothesized	the	existence	of	a	high-risk	group	with	accelerated	progression	of	multiple	
premotor	features.	To	do	so	we	produced	a	novel	system	of	risk	scoring	which	attached	
equivalent	weight	to	both	the	extent	of	the	deficit	and	its	rate	of	decline.	Briefly	over	the	
three	assessment	timepoints	participants	were	scored	1	point	for	each	half	standard	
deviation	the	average	score	was	below	the	trimmed	mean	of	the	combined	GBA	carrier	
group	(max.	4	points)	and	1	point	for	every	half	standard	deviation	reduction	in	scores	from
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Fig	1.	Trimmed	means	of	UPSIT,	MOCA,	BDI	scores	and	RBDSQ		of	combined	cohort	
of	GBA	carriers	(red)	and	controls	(blue)	with	exact	confidence	intervals
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Fig	2.	Trimmed	means	of	UPDRS	II,	UPDRS	III,	RBDSQ	and	
UMSARS	(subscale)	scores	of	combined	cohort	of	GBA	carriers	
(red)	and	controls	(blue)	with	exact	confidence	intervals
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the	beginning	to	end	(max	4	points),	(Fig	3	and	Appendices	section	10.2d).		Using	this	
system,	and	compatible	with	recent	data	suggesting	that	patients	at	risk	of	Parkinson	
disease	share	a	common	risk	profile	104,109,	we	discovered	that	those	with	olfactory	deficits	
were	also	more	likely	to	have	deficits	of	cognition	(MOCA	OR	1.5	p=0.033)	and	depression	
(BDI	OR	1.3	p=0.030).	Figure	4	shows	that	overlap	of	those	with	these	prodromal	features	of	
the	approximately	10%	of	participants	with	the	worst/fastest	deteriorating	prodromal	
features	based	on	our	risk	stratification	system.	(UPSIT	=	3/8	86th	centile	and	above,	MOCA	
=	3/8	91th	centile	and	above,	BDI	=	4/8	86th	centile	and	above)	compared	to	the	control	
group	(UPSIT	2/8	89th	centile,	MOCA	3/8	89th	centile,	BDI	2/8	87th	centile).	Subset	analysis	
showed	that	this	was	also	true	amongst	bi-allelic	GBA	carriers	alone,	in	terms	of	cognition	
(MOCA,	OR	2.95	p=0.006)	but	not	depression.	There	were	no	correlations	between	these	
risk	scores	amongst	the	control	group	(Figure	4	and	supplementary	Table	4).	Figure	5	shows	
the	prospective	trimmed	mean	scores	of	these	3	prodromal	features	in	those	with	the	worst	
UPSIT	scores,	compared	to	the	rest	of	the	cohort	and	emphasise	this	clustering	effect,	
	
3.2c	Illustrative	case	GBA	bi-allelic	participant	who	developed	Parkinson	disease	
	
In	March	2013	one	53	year-old	male	with	established	Gaucher	disease	developed	
bradykinesia,	rigidity	and	a	unilateral	resting	tremor.	At	this	time	he	developed	a	marked	
cognitive	deficit	which	fulfilled	diagnostic	criteria	for	dementia	with	Lewy	bodies	(DLB).	He	
was	homozygous	for	R463C,	a	severe	Gaucher	diseasecausing	mutation	105	which	has	been		
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Trimmed mean of combined GBA group
>0.5 SD = 
1 point
>1 SD = 
2 points
>1.5 SD = 
3 points
>2 SD = 
4 points
1 point for each half standard deviation that average score below 
trimmed mean of GBA group + 1 points for each standard deviation fall 
from baseline to last timepoint. MAX SCORE 8
e.g. average score >0.5 SD from trimmed mean = 1 point +  
Fall in score of >1 SD from trimmed mean = 2 points
TOTAL RISK SCORE 3/8 
Fig	3.	Explanation	of	risk	stratification	system	of	prodromal	PD	features
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Fig	4.	Venn	diagrams	of	overlap	between	GBA	mutations	
carriers	(left)	and	controls	(right)	with	the	worst	UPSIT	
(red	GBA/ctl 86th/89th centile	and	above),	MOCA	(green	
GBA/ctl 91st/89th centile	and	above)	and	BDI	scores	
(brown	GBA/ctl 86th	/	87th	centile	and	above)
Control	group
(35)
3
4 4
4
11 7
11
2
24
(82)
GBA	carrier	group
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Fig	5.	Trimmed	means	of	UPSIT,	MOCA	and	BDI	scores	of	those	
with	highest	smell	risk	score	(green)	compared	to	scores	of	
combined	cohort	of	GBA	carriers	(red)	and	controls	(blue)	with	
exact	confidence	intervals
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described	in	several	patients	with	Parkinson	disease	and	DLB	26,30,175.	A	breakdown	of	his	
prodromal	feature	scores	are	presented	in	table	3	and	(in	the	case	of	cognition,	depression	
and	hyposmia)	are	plotted	graphically	in	figure	6.		
	
Table	3.	prodromal	Parkinson	disease	risk	scores	of	participant	who	developed	
Parkinsonism		
	 Baseline	(2010)	
Score	[centile]	
timepoint		1	(2012)	
Score	[centile]	
timepoint		1	(2014)	
Score	[centile]		
*Parkinsonism	DIAGNOSIS	
UPSIT	 20	[93]	 14	[96]	 17	[95]	
MOCA	 27	[54]	 27	[57]	 21	[87]	
BDI	 4	[82]	 4	[50]	 25	[95]	
UMSARS	 0	 3	[95]	 5	[97]	
RBDSQ	 0		 2	[52]	 5	[85]	
UPDRS	II	 0	 3	[85]	 29	[99]	
UPDRS	III	 0	 3	[50]	 45	[99]	
	
3.2d	Clinical	course	of	those	with	Parkinsonian	features	
	
A	number	of	participants	presented	with	clinical	features	of	Parkinsonism.	A	summary	of	
these	characteristics	is	listed	below	in	table	4.	The	trimmed	mean	of	their	UPSIT,	MOCA	and	
BDI	scores	is	plotted	for	illustrative	purposes	against	those	of	the	rest	of	the	cohort	and	the	
participant	who	developed	Parkinsonism	in	Fig	6.		
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Table	4	Clinical	characteristics	of	participants	with	parkinsonian	features	
age	 sex	 genotype	 Clinical	features	
80	 m	 N370S/N370S	 Parkinson	disease:	Bilateral	rigidity	with	
activation,	asymmetrical	bradykinesia,	gait	
impairment,	bilateral	postural	tremor	GD:	
ERT	4	weekly.	Thrombocytopenia		
85	 m	 N370S/L444P	 Parkinson	disease:	More	prominent	right	pill	
rolling	tremor	with	postural	component.	No	
bradykinesia	or	rigidity	GD:	ERT	4	weekly.	
splenomegaly.	Bone	pain	(teeth)	
75	 m	 N370S/N370S	 Flexed	posture,	bilateral	rigidity,	kinetic	and	
postural	tremor	GD:	ERT	4	weekly	
63	 m	 N370S/L444P	 Parkinson	disease:	Flexed	posture,	resting	
head	tremor,	bilateral	kinetic	hand	tremor	
GD:	ERT	2	weekly.		
53	 m	 R463C/R463C	 Parkinson	disease:	Asymmetrical	rigidity	
and	bradykinesia,	resting	head	and	leg	
tremor		
Parkinson	disease	DIAGNOSIS	2014	GD:	ERT.	
Avascular	necrosis.	
Hypergammaglobulinaemia.		
80	 F	 wt/G250V	 bradykinesia,	asymmetrical	resting	tremor	
80	 m	 wt/N370S	 left-arm	kinetic	tremor,	and	flexed	posture	
New	features	since	timepoint	2	marked	in	bold		
	
ERT:	Enzyme	replacement	therapy	GD:	Gaucher	disease	Parkinson	disease:	
Parkinson	disease	wt:	wild	type	
	
3.2e	What	is	the	significance	of	global	deficits	of	hyposmia,	cognition	and	depression	
amongst	GBA	carriers?	
	
Our	results	show	that	GBA	carriers	have	deficits	in	a	number	of	criteria	which	sweepingly	
are	labelled	prodromal	Parkinson	disease	features.	But	what	are	these	deficits	actually	
indicative	of	pathologically?	It	has	been	shown	previously	that	type	1	Gaucher	disease	
patients	do	exhibit	cognitive	deficits	176	in	spite	of	the	received	wisdom	that	their	central
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Fig	6.	Comparison	of	prodromal	PD	scores	of	participant	who	
developed	PD	(dashed),	participants	with	Parkinsonian features	(orange	
line,	with	GBA	carrier	(red)	and	controls	(blue)	with	exact	confidence	
intervals.
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nervous	system	is	spared.	It	is	useful	at	this	point	to	consider	the	substantial	body	of	
literature	which	shows	that	GBA	Parkinson	disease	has	a	more	pronounced	cognitive	
phenotype	and	that	equally	GBA	is	a	genetic	risk	factor	for	dementia	with	Lewy	bodies	31.	
Does	development	of	Lewy	pathology	(or	indeed	some	other	pathological	process	
implicated	in	Parkinson	disease)	occur	to	a	variable	degree	in	all	GBA	carriers?.	
	
The	clinical	phenotype	of	neuronopathic	Gaucher	disease	includes	supernuclear	gaze	palsy,	
cognitive	impairment,	epilepsy,	ataxia,	bulbar	dysfunction,	myoclonus	and	hydrocephalus,	a	
broad	range	of	neurological	features	which	is	suggestive	of	generalized	rather	than	focal	
neurodegeneration	6,7,10.	That	said	the	former	is	almost	universally	present,	although	this	
may	be	a	reflection	of	physicians’	reluctance	to	make	the	diagnosis	in	its	absence.	None	the	
less	it	is	interesting	that	the	apparent	primary	presentation	of	neuronopathic	Gaucher	
disease	is	one	which	affects	midbrain	structures,	albeit	with	input	from	the	thalamus	and	
cerebellum	177.		Parkinson	disease	similarly	has	a	has	a	predilection	for	brain	stem	
structures,	causing	as	it	does	hyposmia	(olfactory	nucleus	and	bulb),	REM	sleep	dysfunction	
disorder	(predominately	pontine		structures)	163	and	indeed	sometimes	supranuclear	gaze	
palsies	themselves	(although	these	are	more	commonly	a	feature	of	the	taupathy	
progressive	supranuclear	palsy)	178.	It	is	appealing	to	hypothesise	that	GBA	mutations	give	
rise	to	variable	brainstem	neurodegeneration	with	some	unknown	factor	determining	
whether	sufficient	nigral	damage	occurs	to	cause	the	conversion	to	motor	Parkinson	disease	
and	this	is	a	theme	we	shall	develop	further	in	chapter	4.	
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3.2f	Clustering	of	prodromal	Parkinson	disease	features	
	
The	use	of	our	novel	risk	score	system	allows	us	to		quantify	the	extent	of	MoCa,	BDI	and	
UPSIT	the	deficit	across	all	timepoints	and	the	rate	of	decline	of	these	scores.	Clearly	the	
hope	is	that	detection	of	deficits	in	a	number	of	prodromal	Parkinson	disease	features	may	
increase	the	sensitivity	of	detection	of	Parkinson	disease	conversion	as	a	prelude	to	
targeting	neuroprotective	compounds.	Whether	amongst	GBA	carriers	clustering	of	
depression,	cognitive	impairment	and	hyposmia	actually	occurs	in	advance	of	Parkinson	
disease	conversion	remains	to	be	seen	and	can	only	be	answered	by	further	prospective	
assessment.	Considering	the	clinical	course	of	our	Parkinson	disease	convertor	the	most	
striking	point	is	the	extent	of	his	hyposmia,	which	was	by	some	way	the	most	profound	
across	the	entire	cohort.	There	was	evidence	of	mild	features	of	depression,	however	his	
cognitive	impairment	was	in	fact	slightly	better	than	the	average	scores	of	GBA	carriers.	It	
may	be,	of	course,	that	not	all	Parkinson	disease	convertors	develop	the	‘full	house’	of	
prodromal	symptoms,	but	rather	only	a	subset	of	those	which	are	indicative	of	
neuroanatomical	location	of	the	pathology.	Conversely,	of	those	other	participants	with	
Parkinsonian	features	MoCA,	UPSIT	and	BDI	scores	were	consistently	below	the	average	of	
the	GBA	affected	participants	(Fig	6).		
	
3.3	Concluding	remarks	
	
In	this	chapter	we	have	presented	a	five	year	follow	up	of	‘asymptomatic’	GBA	carriers	and	
demonstrated	convincing	deficits	of	cognition	and	olfaction.	As	we	have	stated	there	is	no	
guarantee	that	these	features	are	indicative	of	Parkinson	disease	conversion.	However,	the	
Stephen	Mullin	–	PhD	thesis	
	
	
78	
specificity	of	olfaction	in	particular	to	neurodegenerative	disease	does	lead	to	a	reasonable	
postulation	that	common	histological	processes	are	underway.	Furthermore,	the	clustering	
of	prodromal	Parkinson	disease	symptoms	in	a	subset	of	individuals	further	emphasises	our	
hypothesis.	Whilst	synuclein	pathology	has	yet	to	be	noted	in	Gaucher	cases	without	clinical	
signs	of	Parkinsonism,	only	a	handful	of	post	mortems	have	been	carried	out	to	date	on	
these	patients	46,179,180	and	in	many	cases	it	is	not	clear	whether	synuclein	
immunofluorescence	was	convincingly	assessed.	It	would	be	interesting	at	post	mortem	to	
assess	the	prevalence	of	lewy	bodies	amongst	the	brains	of	aged	GBA	carriers	without	
Parkinson	disease	compared	to	controls,	although	logistically	this	is	of	course	highly	
problematic.	The	existing	cohort	study	is	underpowered	to	answer	the	range	of	questions	
which	arise	from	these	findings	(e.g	are	there	differential	prodromal	Parkinson	disease	
features	in	different	GBA	mutations,	can	these	be	correlated	with	biomarkers	and	can	
higher	risk	individuals	be	selected	for	neuroprotective	therapies).	In	the	next	chapter	we	
shall	propose	a	mechanism	to	address	this	issue	and	hence	to	expand	the	size	and	increase	
the	sustainability	of	prospective	follow	up	of	these	participants.				
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Chapter	4	-	Internet	based	Parkinson	disease	prodromal	assessment	shows	feasibility	of	
remote	assessment	for	prodromal	Parkinson	disease	signs	amongst	GBA	carriers	
	
4.0	Introduction	
	
The	inherent	difficulties	associated	with	prospective	assessment	of	disease	cohorts	are	well	
known,	namely	that	ageing,	disease	burden	or	simply	study	fatigue	lead	cumulatively	to	a	
very	high	attrition	rate	amongst	participants.	Moreover,	conventional	assessment	of	cohorts		
(especially	one	as	in	this	case	that	is	geographically	disparate)	is	time	consuming	and	
expensive,	primarily	on	account	of	the	travel	and	time	costs	associated	with	participants	
travelling	to	assessors	(or	vice	versa).	Finally	the	necessity	for	different	assessors	to	carry	
out	assessments	at	different	timepoints	introduces	a	degree	of	inter	assessor	variability	
which	is	particularly	pertinent	for	clinical	assessments	associated	with	a	degree	of	
subjectivity,	such	as	the	UPDRS.	In	all	cases	these	limitations	are	compounded	with	
increasing	years	of	assessment.					
	
In	the	above	analyses	we	have	shown	trends	towards	a	difference	in	the	motor	symptoms	
and	signs	(UPDRS	II	and	III	respectively),	REM	sleep	behaviour	disorder	(RBDSQ),	BDI	(BDI),	
autonomic	symptoms	(UMSARS	subscale)	as	well	as	the	significant	differences	in	hyposmia	
(UPSIT)	and	cognition	(MoCa)	already	exhibited.	Speculatively	we	can	suggest	that	with	a	
larger	cohort	size	these	trends	would	be	likely	to	translate	into	significant	differences.	
Moreover	the	requirement	for	larger	cohorts	is	not	only	academic.	A	recurrent	theme	of	
this	thesis	is	the	potential	be	able	to	risk	stratify	GBA	mutation	carriers	in	terms	of	their	
Parkinson	disease	risk,	with	an	eye	to	effective	targeting	of	future	neuroprotective	drugs.	If	
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this	is	to	be	realised	then	a	reliable,	convenient,	reproducible	and	above	all	cost	effective	
method	must	be	found	to	clinically	assess	GBA	carriers	for	signs	of	prodromal	Parkinson	
disease.									
	
4.1	An	internet	based	platform	for	clinical	assessment	of	prodromal	Parkinson	disease	
amongst	GBA	carriers	
	
The	obvious	solution	to	this	problem	is	an	internet	based	platform.		At	first	glance	the	
concept	is	entirely	feasible.	Of	the	assessments	carried	out	in	the	study	described	in	chapter	
2,	only	the	UPDRS	III	and	MoCa	must	be	carried	out	in	person,	the	rest	being	either	
questionnaires	or	smell	tests	that	have	been	used	and	validated	as	postal	assessments.	
Moreover,	in	terms	of	both	motor	dysfunction	and	cognition,	online	assessments	exist	
which	have	been	validated	in	Parkinson	disease	patients.	A	prototype	for	this	approach	
exists	in	the	PREDICT	PD	study	181,182.	PREDICT	PD	is	an	online	assessment	portal	which	aims	
to	identify	prodromal	signs	of	Parkinson	disease	amongst	members	of	the	general	
population.	The	model	involves	subjects	signing	up	by	logging	on	to	the	website.	On	a	yearly	
basis	participants	undertake	a	series	of	online	questionnaires	(hospital	anxiety	and	
depression	scale,	REM	sleep	behaviour	disorder	questionnaire	and	a	number	of	validated	
questions	related	to	other	prodromal	Parkinson	disease	features	and	risk	factors	such	as	
constipation,	head	trauma	and	outdoor	living).	Participants	also	undertake	the	BRAIN	test,	a	
validated	assessment	of	bradykinesia	in	which	participants	tap	sequentially	the	“;”	and	“s”	
keys	as	fast	and	accurately	as	possible	183.	Stratification	of	the	cohort	using	an	algorithm	
based	on	established	odds	ratios	of	Parkinson	disease	risk	associated	with	the	various	
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features	found	that	higher	risk	participants	had	worse	features	of	hyposmia	(UPSIT),	REM	
sleep	behaviour	disorder	(RBDSQ)	and	bradykinesia	(BRAIN	test).		
	
Using	this	prototype	we	sought	to	develop	a	platform	for	longitudinal	assessment	of	this	
cohort.	Whilst	we	were	able	to	directly	mimic	many	aspects	of	the	PREDICT	PD	portal,	there	
were	a	number	of	areas	in	which	it	was	necessary	to	develop	or	enhance	it	for	our	own	
purposes.		These	were	namely;	the	addition	of	more	comprehensive	questionnaire	of	non-
motor	Parkinson	disease	symptoms	which	prompted	the	addition	of	the	UPDRS	part	II	
questionnaire	to	the	portal	and	more	significantly	the	incorporation	of	facility	to	allow	
cognitive	testing	of	participants	within	the	portal.	This	is	of	particular	importance	in	this	
group	because	the	cognitive	phenotype	phenotype	appears	to	be	more	pronounced	and	
GBA	is	an	established	genetic	risk	factor	for	dementia	with	Lewy	bodies	26,28,31.	The	latter	
was	a	significant	challenge.	Neuropsychometric	testing	entails	considerable	complexity	and	
traditionally	has	required	a	facilitator	to	instruct	and	direct	participants.	Because	of	this	we	
opted	to	acquire	an	‘off	the	shelf’	solution	in	order	to	minimise	the	amount	of	development,	
testing	and	validation	work	required.	After	considering	the	products	currently	available	we	
settled	on	the	Cogtrack	package.		Based	on	the	clinical	dementia	research	assessment	(CDR),	
a	computerised	package	has	been	used	for	over	30	years.	It	is	a	multi	domain	cognitive	
assessment	panel	validated	in	both	Parkinson	disease	and	Alzheimers	type	dementia.	Its	
principle	advantage	is	its	simplicity.	The	components	of	the	package	require	input	of	either	
one	or	two	keyboard	based	commands	only	(Fig	1-8).	Moreover,	they	have	been	used	
prospectively	in	a	number	of	clinical	trials	184,	a	major	consideration	given	the	stated	aim	of		
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Fig	1.	Screenshot	of	rapsodi consent	screen Fig	2.	Screenshot	of	rapsodi BRAIN	tap	test
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Fig	3	screenshot	of	simple	reaction	time	task.	The	
subject	is	asked	to	repeatedly	press	on	the	right	key	
button	when	a	“à yes”	cue	appears	on	the	screen.	
Fig	4 screenshot	of	digital	vigilance	task.	The	subject	
is	asked	to	press	the	right	key	button	when	a	number	
cue	matching	a	number	permanently	placed	next	to	
it	on	the	screen	appears.	
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Fig	5.	Choice	reaction	time	The	subject	is	asked	to	press	the	left	and	right	buttons	in	response	to	cues	indicating	
“yes	à”	and	“noß”.	
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Fig.	6	Spatial	working	memory.	A	3x3	grid	with	lightbulbs	in	four	of	the	boxes	in	shown.	In	a	new	screen	
successively	lightbulbs	appear	in	one	of	the	boxes	and	subjects	indicate	whether	the	light	bulb	was	previously	
present	in	the	box	by	pressing	left	(no)	or	right	(yes).
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Fi.g 7.	numeric	working	memory.	A	series	 numbers	are	
shown.	The	subject	is	then	asked	to	assess	whether	
sequential	of	numbers	that	flashes	on	the	screen		are	
part	of	that	original	sequence	by	pressing	left	(no)	or	
right	(yes).
Fig	8.	A	series	of	images	are	shown	to	participants	at	the	
beginning	of	the	battery,	the	images	interspersed	with	
distractor	images	which	are	similar	to	the	original	
stimulus	(e.g a	red	car	and	a	blue	car,	a	flag	blowing	to	
the	right	and	a	flag	blowing	to	the	left).	For	each	image	
the	subject	selects	whether	it	is	an	original	image	(right)	
or	a	new	image	(left).	
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in	the	future	utilising	the	rapsodi	portal	as	a	tool	for	the	targeting	of	neuroprotective	
therapies.	
	
4.2	Validation	of	Cogtrack	cognitive	tests		
	
The	most	striking	challenge	was	the	lack	of	validation	data	for	the	unassisted	use	of	the	
software.	A	panel	of	the	software	has	been	available	for	some	years	on	the	internet	which	
has	allowed	the	collection	of	data	from	some	93,334	participants	who	undertook	
assessment	using	the	portal	unassisted.		This	was	compared	with	5,989	age	matched	
controls	who	undertook	the	portal	in	clinic.	Therefore	the	utility	of	using	the	panel	in	such	a	
manner	is	established.	That	said,	no	data	exists	on	the	applicability	of	unassisted	use	of	the	
cogtrack	panel	in	the	Parkinson	disease	population.		To	test	this	we	carried	out	some	
validation	studies.	Five	Parkinson	disease	and	three	control	subjects	were	asked	to	
complete	the	cogtrack	panel	on	two	occasions	(one	assisted,	one	unassisted)	2-4	weeks	
apart.	Participants	were	randomised	as	to	whether	they	carried	out	the	assisted	or	
unassisted	task	first.	Five	control	and	five	Parkinson	disease	participants	were	enrolled,	
however	only	3	participants	from	each	group	completed	both	tasks.	Although	the	cogtrack	
panel	generates	a	number	of	outcomes	which	combine	the	measurements	taken	for	each	
task,	we	chose	to	analyse	a	range	of	individual	outputs.	These	outputs	are	displayed	in	
figures	9-12.	A	full	output	of	the	medians	and	interquartile	ranges	of	the	outputs	is	listed	in	
the	supplementary	table	5	(Appendices	10.3b).		In	all	cases	differences	between	assisted	
and	unassisted	outputs	were	not	statistically	significant	amongst	the	unassisted	and	assisted	
groups.	Data	was	collected	by	SM	and	Ana	Sanz	Perez.	Analysis	was	carried	out	by	SM.	
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Fig	9.	Comparison	of	median	%	
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assisted	and	unassisted	
administration	of	tests
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Fig	10.	Comparison	of	median	%	accuracy	(error	bars	IQR)	with	Wilcoxon	rank	sum	significance	testing	between	assisted	and	
unassisted	administration	of	tests	in	control	and	PD	groups
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unassisted	administration	of	
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Fig	12.	Comparison	of	median	response	times	of	all	participants		(error	bars	IQR)	with	Wilcoxon	rank	sum	significance	testing
between	assisted	and	unassisted	administration	of	tests
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2 Participant	approached	in	person	or	by	telephone	and	asked	to	
participate.	Process	includes	
genetic	counselling	for	genetic	
tests	(GBA	and	LRRK2)	
3 Participant	sent	a	token	
via	email.
1 Index	case	identified.				
Either	known	Gaucher
diagnosis,		known	GBA	
PD	or	familial	PD	case.
4 Participant	logs	in	and	fills	out	online	consent	form,	
including	preferences	for	
disclosure	of	genetic	tests
6 Participant	carries	out	
BRAIN	test	for	
bradykinesia
5 Participant	fills	out	demographic		information7 Participant	completes	
UPDRS	II,	RBDSQ,	
HADS
8 Participant	completes	
Cogtrack battery
9 Participant	sent	smell	
test	and	saliva	
genotyping	kit	in	the	post
Participant	sends	smell	
test	and	saliva	
genotyping	kit	back	in	
prepaid	envelope Assessments	
repeated	every	
18	months
Identification	and	genetic										
counselling	of	participants
enrolment
assessm
ent
Fig	13.	Flow	diagram	of	the	process	of	assessment	in	the	rapsodi study
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4.3	Logistical	aspects	of	the	rapsodi	study.	
	
The	rapsodi	study	is	designed	ultimately	to	serve	a	cohort	of	a	1000+	subjects	over	a	25	year	
period.	As	such,	it	was	vital	to	implement	sustainable	and	scalable	systems	to	allow	the	
study	to	be	conducted	and	data	to	be	collected	in	a	manageable	and	secure	manner.	Some	
of	the	particular	challenges	(and	solutions)	are	described	below.	An	overview	of	the	study	
‘journey’	is	provided	in	Fig	13.	
	
4.4	Online	consent.		
	
A	major	challenge	was	the	necessity	for	the	consent	process	to	be	online,	as	otherwise	
subjects	would	have	to	be	visited	in	person,	defeating	the	entire	purpose	of	the	study.	This	
was	also	the	case	in	the	PREDICT	PD	study,	but	an	added	complication	for	rapsodi	was	that	
the	process	must	also	allow	participants	to	make	decisions	regarding	whether	they	wish	to	
have	the	results	of	genetic	testing	for	LRRK2	and	GBA	revealed.	We	concluded	in	light	of	this	
that	unlike	PREDICT	PD,	a	conversation,	in	person	or	by	telephone	prior	to	undertaking	the	
consent	process	would	be	necessary.	During	this	conversation	genetic	counselling	for	GBA	
and	LRRK2	mutations	is	offered	in	addition	to	more	generalised	overview	of	the	study.		
Furthermore,	the	participant	information	sheet	differed	depending	on	the	type	of	
participant	in	question.	A	scheme	was	devised	which	utilised	branching	logic	(i.e	a	series	of	
questions	directed	participants	to	the	correct	PIS)	in	order	to	simplify	the	consent	process.		
The	design	of	this	process	was	key	in	order	to	ensure	subjects	received	adequate	
information	prior	to	taking	part	in	the	study	but	in	a	manner	which	was	not	confusing	or	
contradictory.	A	schematic	of	this	consent	process	is	included	in	Fig	14.	We	trialled	the	
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procedure	amongst	a	panel	of	Parkinson	disease,	Gaucher	and	GBA	carriers	and	adjusted	
the	process	on	the	basis	of	the	feedback	obtained.			
	
4.5	Processing	of	postal	saliva	samples		
	
There	were	substantial	complexities	associated	with	DNA	processing.	We	required	a	
dynamic	system	that	allowed	DNA	to	be	purified,	analysed	and	the	results	available	for		
discussion	with	participants	as	required.	This	process	involved	a	number	of	operators	at	
different	sites.	Briefly	samples	were	received	at	the	department	of	clinical	neuroscience	
(DCN),	UCL	IoN,	Royal	Free	Campus.	DNA	samples	are	purified	in	house,	and	delivered	to	
health	service	laboratories	(Health	service	laboratories	(HSL)	-	Euston	road)	for	genotyping	
and	are	then	retrieved	and	databased	at	the	DCN.	We	therefore	chose	to	set	up	a	cloud	
based	database	for	the	logging	the	receipt	and	transfer	of	DNA	samples	as	well	as	recording	
the	results	of	their	analysis.	This	was	achieved	using	the	REDCAP	platform.	Date	of	receipt	of	
initial	sample	(DCN),	date	of	purification	(DCN),	date	of	receipt	of	purified	DNA	(HSL),	
genotyping	date	(HSL),	genotyping	result	(HSL),	date	of	databasing	of	purified	DNA	(DCN)	
are	recorded	in	a	pseudo	anonymised	manner	(i.e	study	numbers	only).		A	screenshot	of	the	
database	is	shown	in	Fig	15		
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Pre-study	
discussion	
including	details	
of	study,	genetic	
counselling	
related	to	
LRRK2	PD	risk	
and	GBA	
PD/Gaucher risk
Do	you	have	Gaucher disease?
Are	you	a	relative	of	someone	
with	Gaucher disease?
Are	you	a	a	spouse	of	
someone	with	Gaucher
disease?
Do	you		have	Parkinson’s	
disease?
Are	you	a	relative	of	someone	
with	Parkinson’s	disease?
Are	you	a	spouse	of	someone	
with	Parkinson’s	disease?
Gaucher disease	PIS
Parkinson’s	disease	PIS
Relative	of	someone	
with	Gaucher PIS
Spouse	of	someone	
with	Gaucher/	
Parkinson’s	PIS
Relative	of	someone	
with	PD	PIS
YES
YES
YES
YES
YES
NO
NO
NO
NO
NO
MAIN	CONSENT
Do	you	wish	to	know	
GBA	genotyping	result?
Do	you	wish	to	know	
LRRK2	genotyping	result?
Proceed	to	study
Fig	14.	Flow	diagram	of	the	process	of	consent	in	the	rapsodi study
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4.6	Family	tree	mapping	
	
A	key	component	of	the	future	analyses	envisaged	will	be	the	impact	of	a	family	history	of	
Gaucher	disease,	Parkinson’s	or	(presumed	lewy	body)	dementia	in	terms	of	the	potential	
for	Parkinson	disease	conversion.	The	rationale	is	of	course	that	these	factors	are	highly	
likely	to	be	surrogate	markers	of	genetic	cofactors	that	may	be	implicated	in	the	variable	
penetrance	of	these	GBA	mutation	associated	conditions.		In	a	large	cohort	such	as	this,	
where	many	of	the	participants	are	likely	to	be	related,	the	process	of	recording	and	using	
this	information	quickly	becomes	problematic.	To	resolve	these	issues	we	developed	a	
specialist	pedigree	recording	software	programme.	Screenshots	of	the	programme	are	
shown	in	Figure	16.		
	
4.7	Data	protection	and	security	
	
Of	paramount	concern	was	ensuring	the	security	of	the	data	captured.	To	ensure	this	was	
the	case	we	mimicked	the	approach	adopted	by	PREDICT	PD,	namely	that	personal	
identifiers	and	assessments	were	stored	on	separate	servers.	We	also	specified	that	data	
should	be	stored	on	servers	stamped	with	the	ISO27001	accreditation.	This	is	the	highest	
level	of	security	and	is	the	same	as	used	by	the	online	banking	industry.	We	also	employed	
24bit	encryption	to	the	site.	Moreover	the	administrator	logins	for	the	site	are	protected	
with	two	factor	user	authentication,	whereby	in	order	to	login,	a	user	must	enter	a	code	
sent	to	their	email	or	mobile	phone.	A	schematic	of	the	layered	security	design	in	included	
in	Fig	14
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Fig	15.	Screenshot	of	REDCap database	for	genotyping	sample	processing	and	results
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Fig	16.	Screenshot	of	bespoke	family	tree	mapping	software	developed	for	the	rapsodi portal;	the	
programme can	be	used	to	quickly	and	efficiently	recorded	detailed	and	complex	family	histories	as	
part	of	the	initial	telephone	consulantion with	the	patient.
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clinical	and	
genetics	data
ISO270001	stamped	
24bit	encryption	
environment
participant
identifiers
username	and	
password	login
Two	factor	
phone/email	
authentication
researcherrData	flow
Fig	17.	Layered	security	design	of	rapsodi portal.	
Note	that	identifiers	and	clinical/genetics	data	
stored	on	separate	servers	within	an	IS0270001	
stamped	security	environment,	protected	by	a	two	
factor	administrator	login	security	system
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4.8	Cohort	Characteristics	
	
Table	1	-	Characteristics	of	rapsodi	cohort	from	September	2016	–	May	2017	
	 	
age	(yr)	 male	(%)	
fhx	
Parkinson	
disease	
(%)	
years	of	full	time	
education	(yr)	 ever	smoked	(%)	
control	 mean	 51.4	 63.2%	 34.2%	 15.6	 28.9%	
N=38	 median	 51.0	 	 	 16.0	 	
carrier	 mean	 60.7	 49.1%	 24.6%	 13.1	 33.3%	
n=57	 median	 63.0	 	 	 13.0	 	
bilalleic	 mean	 49.4	 52.5%	 28.8%	 14.9	 30.5%	
N=59	 median	 51.0	 	 	 15.0	 	
Parkinson	
disease	 mean	 64.8	 57.5%	 30.0%	 15.1	 20.0%	
N=40	 median	 63.0	 	 	 16.0	 	
Significant	difference?	 p<0.05	 ns	 ns	 p<0.05	 ns	
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4.9	Analysis	plan	
	
Please	note	at	the	time	of	analysis	data	from	the	UPSIT	assessments	was	not	available	
	
4.10a	Questionnaires	
	
Broadly	speaking	we	have	adhered	to	the	analysis	plan	stipulated	in	chapter	3.	Examination	
of	data	by	visual	inspection	showed	that	none	of	the	questionnaire	assessments	was	
normally	distributed.	This	was	mostly	due	to	the	ceiling	and	floor	effects	of	the	various	
assessment.	Where	recognised	clinical	thresholds	exist	we	have	used	these	to	convert	the	
assessments	into	an	ordinal	dataset.	These	are	namely:	
• RBDSQ:	>5	REM	sleep	disorder	172	
• HADS:	>11	Depression	185	
	
In	these	cases	we	then	entered	the	variables	into	an	ordinal	logistic	regression	model	which	
included	the	following	coovariates;	age,	sex,	FHx	Parkinson	disease,	years	of	education,	
smoking	status.	The	primary	analysis	compared	all	GBA	participants	with	the	control	group	
and	all	Parkinson	disease	participants	with	the	control	group.	Subset	analysis	comparing	
carrier	and	biallelic	participants	individually	with	controls	was	then	undertaken	in	the	event	
of	a	significant	correlation	of	the	former.		
	
Where	transformation	of	the	dataset	into	ordinal	categories	was	not	possible	(UPDRS	II)	we	
undertook	a	Mann	U	Whitney	test	once	again	comparing	controls	with	a)	the	combined	
group	of	GBA	carriers	and	b)	the	Parkinson	disease	group.	Subset	analyses	then	compared	
individual	carrier	and	bi-allelic	groups	to	controls	in	the	event	of	associations.		
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4.10b	Bradykinesia	akinesia	assessment	(BRAIN)	
	
The	BRAIN	test	asks	the	subject	to	sequentially	tap	on	the	“s”	and	“;”	keys	as	quickly,	
regularly	and	accurately	as	possible.	It	has	three	major	outputs.	The	Kinesis	score	(KS30	-	
how	many	tap	in	30	seconds),	the	akinesis	time	(AT30	-	dwell	time	over	keys),	the	dysmetria	
score,	a	weighted	index	which	defines	the	number	of	incorrectly	hit	keys	activated	(DS30	-	1	
point	for	correct	key,	2	points	for	adjacent	key,	3	for	other	keys)	and	the	variance	of	the	
time	interval	between	each	keystroke	(IS30).	Validation	studies	show	it	is	able	to	identify	
Parkinson	disease	subjects	with	sensitivity	and	specificity	183.	A	screenshot	of	the	BRAIN	test	
is	shown	in	figure	2.	
	
We	began	by	assessing	outcomes	for	normality.	Of	the	four	outcomes	outcomes	only	the	
KS30	score	was	parametrically	distributed	(visual	inspection	and	Schapiro	wilks	test).	For	
this	outcome	we	elected	to	use	a	linear	regression	model	which	included	age	as	a	covariate	
to	test	for	significant	differences.	For	the	other	analyses	the	distribution	was	not	parametric	
and	so	a	Kruskal	Wallis	test	was	performed	and	pairwise	analyses	(comparing	control	with	
GBA,	Parkinson	disease,	het	and	biallelic	populations)	was	made	using	a	Wilcoxon	rank	sum	
test.			
	
4.10c	Cogtrack	
Overview	of	the	Cogtrack	battery	and	outputs.	
	
The	Cogtrack	battery	used	consisted	of	the	following	components:	
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Simple	reaction	time	(Fig	3).	
	
The	subject	is	asked	to	repeatedly	press	on	the	right	key	button	when	a	“à	yes”	cue	
appears	on	the	screen.	Mean	(SRT)	and	median	reaction	time	(SRT),	standard	deviation	of	
reaction	time	(SRTSD)	and	coefficient	of	variance	are	recorded	(SRTCV).	
	
Digital	vigilance	(Fig	4).	
	
The	subject	is	asked	to	press	the	right	key	button	when	a	number	cue	matching	a	number	
permanently	placed	next	to	it	on	the	screen	appears.	Reaction	time	(VIGRT),	Percentage	of	
targets	detected	(VIGACC),	Number	of	false	alarms	(VIGFA),	Standard	deviation	of	reaction	
time	(VIGSD)	and	Coefficient	of	variance	of	reaction	time	(VIGCV)	are	recorded.		
	
Choice	reaction	time	(Fig	5).	
		
The	subject	is	asked	to	press	the	left	and	right	buttons	in	response	to	cues	indicating	“press	
à/ß	now”.	Mean	(CRT)	and	median	(CRTM)	reaction	time,	reaction	time	standard	
deviation	(CRTSD)	and	coefficient	of	variance	(CV%)	were	all	recorded.		
	
Spatial	working	memory	(Fig	6).	
	
A	3x3	grid	with	lightbulbs	in	4	of	the	boxes	in	shown.	Successively	lightbulbs	appear	in	the	
boxes	and	subjects	indicate	whether	the	light	bulb	was	previously	present	in	the	box	by	
pressing	left	(no)	or	right	(yes).	Mean	and	median	reaction	time	to	the	original	stimuli	(i.e	
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bulbs	which	were	present	in	the	presented	image	–	SPMORT,	SPMORTM)	and	new	stimuli	
(those	that	weren’t	–	SPMNRT,	SPMNRTM),	accuracy	of	response	to	presented	stimuli	to	
original	(SPMOACC1)	and	new	stimuli	(SPMNACC1),	the	standard	deviation	of	the	reaction	
time	(SPMSD)	and	the	coefficient	of	variance	of	the	reaction	time	(SPMCV)	are	recorded.	
	
Numeric	working	memory	(Fig	7).	
	
A	series	of		numbers	are	shown.	The	subject	is	then	asked	to	assess	whether	a	series	of	
numbers	that	flash	on	the	screen		are	part	of	that	original	sequence.	Mean	and	median	
reaction	time	to	the	original	stimulus	(NWMORT	and	NWMORTM),	new	stimulus	(NWMNRT	
and	NWMNRTM),	a	combined	reaction	time	to	both	stimuli	(NWMRT	and	NWMRTM),	the	
standard	deviation	(NWMSD)	and	coefficient	of	variance	(NWMCV)	are	recorded.		
	
Picture	recognition	task	(Fig	8).	
	
A	series	of	images	are	shown	to	participants	at	the	beginning	of	the	battery,	the	images	
interspersed	with	distractor	images	which	are	similar	to	the	original	stimulus	(e.g	a	red	car	
and	a	blue	car,	a	flag	blowing	to	the	right	and	a	flag	blowing	to	the	left).	For	each	image	the	
subject	selects	whether	it	is	an	original	image	(right)	or	a	new	image	(left).	Accuracy	of	
responses	to	original	(DPICOA)	and	new	stimulus	(DPICNA),	mean	and	median	reaction	time	
to	the	original	(DPICORT,	DPICORTM),	new	stimulus	(DPICNRT,	DPICNRTM),	combined	
reaction	time	(DPICRT,	DPICRTM),	standard	deviation	of	the	reaction	time	(DPICSD),	and	
coefficient	of	variance	of	the	reaction	time	(DPICCV)	are	recorded.	
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Approach	to	analysis	of	dataset.	
	
Validation	data	(from	Wesnes	cognition	previous	research	portfolio)	exists	based	on	484	
Parkinson	disease	and	1896	age	matched	controls	exists.	These	data	revealed	deficits	in	a	
number	of	domains	(Fig	18).	Most	prominently	this	was	evident	in	the	power	of	attention.	
This	score	is	the	sum	of	SRTM,	CRTM,	VIGRT	outputs.		Moreover,	differences	were	also	
noted	across	the	following	outcomes	SPMORTM,	SPMNACC,	DPICNACC,	DPICNACC,	
DPICNRTM.	Previous	data	based	on	assessments	of	Gaucher	patients	found	deficits	in	power	
of	attention	and	speed	of	memory	composite	scores	186.	Unfortunately	this	latter	score	
includes	outcomes	drawn	from	the	word	recognition	task	that	we	chose	to	omit	from	the	
battery	because	our	testing	showed	a	disproportionate	number	of	dropouts	from	this	task.		
	
Although	guided	by	these	data,	given	that	this	is	the	first	time	these	tools	have	been	used	
on	heterozygote	GBA	carriers,	we	chose	to	analyse	each	output	individually	and	then	where	
possible	(power	and	continuity	of	attention),	to	also	compare	these	composite	scores.		
	
For	each	outcome	variable	normaility	was	assessed	using	the	Schapiro	Wilks	test.	The	
overwhelming	majority	of	outcomes	failed	to	meet	the	criteria	for	disproval	of	the	null	
hypothesis	that	results	distribution	were	non	Gaussian	(sup.	table	7,	section	10.4).	This	left	
us	with	a	problem.	Because	formal	thresholds	were	not	available	for	the	cogtrack	tests	we	
were	unable	to	construct	an	ordinal	regression	model	and	hence	were	unable	to	include	co-
ovariates	in	the	analysis.	Although	in	most	respects	the	populations	were	broadly	balanced,	
there	were	discrepancies	in	the	age	and	years	of	education	which	were	inherent		
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Profile of Cognitive Deficits in PD
Effect Sizes 
Glass's Effect Size
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Power of Attention
Continuity of Attention
Articulatory WM %
Articulatory WM RT
Spatial WN %
Spatial WN RT
Word Recognition %
Word Recognition RT
Picture Recognition %
Picture Recognition RT
Fig	18.	Summary	Glass	effect	size	
of	cogtrack battery	comparing	
484	PD	patients	(mean	age	66.7	
yrs,	SD	10.4)	and	1896	age-
matched	controls (courtesy	of	
Prof. Keith	Wesnes)
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to	the	study	design	as	described	previously.	Although	sub	optimal	we	chose	to	analyse	the	
data	without	taking	into	account	coovariates.	We	were	conscious	of	the	risk	of	type	1	error	
due	to	multiple	comparisons,	so	in	the	first	case	a	kruschal	Wallis	test	looking	for	differences	
between	the	four	study	groups.	In	the	event	of	significant	associations	we	carried	out	
further	pairwise	analyses	comparing	1)	GBA	vs	control	2)	Parkinson	disease	vs	control	3)	
carrier	vs	control	4)	biallelic	vs	control	5)	carrier	vs	biallelic	
	
4.11	Results	
Data	was	collected	by	SM	and	Sarah	Cable.	
	
4.11a	Questionnaires		
Descriptive	statistics	together	with	statistical	test	results	are	shown	below	in	Tables	2	and	3.	
Table	2	–	Questionnaire	scores	from,	rapsodi	portal	
	 CTL	 Parkinson	
disease	
HET	 BIA	 GBA	
RBDSQ	,	median	(mean)	 3	(4.0)	 5	(5.4)	 2	(3.0)	 3	(3.2)	 2	(3.1)	
HADS,	median	(mean)	 5	(8.3)	 10	(10.6)	 5	(7.2)	 8	(8.8)	 7	(8.0)	
UPDRS	II,	median	(mean)	 0	(1.5)	 8	(8.9)	 0	(2.8)	 0	(1.5)	 0	(2.1)	
	
Table	3	–	significance	testing	of	questionnaires	vs	controls	
	 RBDSQ*	
OR	[95%CI],	p	value	
UPDRS	II**	
Z	score,	p	value	
HADS*		
OR	[95%CI],	p	value		
GBA	 0.69	[-0.26-1.81]	
p=0.453	
-0.499	
p=0.62	
0.57	(0.08-4.10)	
p=0.581	
Parkinson	disease	 1.18	[1.14-9.35]	
p=0.027	
-5.688	
p<0.0001	
1.02	(0.12-8.17)	
p=0.980	
*Ordinal	logistic	regression		**Wilcoxon	rank	sum	
	
These	findings	are	interesting	in	that	for	both	RBDSQ	and	UPDRS	II	the	assessments	were	
able	to	show	definable	deficits	amongst	Parkinson	disease	subjects.	This	is	not	suprising	in	
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itself,	however	does	show	that	within	this	population	these	symptoms	can	be	detected	by	
remote	online	assessment.	The	HADS	score	shows	no	difference	between	the	Parkinson	
disease	and	control	group.	Exploration	of	the	dataset	shows	that	the	median	values	are	
distinct.	The	thresholding	value	5/6	may	not	adequately	differentiate	the	differences	in	
depression	scores	between	the	two	groups.	Indeed	a	Wilcoxon	rank	sum	pairwise	analysis	
using	the	continuous	data	does	show	a	significant	difference	(z=-2.129	p=0.033)	between	
the	two,	which	perhaps	implies	the	thresholding	value	is	too	low.	Altogether,	using	a	
positive	control	population	of	those	with	established	Parkinson	disease,	these	data	suggests	
this	approach	is	able	to	detect	these	prodromal	Parkinson	disease	features.	
	
It	is	unsurprising	that	the	assessments	were	not	able	to	discern	any	differences	in	UPDRS	II,	
HADS	or	RBDSQ	scores.	Associations	using	only	marginally	smaller	group	sizes	were	not	seen	
in	chapter	3.		
	
4.11b	Bradykinesia	akinesia	assessment	(BRAIN)	
group	 KS30	 AT30	(msec)	 DS30	 IS30	
control	mean	 57.82	 83.54	 1.04	 74549.77	
control	median	 60.00	 77.50	 1.00	 13514.33	
heterozygote	mean	 54.74	 101.69	 1.04	 68335.57	
heterozygote	median	 53.00	 88.00	 1.00	 17588.59	
biallelic	mean	 60.50	 84.50	 1.09	 31627.65	
biallelic	median	 60.00	 80.00	 1.00	 6402.78	
GBA	mean	 58.32	 93.07	 1.06	 51063.86	
GBA	median	 58.00	 82.00	 1.00	 9768.34	
Parkinson	disease	
mean	 48.40	 102.05	 1.04	 96806.40	
Parkinson	disease	
median.		 46.50	 94.50	 1.00	 36413.95	
Table	4.	Summary	outputs	of	BRAIN	test	
These	analysis	is	shown	below	and	box	plots	are	displayed	in	figures	19-21.	 	
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group	 Coef.	 t	 p	value	 95%	CI	
heterozygote	 -.5558149	 -0.18	 p=0.859	 [-6.73-5.62]	
biallelic	 0.4292081	 0.15	 p=0.883	 [-5.36-	6.22]	
Parkinson	
disease	 -7.352564	 -2.06	 p=0.042	 [-14.42-0.28]	
Table	5.	Linear	regression	results	of	KS30	model	including	age	and	study	group	
	 multivariate	 Parkinson	
disease	
GBA	 het	 bia	
AT30	 p=0.1915	 	 	 	 	
IS30	 p=0.0151	 p=0.0248	 p=0.9605	 p=0.3805	 P=0.3496	
DS30	 p=0.8246	 	 	 	 	
Table	6.	Kruskal	Wallis	(+/-	spearman’s	rank)	testing	for	differences	between	study	
groups.	
	
For	the	KS30	and	AT30	significant	differences	were	shown	between	the	Parkinson	disease	
and	control	groups.	These	results	are	unsurprising,	although	do	prove	the	utility	of	the	tool	
in	these	studies.	Otherwise	there	are	no	significant	differences	between	GBA	carriers	and	
controls,	although	there	are	hints	of	a	trend	toward	this	result	in	terms	of	the	KS30,	AT30	
and	IS30	scores	in	the	heterozygote	group.	This	trend	is,	however,	not	replicated	amongst	
the	biallelic	group.	One	explanation	might	be	that	these	participants	are	younger.	Our	
regression	model	clearly	showed	that	age	was	a	highly	significant	determinant	of	the	KS30	
score	(p<0.0001),	and	accordingly	the	fact	that	this	group	is	some	10	years	younger	may	
provide	an	explanation	for	the	difference.	To	date	we	have	found	no	convincing	evidence	of	
motor	deficits	aside	(amongst	these	patients)	from	trends	amongst	the	UPDRS	II	and	III	
scores	(chapter	2)	and	quite	simply	it	may	be	that	such	deficits	do	not	exist.	Alternatively	it	
may	be	that	a	more	stratified	approach	is	required	which	we	shall	discuss	more	in	depth	at	
the	conclusion	of	the	chapter.		
Stephen	Mullin	–	PhD	thesis	
	
	
110	
	
	
Fig.19	Box	plots	of	kinesia
times	(KS30)	of	control,	
hetrozygote,	biallelic and	PD	
individuals.	NB	no	
significance	bar	as	regression	
model	used.
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p=0.1915
Fig.20	Box	plots	of	akinesia	
times	(AT30)	of	control,	
hetrozygote,	biallelic and	PD	
individuals
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Fig.21	Box	plots	of	IS30 score	
of	control,	hetrozygote,	
biallelic and	PD	individuals
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4.11c	Cogtrack		
	
A	total	of	171	(25	controls,	55	carriers,	52	biallelic,	38	Parkinson’s)	undertook	the	cogtrack	
battery.	A	summary	table	of	statistics	(median	and	mean)	for	the	outputs	are	displayed	in	
the	appendices	(supp.	table	6,	section	10.4).	Analyses	based	on	the	plan	described	above	
are	shown	in	table	7.	
	
Visual	memory	is	impaired	in	all	groups	compared	to	controls.	
	
GBA	carriers	appear	to	display	deficits	in	reaction	time	across	a	range	of	tasks.	The	most	
interesting	finding	is	the	very	consistent	differences	in	reaction	times	compared	to	controls	
amongst	all	groups	in	the	spatial	working	memory	task.		Moreover	in	GBA	and	biallelic	vs	
control	subjects	significance	differences	exist	in	terms	of	the	accuracy	of	response	to	the	
original	stimulus	(and	this	is	mimicked	in	terms	of	strong	trends	in	the	other	two	pairwise	
analyses	(carrier	z=1.876	p=0.0607,	Parkinson	disease	z=1.954	p=0.0507).	Box	plots	of	these	
outputs	are	displayed	in	Figures	22-23.	
	
	Visual	deficits	are	an	established	field	of	enquiry	in	the	context	of	Parkinson’s187	and	there	
is	evidence	this	is	a	disproportionate	feature	amongst	GBA	Parkinson’s	cases.	33	It	is	
therefore	striking	that	amongst	this	task	the	differences	in	reaction	times	are	so	prominent.	
The	task	combines	tests	of	both	visual	memory	and	visual	perception,	therefore	it	would	be	
interesting	if	future	assessments	could	further	dissect	the	relative	contributions	of	the	two	
processes.		
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Fig.22	Box	plots	of	%	accuracy	of	response	in	spatial	working	memory	task	(SPMACC)	of	control,	hetrozygote,	biallelic and	PD	
individuals
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Fig.23	Box	plots	of	reaction	time	in	spatial	working	memory	task	(SPMRT)	of	control,	heterozygote,	biallelic and	PD	individuals
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More	generally	its	seems	that	there	are	deficits	in	the	reaction	times	of	all	groups	compared	
to	controls.	This	is	consistent	with	previous	validation	data	which	found	that	the	power	of	
attentions	composite	score	is	reduced	in	Parkinson	disease	subjects	(Fig	18).	The	continuity	
of	attention	composite	is	comprised	of	the	reaction	time	elements	of	the	simple	reaction	
time,	choice	reaction	time	and	digital	vigilance	tasks	and	was	reduced	in	GBA	vs	CTL	and	HET	
vs	CTL	in	these	data.	Trends	(biallelic	z=-1.414	p=0.1572	and	Parkinson	disease	z=-1.546	
p=0.1221)	were	present	amongst	the	other	two	groups.	It	is	likely	therefore	that	given	
sufficient	power	all	study	groups	would	show	a	significant	result.		
	
These	results	are	primarily	informative	because	they	will	allow	rationalisation	of	the	portal	
in	order	to	minimise	the	number	of	tests	undertaken.	The	intent	of	the	rapsodi	project	is,	
rather	than	to	phenotype	the	cognitive	impairment	present	in	these	participants,	to	provide	
a	screening	assessment	which	will	enable	stratification	of	the	cohort.			The	current	battery	
takes	on	average	20min.	Retention	within	the	study	is	aided	by	making	the	patient	
experience	as	quick	as	possible,	hence	we	hope	the	basis	of	these	results,	to	rationalise	the	
battery	based	on	the	most	sensitive	assessments.		
	
4.12	Concluding	remarks	
	
In	this	chapter	we	have	demonstrated	the	utility	of	an	internet	based	assessment	for	
prodromal	Parkinson	disease	features	amongst	GBA	carriers.	It	will	hopefully	assure	the	
sustainability	of	the	assessment	of	cohorts	of	GBA	carriers	for	these	signs	and	the	drastic	
enlargement	of	this	cohort.	Significant	differences	were	recorded	for	aspects	of	the	
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cognitive	assessment;	in	particular	reaction	times	across	the	board	(and	in	particular	for	
spatial	working	memory	tasks)	showed	consistent	and	definable	deficits.	In	terms	of	the	
other	assessments	it	may	be	that	increased	study	numbers	may	bring	these	deficits	out,	or	
on	the	other	hand	that	by	identifying	outliers	within	the	groups	we	may	be	able	to	define	
higher	risk	individuals.					
	
The	process	of	optimisation	of	rapsodi	is	still	underway	and	is	unremitting,	as	the	key	will	be	
making	the	process	of	prospective	assessment	as	simple	and	engaging	as	possible	and	
refining	and	scaling	the	processes.	New	challenges	lie	ahead	such	as	incorporating	and	
validating	the	use	of	touch	screen	devices.	That	said,	the	promise	of	such	an	approach	is	
nearly	limitless.		For	instance	there	is	the	very	real	prospect	of	incorporating	biomarkers	
such	as	GCase	activity	(which	can	be	collected	on	peripheral	blood	spots)	into	the	
assessment	process.	Stratification	of	the	cohort	into	high	and	low	risk	participants	could		
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Table	7.		Significance	testing	for	outputs	for	cogtrack	battery	
x	 multivariate	 GBA	vs	CTL	
Parkinson	
disease	vs	
CTL	
HET	vs	
CTL	 BIA	vs	CTL	 test	 multivariate	 GBA	vs	CTL	
Parkinson	
disease	vs	
CTL	
HET	vs	
CTL	 BIA	vs	CTL	
SRT		 p=0.0092	 p=0.001	 ns	 p=0.0015	 p=0.049	 SPMSD		 p=0.0054	 p=0.0012	 p=0.0011	 p=0.0041	 p=0.0021	
SRTM		 p=0.0351	 p=0.014	 ns	 ns	 p=0.007	 SPMCV		 p=0.0040	 p=0.0035	 p=0.0009	 p=0.0066	 p=0.0085	
SRTSD	 ns	 -	 -	 -	 -	 NWMOACC		 ns	 -	 -	 -	 -	
SRTCV		 ns	 -	 -	 -	 -	 NWMNACC		 ns	 -	 -	 -	 -	
VIGACC		 ns	 -	 -	 -	 -	 NWMORT		 p=0.0117	 p=0.0174	 p=0.0097	 p=0.0048	 ns	
VIGRT	 p=0.0001	 p=0.0024	 p=0.0003	 p=0.0003	 ns	 NWMNRT		 ns	 -	 -	 -	 -	
VIGFA		 p=0.0065	 ns	 ns	 ns	 p=0.0282	 NWMRT		 ns	 -	 -	 -	 -	
VIGSD		 p=0.0062	 p=0.0161	 p=0.0004	 p=0.0058	 ns	 NWMORTM		 p=0.0235	 ns	 ns	 p=0.0115	 ns	
VIGCV	 ns	 -	 -	 -	 -	 NWMNRTM		 ns	 -	 -	 -	 -	
CRTACC		 ns	 -	 -	 -	 -	 NWMRTM		 p=0.0400	 ns	 p=0.0204	 ns	 ns	
CRT		
p=0.0179	 ns	 ns	 p=0.0403	 ns	
NWMSD		
p=0.0495	 p=0.0100	 p=0.0076	 p=0.0137	 p=0.0250	
CRTCV		 -	 	-	 	-	 	-	 	-	 DPICNA		 ns	 -	 -	 -	 -	
SPMOACC		 P=0.0413	 p=0.0226	 ns	 ns	 p=0.0197	 DPICORT		 ns	 -	 -	 -	 -	
SPMNACC		 ns	 	-	 -		 -		 -		 DPICNRT		 ns	 -	 -	 -	 -	
SPMORT		 p=0.0026	 p=0.001	 p=0.0094	 p=0.0003	 p=0.0182	 DPICRT		 ns	 -	 -	 -	 -	
SPMNRT		 p=0.0010	 p=0.0001	 p=0.0025	 p=0.0002	 p=0.0008	 DPICORTM		 ns	 -	 -	 -	 -	
SPMRT		 p=0.0004	 p=0.0001	 p=0.0007	 p=0.0001	 p=0.0021	 DPICNRTM		 ns	 -	 -	 -	 -	
SPMNRT
M		 p=0.0024	 p=0.0021	 ns	 p=0.0015	 p=0.0139	 DPICSD		 ns	 -	 -	 -	 -	
SPMRTM		 p=0.0002	 p=0.0001	 p=0.0134	 p<0.0001	 p=0.0047	 DPICCV		 ns	 -	 -	 -	 -	
Composite	scores	
POA	 p=0.0097	 p=0.0151	 ns	 p=0.0027	 ns	 	 		 		 		 		 		
Stephen	Mullin	–	PhD	thesis	
	
	
119	
allow	development	of	new	biomarkers	of	Parkinson	disease	conversion.	There	is	a	realistic	
prospect	of	extending	the	study	of	a	multinational	basis	to	other	Parkinson	disease	and	
Gaucher	cohorts.	Such	big	data	allows	us	to	tackle	questions	touched	on	already	in	this	
thesis,	such	as	the	risk	associated	with	the	300	individual	Gaucher	associated	GBA	
mutations	in	terms	of	Parkinson	disease	or	the	role	of	other	genetic	and	epigenetic	
modifiers	in	this	conversion.						
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Chapter	5	-	Novel	biomarkers	implicating	neuroinflammation	in	the	aetiology	of	GBA	
Parkinson	disease	
	
5.0	Introduction		
	
Biomarkers	which	correlate	with	the	conversion	to	Parkinson	disease	amongst	GBA	carriers	
are	of	interest	for	two	reasons.	In	the	first	case	they	may	help	to	identify	those	who	are	at	
high	risk	of	conversion	to	allow	targeting	of	novel	neuroprotective	therapeutics.	More	
broadly	they	may	have	relevance	as	screening	tools	to	identify	those	in	the	prodromal	phase	
of	idiopathic	Parkinson	disease.		We	have	discussed	the	use	in	chapter	4	of	clinical	
assessments	to	identify	features	of	the	so	called	prodromal	phase	of	Parkinson	disease.	
These	assessments	are	cheap,	non	invasive	and	as	we	have	shown	have	utility	in	the	context	
of	an	internet	based	assessment	portal,	making	their	use	in	population	based	screening	
plausible.	That	said	the	features	they	define	are	on	the	whole	common	and	although	we	
have	presented	evidence	of	clustering	in	certain	subjects,	in	isolation	they	may	be	
insufficient	to	adequately	define	who	is	at	risk	of	Parkinson	disease	conversion.	In	this	case	
a	second	line	of	screening	and	assessment	may	increase	their	specificity.	As	such	there	is	a	
requirement	for	robust	markers	of	Parkinson	disease	conversion	amongst	GBA	carriers.	In	
this	chapter	I	shall	describe	various	experiments	which	have	attempted	to	validate	and	
reveal	novel	biomarkers	of	Parkinson	disease	conversion	amongst	GBA	carriers,	namely	PET	
imaging	assessing	for	dopaminergic	loss	and	glial	inflammation,	serum	ELISA	antibody	
screening	for	a	number	of	known	neurodegenerative	and	inflammatory	markers	and	a	
hypothesis	generating	screen	in	the	urine	of	GBA	carriers	with	evidence	of	prodromal	
Parkinson	disease	signs.	Our	findings	directly	implicate	the	established	alpha	synuclein	
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pathway	is	the	pathogenesis	of	Parkinson	disease	conversion	amongst	GBA	carriers	as	well	
more	broadly	highlighting	the	role	of	central	nervous	system	inflammation	(and	to	an	extent	
peripheral	inflammation)	in	this	process.		
	
5.1	PET	imaging	of	dopaminergic	loss	and	glial	activation		
5.2	PET	imaging		
	
PET	imaging	is	an	established	diagnostic	tool	in	Parkinson’s	and	other	neurodegenerative	
conditions.	Ligands	designed	to	mimic	molecules	(such	as	glucose)	or	to	bind	to	epitopes	on	
other	proteins	(such	as	beta	amyloid)	accumulate	in	the	brain.	Gamma	rays	emitted	
indirectly	by	the	positron	emitting	radionucleotide	attached	to	the	biologically	active	
molecule	are	detected	and	form	the	basis	of	images	produced.	PET’s	use	in	Parkinson’s	is	
established.	SPECT	Dopamine	active	transporter	(DAT)	has	been	shown	to	be	able	to	detect	
dopaminergic	loss	within	the	brain	of	Parkinson’s	patients	with	sensitivity	and	specificity	188.	
SPECT	imaging	measuring	cerebral	perfusion	has	been	shown	to	increase	the	specificity	of	
the	diagnosis	of	Alzheimer’s	disease	and	ligands	which	bind	to	the	beta	amyloid	appear	to	
be	able	to	detect	the	accumulation	of	plaques	in	the	brain	189.		It	would	therefore	seem	the	
obvious	tool	to	investigate	in	vivo	processes	ongoing	in	those	at	higher	risk	of	developing	
Parkinson	disease.	
	
5.3	PET	imaging	of	GBA	mutation	carriers	
	
Only	a	few	molecular	imaging	studies	have	investigated	the	integrity	of	the	dopaminergic	
nigrostriatal	system	in	Parkinson	disease	patients	positive	for	GBA	mutations	and	the	
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number	of	patients	included	is	limited.	Reduced	striatal	18F-DOPA	uptake	has	been	observed	
190,191	as	has	reduced	striatal	dopamine	transporter	(DaT)	binding	192,193	and	altered	striatal	
asymmetry	194.	There	have	to	date	been	no	PET	imaging	studies	in	GBA	carriers	who	do	not	
Parkinson	disease.	
	
5.4	Neuroinflammation	in	Parkinson	disease	
	
Since	the	discovery	of	increased	numbers	of	MHC	class	II	activated	glial	cells	in	the	
substantia	nigra	of	Parkinson’s	patients	195,196	neuroinflammation	and	specifically	the	role	of	
glial	activation	in	the	aetiology	of	Parkinson	disease	has	been	closely	scrutinised	197	Under	
normal	physiological	conditions,	microglia	are	quiescent	and	distributed	across	the	central	
nervous	system.	However,	microglia	become	activated	in	response	to	a	pathologic	insult,	
primarily	at	the	site	of	injury,	causing	a	prolonged	release	of	pathological	cytokines	198	
Epidemiological	evidence	suggests	a	protective	effect	associated	with	various	non	steroidal	
anti	inflammatory	drugs.199-201	Genetic	studies	have	shown	that	a	number	of	
polymorphisms	in	the	TNF	alpha	and	other	immunomodulatory	genes	have	protective	or	
causative	effects	in	terms	Parkinson	disease	development	202,203.	A	number	of	studies	have	
found	upregulated	levels	of	various	peripheral	cytokines	in	Parkinson	disease	patients	
implying	that	peripheral	immune	upregulation	may	be	a	surrogate	of	these	central	
inflammatory	processes	204-206.	Thus	there	is	significant	evidence	from	a	number	of	sources	
of	a	role	for	immune	dysregulation	in	the	aetiology	of	Parkinson	disease,	it	however	remains	
to	be	seen	whether	central	immune	modulation	is	a	pathogenic	or	protective	mechanism.	
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5.5	Immune	dysregulation	in	Gaucher	disease	
	
Immune	dysregulation	is	a	profound	feature	of	Gaucher	disease	and	has	been	linked	to	a	
variety	of	clinical	phenotypes.	207-210	Although	limited	post	mortem	data	exists	from	
neuronopathic	Gaucher	diseasepatients,	glial	activation	does	appear	to	be	an	established	
feature	48,211,	and	these	findings	are	replicated	in	mouse	models	of	the	disease	212.	
Peripherally,	Gaucher	disease	patients	have	been	shown	to	have	upregulation	of	IL-6	and	10	
213.		Given	the	correlation	of	those	neuronopathic	Gaucher	diseasemutations	with	increased	
Parkinson	disease	pathogenicity	22,	it	would	seem	plausible	that	neuroinflammation	forms	a	
significant	aspect	of	GBA	Parkinson	disease.	
	
5.6	PK11195	–	a	ligand	for	the	detection	of	glial	activation	
	
The	isoquinolone	PK11195	is	an	experimental	ligand	which	is	thought	to	bind	to	regions	of	
microglial	activation.	It	is	a	partial	antagonist	of	central	benzodiazepine	receptors	associated	
the	GABA	related	channels,	however	what	the	exact	source	of	the	upregulation	of	PK11195	
binding	is	in	the	presence	of	microglial	activation	is	not	clear.	Variously	PK1195	has	been	
described	to	bind	to	astrocytes,	various	haematogenous	infiltrates	and	microglial	cells	
themselves.198	None	the	less	it	appears	to	be	a	robust	in	vivo	measure	of	glial	upregulation	
as	shown	by	a	number	of	in	vivo	studies	51,214,215.	Two	studies	using	the	ligand	have	shown	
upregulation	of	PK11195	binding	in	the	midbrain	and	brainsterm	respectively	49,216	and	
additionally	in	the	former	within	the	frontal	and	temporal	cortex	216.	On	the	basis	of	these	
findings	we	selected	the	PK11195	ligand	as	suitable	investigative	paradigm	for	qualification	
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of	the	role	of	central	nervous	system	glial	activation	and	neuroinflammation	in	non	
Parkinson	disease	GBA	carriers.	
	
5.7	Aims	
	
1) 	To	investigate	whether	dopaminergic	loss	and	glial	activation	are	present	in	pre	
specified	regions	of	interest	in	the	brains	of	GBA	carriers.	
2) To	see	whether	these	changes	correlate	with	the	presence	of	features	of	prodromal	
Parkinson	disease,	mutations	severity,	GCase	activity	and	various	serum	biomarkers	
of	neurodegeneration/inflammation.		
		
5.8	Methods	
	
The	current	study	was	conducted	between	the	16th	of	November	2015	and	17th	of	
November	2016.	Nine	subjects	who	were	either	bilallelic	(homozygous	or	compound	
heterozygous)	or	heterozygous	carriers	of	a	Gaucher	disease	associated	GBA	mutation	
(Table	1)	were	recruited	from	an	established	cohort	at	the	Department	of	Clinical	
Neuroscience,	University	College	London,	United	Kingdom	to	participate	in	the	current	PET	
study.	All	subjects	were	genotyped	at	the	lysosomal	storage	disease	unit	(LSDU),	Royal	Free	
hospital	London,	UK,	using	a	two	stage	process	of	high	resolution	melting	of	exons	1-11	of	
the	GBA	gene	with	subsequent	sanger	sequencing	of	any	exons	which	deviated	from	the	
reference	curve.	Biallelic	carriers	were	all	type	1	(non	neuronopathic)	Gaucher	disease	
subjects	whilst	heterozygous	carriers	were	drawn	from	kindred	of	Gaucher	diseasepatients.	
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No	subjects	in	this	study	were	genetically	related.	GBA	subjects	were	recruited	by	SM,	
controls	were	recruited	by	Dr	Morten	Stokholm.	
	
	Carriers	were	each	examined	with	two	PET	scans	using	11C-PK11195	and	18F-DOPA,	one	MRI	
scan,	and	a	clinical	neurological	examination.	Prodromal	Parkinson	disease	features	were	
further	characterised	with	the	following	assessment	scales:	University	of	Pennslyvannia	
smell	identification	test	(UPSIT	–	hyposmia)	169,	Montreal	cognitive	assessment	(MoCA	-	
cognition)	170,	Rapid	eye	movement	sleep	behaviour	disorder	questionnaire	(RBDSQ	-	REM	
sleep	behavious	disorder)	172,	Non	motor	symptoms	scale	(NMSS	–	non	motor	Parkinson	
disease	features)	217,218,	Unified	Parkinson	disease	rating	scale	parts	II	and	III	(UPDRS	II	&	III	
–	motor	symptoms	and	signs	of	Parkinson	disease)	and	Beck’s	depression	inventory	(BDI)	
171.	
	
All	scans	and	examinations	were	performed	at	the	Department	of	Nuclear	medicine	&	PET	
centre,	Aarhus	University	Hospital,	Denmark.	For	comparison	of	PET	studies,	in-house	PET	
data	from	29	healthy	controls	subjects	were	included,	20	healthy	controls	with	11C-PK11195	
PET	and	9	with	18F-DOPA	PET.	These	control	subjects	have	been	previously	recruited	
recruited	219.			
5.8a	PET	and	MRI	
	
	
In	 brief,	 PET	 scans	 were	 performed	 on	 an	 ECAT	 HRRT	 CTI/Siemens	 system	 with	 an	
intravenously	injection	of	tracer	and	dynamic	PET	images	were	obtained	for	60.5	and	94.5	
minutes	and	subsequently	rebinned	 into	24	and	26	frames,	 for	11C-PK11195	and	18F-DOPA	
respectively.	 One	 hour	 prior	 to	 18F-DOPA	 PET	 an	 oral	 150	 mg	 dose	 of	 carbidopa	 was	
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administered	 to	 the	 participants.	 Both	 image	 series	 were	 reconstructed	 using	 3D	 OSEM	
(ordered	subsets	expectation	maximization)	and	resolution	recovery	modelling	(PSF)	with	10	
iterations	and	16	subsets.	Reconstructed	 images	consisted	of	207	axial	 image	slices	with	a	
1.22	mm	voxel	size.	Each	study	participant	had	a	structural	MRI	3D	sequence	performed	for	
co-registration	of	PET	images	(3	T	MAGNETOM	Skyra	or	Trio,	Siemens	Healthcare).	
	
5.8b	Image	analysis	
	
	
PET	images	were	examined	with	a	region	of	interest	(ROi)	approach	using	the	PNEURO	
module	in	PMOD	software	v	3.6	(PMOD	technologies	Ltd.	Switzerland)	and	at	a	voxel	level	
using		Statistical	Parametric	Mapping	(SPM12,	Wellcome	Trust	Centre	for	Neuroimaging,	
UCL).	Image	analysis	was	performed	as	previously	described	219.	In	brief,	parametric	maps	
with	regional	binding	potentials	(BPND)	and	influx	constants	(Ki)	were	generated	for	the	11C-
PK11195	and	18F-DOPA	PET	images,	respectively.	It	is	reasonable	to	expect	that	microglial	
activation	may	be	present	throughout	the	brain	in	a	population	at-risk	of	developing	
neurodegenerative	disorders.	In	view	of	this,	one	cannot	depend	on	an	anatomic	brain	
region	devoid	of	specific	ligand	binding	to	be	used	as	reference	region.	Therefore,	we	used	
the	supervised	cluster	analysis	to	extract	an	individual	reference	tissue	non-specific	input	
function	and	the	simplified	reference	tissue	model	219	to	generate	parametric	BPND	maps	
with	11C-PK11195.		The	18F-DOPA	parametric	maps	with	influx	constants	(Ki)	were	generated	
using	the	Patlak	graphical	approach	with	occipital	lobe	grey	matter	as	a	non-specific	
reference	tissue	input	function.	The	equilibration	time	was	set	to	25	minutes.	Image	analysis	
was	carried	out	by	Dr	Morten	Stokholm.	
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5.8c	Selection	of	regions	of	interest	
	
The	caudate	and	putamen	have	been	established	to	be	the	most	sensitive	areas	of	the	brain	
for	detecting	dopaminergic	loss	using	the	18F-DOPA	ligand	and	hence	were	selected	as	sole	
regions	of	interest	for	the	18F-DOPA	analysis.	11C-PK11195	is	an	experimental	ligand	which	
binds	in	the	presence	of	migroglial	activation.	Previously	signal	was	increased	amongst	early	
Parkinson	disease	cases	across	the	basal	ganglia,	therefore	the	pallidum,	caudate	and	
substantia	nigra	were	selected	as	regions	which	were	representative	of	this	region.		
	
5.8d	Statistical	analysis	
	
Statistical	analyses	and	graphs	were	performed	on	Stata	v14.2	(StataCorp	4905	Lakeway	Dr.,	
College	Station,	TX	77845).	Distributions	of	DOPA	and	11C-PK11195	signal	intensity	and	
Parkinson	disease	prodromal	assessments	were	assessed	by	visual	inspection.	Because	all	
distributions	could	not	consistently	be	confirmed	to	be	parametric	DOPA	and	PK	signal	for	
specified	regions	of	interest	were	compared	in	carrier	and	control	groups	using	the	
Wilcoxon	Rank	sum	test	(p<0.05).	Secondary	analyses	were	undertaken	correlating	18F-
DOPA	/11C-PK11195	signal	intensity	with	prodromal	risk	scores,	GCase	activity,	number	of	
severe	mutatations	possessed	and	serum	ELISA	quantification	of	levels	of	alpha	synuclein,	
IL6,	IL8,	TNF	alpha	(Spearman’s	rank	test,	p<0.05).		Statistical	analysis	was	carried	out	by	SM.	
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5.9	Results	(PET	imaging)	
	
	
Nine	GBA	positive	carriers	(5	biallelic	and	4	heterozygote)	and	29	age	and	sex	matched	
controls	were	included	in	the	final	analysis.	Demographics	and	clinical	characteristics	of	the	
GBA	positive	and	control	participants	are	listed	in	table	1.		Genotypes	of	the	GBA	carriers	
are	listed	in	table	2.		
	
	
Table	1.	Characteristics	of	control	and	GBA	carrier	groups	
	 Bi-allelic	
GBA	
Heterozygous	
GBA	
Combined	
GBA		
Control	
(PK11195)	
Control	
(F-DOPA)	
N	 5	 4	 9	 20	 9	
mean	age	[median]	
(yr)	
64.5	 62	 63.5	 66.5	 64.7	
male	(%)	 50.0	 40.0	 44.4	 55	 56	
%	with	a	severe	
mutation	
60.0	 50.0	 55.5	 -	 	
mean	UPSIT	
[median]	
33.5	[33.5]	 32.0	[31]	 32.7	[33]	 -	 	
mean	MoCa	
[median]	
27.0	[26]	 28.0	[29]	 27.6	[27]	 -	 	
mean	MMSE	
[median]	
29.8	[30]	 27.6	[28]	 28.6	[29]	 -	 	
mean	UPDRS	II	
[median]	
1.8	[1]	 3.0	[3]	 2.4	[2]	 -	 	
mean	UPDRS	III	
[median]	
13.3	[10]	 5.8	[6]	 9.1	[6]	 -	 	
mean	BDI	[median]	 2.5	[3]	 3.4	[4]	 3.0	[3.2]	 -	 	
mean	NMSS	
[median]	
10.5	[13.25]	 16.8	[16]	 15.2	[15]	 -	 	
mean	GCase	activity	
[median]	
1.34	[1.34]	 8.53	[7.52]	 4.77	
[1.98]	
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Table	2.	Mutations	of	GBA	carrier	group;	*denotes	severe	mutation,	**denotes	null	
mutation	
Biallelic		 Heterozygous			
N370S/L444P*	 N370S/wt	
N370S/IVS	2+1*	 N370S/wt	
N370S/F216Y	 V394L*/wt	
N370S/R359X**	 RecNcil	(L444P/A456P/V460V)*/wt	
N370S/V447E	 	
	
5.9a	GBA	carriers	exhibit	microglial	activation	restricted	to	substantia	nigra	but	without	
evidence	of	dopaminergic	loss	
	
Of	the	regions	of	interest	surveyed	(full	breakdown	in	table	3)	only	the	substantia	nigra	
showed	a	significant	increase	in	11C-PK11195	uptake	(Wilcoxon	rank	sum,	left	p=0.0008,	
right	p=0.0016)	amongst	GBA	carriers	compared	to	controls	(Figure	1).	Increased	nigral	
uptake	was	relatively	consistent	across	the	GBA	group	compared	to	controls	(Figure	1).	The	
specificity	of	the	increase	in	glial	activation	is	intriguing.	One	might	expect	a	more	
generalised	increase	in	PK11195	uptake	in	these	patients,	but	the	very	defined	increase	in	
inflammation	in	the	region	most	prominently	affected	neuropathologically	in	Parkinson	
disease	implies	that	some	as	yet	unknown	factor	makes	the	region	especially	prone	to	glial	
activation	of	this	type.	There	is	already	a	substantial	literature	on	the	selective	vulnerability	
of	this	and	other	regions	preferentially	affected	in	Parkinson	disease	77,220,221.	Whatever	its	
underlying	basis,	the	implication	of	these	findings	is	that	to	some	extent,	the	biochemical	
process	that	lead	to	Parkinson	disease	conversion	is	ongoing	to	a	variable	extent	in	the	vast	
majority	of	GBA	Parkinson	disease	carriers	with	the	caveat	that	in	only	a	proportion	will	it	be	
sufficient	to	cause	the	development	of	motor	Parkinson	disease	features	14.	There	was	no	
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Fig	1.	Box	plots	of	PK11195	uptake	
in	the	left	and	right	substantia	of	
control	and	GBA	carrier	participants
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Fig	2.	scatter	plot	showing	DOPA	uptake	(x)	PK11195	uptake	(y)	in	left	(red)	and	right	(blue)	Putamen	(left)	and	Caudate	
(right)	of	GBA	carriers	
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correlation	between	nigral	PK11195	with	Putamen	(left	p=0.8984,	right=0.9322)	or	Caudate	
(left	p=0.9661,	right	0.9661)	L-DOPA	signal	(scatter	graph	Fig.	2),	implying	that	the	
inflammation	is	independent	(or	possibly	in	advance)	of	dopaminergic	loss.		
	
Table	3.	p	values	for	comparison	(Spearman’s	rank)	of	DOPA	and	PK11195	signal	in	GBA	
carrier	and	control	group	(p<0.05)	
	 DOPA	(left)	 DOPA	(right)	 PK11195	(left)	 PK11195	(right)	
Substantia	nigra	 -	 -	 p=0.0008	 p=0.0016	
Putamen	 p=0.681	 p=0.509	 p=0.220	 p=0.220	
Caudate	 p=0.719	 p=0.627	 p=0.300	 p=0.509	
	
5.9b	Increase	in	nigral	11C-PK11195	uptake	correlates	with	deficits	in	olfaction	amongst	GBA	
carriers	
	
There	was	a	negative	correlation	between	nigral	11C-PK11195	uptake	and	UPSIT	score	(left	
p=0.0058,	right=0.0317	Figure	3).	There	were	no	other	significant	correlation	for	the	other	
prodromal	Parkinson	disease	features	assessed	(full	details	in	table	4).	It	is	certainly	
noteworthy	that	the	only	correlation	obtained	in	these	analyses	was	with	the	degree	of	
olfactory	loss.	Hyposmia	has	been	shown	to	be	increased	in	established	Parkinson	disease	
subjects	compared	to	controls	222,223	and	as	we	saw	in	the	previous	chapter	is	consistently	
worse	and	deteriorates	at	a	faster	rate	amongst	GBA	carriers.	Anatomically	the	olfactory	
nucleus	and	substantia	nigra	are	spatially	close	within	the	upper	mesencephalon	and	direct	
projection	are	present	from	the	olfactory	nucleus	to	the	striatal	system.224.	It	therefore	
seems	plausible	that	nigral	glial	activation	projects	to	the	olfactory	nucleus	and	bulb	and	is	
either	causative	of	or	a	result	of	underlying	neurodegeneration	in	both	regions.	
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Fig	3.	scatter	plot	of	
correlation	of	UPSIT	score	
(x)	PK11195	uptake	(y)	in	
left	(red)	and	right	(blue)	
substantia	nigra amongst	
GBA	carriers	
1
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
-.2
-.1
0
.1
.2
.3
PK
11
19
5 
up
ta
ke
28 30 32 34 36 38
UPSIT score
right left
substantia nigra PK11195 uptake plotted against UPSIT score
Stephen	Mullin	–	PhD	thesis	
	
	
134	
	
	
	
	
	
	
	
	
	
	
	
	
5.9c	GCase	activity	is	positively	correlated	with	nigral	11C-PK11195	uptake	
	
There	was	a	positive	correlation	between	GCase	activity	and	nigral	11C-PK11195	uptake	on	
the	right	(p=0.0159)	and	strong	trend	on	the	left	(p=0.0769).	This	is	a	puzzling	finding	given	
the	established	literature.	Reduced	GCase	activity	as	has	been	discussed	previously	is	
thought	to	be	implicated	in	the	pathological	mechanism	under	Parkinson	disease	conversion	
in	both	idiopathic	Parkinson	disease	and	in	terms	of	Parkinson	disease	risk	amongst	GBA	
carriers.	This	correlation	must	be	treated	with	caution.	Biallelic	GBA	carriers	have	extremely	
low	GCase	activity	whilst	heterozygotes	have	much	higher	levels	on	account	of	the	
remaining	wild	type	allele.	In	this	population,	this	has	resulted	in	a	binomial	distribution	
(Figure	4)	which	may	have	given	rise	to	a	false	correlation	(Fig	5).	Alternatively	this	may	
provide	evidence	of	a	potential	neuroprotective	effect	associated	with	the	glial	activation	at	
the	substantia	nigra.
Table	4.	p	values	for	correlation	(Wilcoxon	rank	sum)	of	nigral	PK11195	
signal	and	prodromal	Parkinson	disease	feature	assessment	scores/	
putative	Parkinson	disease	biomarkers	(p<0.05)	
	 left	 right	
UPSIT		 p=0.006	 p=0.031	
Blood	leucocyte	GCase	activity	 p=0.076	 p=0.016	
MoCa		 p=0.192	 p=0.174	
RBDSQ	 p=0.379	 p=0.328	
BDI		 p=0.542	 p=0.095	
MMSE	 p=0.423	 p=0.110	
UPDRS	II	 p=0.343	 p=0.525	
UPDRS	III		 P=0.764	 p=0.813	
NMSS	 p=0.949	 p=0.177	
	severe/null	mutation	 p=0.379	 p=1.000	
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5.9d	No	deficits	in	18F-DOPA	signal	amongst	GBA	carriers	
	
There	were	no	significant	decrements	in	18F-DOPA	uptake	amongst	GBA	carriers	compared	
to	controls.	There	did	not	appear	to	be	a	correlation	between	the	increase	nigral	11C-
PK11195	and	putamen	(left	p=0.898,	right=0.932)	or	caudate	18F-DOPA	reduction	in	the	GBA	
group	(left	p=0.9661,	right	p=0.9661).	Interestingly	there	was	substantial	variability	of	DOPA	
signal	in	both	the	putamen	and	caudate	compared	to	the	control	group	with	highest	and	
lowest	DOPA	signals	within	the	study	recorded	amongst	a	portion	of	the	GBA	carrier	
participants	(Figure	6).	Upregulation	of	DOPA	signal	has	been	recorded	in	other	‘at	risk’	
Parkinson	disease	groups	other	studies	225.		Speculatively	this	might	represent	a	positive	
feedback	mechanism	in	the	context	of	ongoing	(but	not	complete)	dopaminergic	neuronal	
damage,	although	I	must	stress	we	have	no	evidence	to	support	this	hypothesis.	Normal	
DOPA	scans	are	common	in	the	context	of	established	idiopathic	Parkinson	disease	226-228,	
therefore	it	is	not	surprising	that	in	the	these	patients,	who	are	largely	free	of	motor	
features	of	Parkinson	disease,	these	scans	are	otherwise	broadly	unremarkable.	In	terms	of	
potential	neuroprotective	interventions	these	findings	are	encouraging,	as	they	show	that	in	
those	with	possible	prodromal	signs	of	Parkinson	disease	the	dopaminergic	system	is	still	
broadly	intact	and,	plausibly,	could	be	saved	if	some	mechanism	to	halt	the	underlying	
pathological	process	were	found.		
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Fig	6.	Box	plots	of	DOP	uptake	in	the	left	and	right	Caudate	(left)	and	Putamen	(right)	of	control	and	GBA	carrier	participants
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5.10	Peripheral	markers	of	neurodegeneration	and	inflammation	as	putative	biomarkers	of	
Parkinson	disease	conversion	amongst	GBA	carriers	
	
Given	the	literature	described	in	the	introduction	to	this	chapter	and	the	focal	glial	
activation	found	using	the	PK11195	ligand,	we	endeavoured	to	find	out	whether	there	was	
evidence	of	peripheral	immune	dysregulation	and	or	other	markers	of	neurodegeneration	in	
GBA	carriers	compared	to	controls	and	whether	these	increases	correlated	with	Parkinson	
disease	prodromal	features	amongst	GBA	carriers.		
	
5.11	Aims	(ELISA	biomarkers)	
	
1) To	understand	whether	IL6,	IL8,	TNF	alpha,	alpha	synuclein	and	tau	were	
upregulated	amongst	GBA	carriers	compared	to	controls	in	blood	serum.	
2) To	ascertain	whether	the	above	biomarkers	correlated	with	the	presence	of	
prodromal	Parkinson	disease	features,	number	of	severe	mutations	or	GCase	
activity.	
	
5.12	Methods	(ELISA	biomarkers)	
	
We	collected	serum	(11	heterozygotes,	28	biallelic)	of	39	members	of	the	existing	cohort	
supplemented	by	27	controls,	17	heterozygous,	39	homozygous,	19	idiopathic	Parkinson	
disease	and	7	GBA	Parkinson	disease	subjects.		We	measured	concentrations	of	three	
cytokines	(Interleukin	6,	interleukin	8	and	TNF	alpha)	which	have	been	previously	been	
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suggested	to	be	upregulated	in	Parkinson	disease	along	with	the	established	
neurodegenerative	markers	alpha	synuclein	and	tau.		
	
Separately	we	collected	blood	leucocyte	pellets	and	carried	out	a	GCase	activity	assays	on	
59	samples	(12	controls,	21	heterozygotes,	26	biallelic-	charactersitics	table	5).	Of	these	
there	were	ELISA	and	GCase	data	available	for	14	biallelic	and	5	hetrozygote	carriers	only	for	
whom	qualification	of	ELISA	biomarkers	had	been	carried	out.	Samples	were	collected	by	
SM	and	Dr	Michelle	Beavan,	analysis	was	carried	out	on	our	behalf	in	the	laboratories	of	
Henrik	Zetterberg.	GCase	assays	were	carried	out	by	Dr	Marco	Toffoli	and	Dr	Micol	Avenali.	
	
Median	values	of	the	levels	of	these	cytokines	in	each	respective	group	are	shown	below	
together	with	the	demographics	of	each	group	(table	5).	Because	of	the	relatively	small	
study	numbers	and	the	large	number	of	study	groups,	we	kept	comparisons	to	a	minimum,	
opting	to	carry	out	one	primary	analysis,	namely	a	comparison	of	control	participants	with	a	
combined	group	of	GBA	carriers.	In	the	event	of	significant	correlations	we	carried	out	a	
further	subset	analysis	comparing	biallelic	and	heterozygous	groups	individually	with	
controls.	For	each	cytokine	we	also	attempted	to	correlate	levels	with	the	combined	risk	
score	derived	from	UPSIT,	MOCA	and	BDI	scores	(see	chapter	3,	section	3.2b).	We	carried	
out	further	subset	analyses	correlating	biomarkers	levels	with	GCase	activity	and	with	the	
number	of	severe	mutations.	
	
	Because	there	was	substantial	variation	in	the	age	and	sex	of	participants	we	opted	to	use	
an	ordinal	regression	model	(see	chapter	2)	taking	into	account	age	and	sex	for	all	analyses.	
This	was	also	necessary	as	the	for	ELISA/GCase/number	of	severe	mutations	the	data	was	
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not	consistently	parametric.	In	the	case	of	the	ELISA	samples	upper	and	lower	limits	of	
sensitivity	of	the	assay	also	precluded	the	use	of	parametric	statistical	tests.	To	do	this	we	
divided	the	continuous	outputs	into	10	equal	strata	scores,	low	to	high:	0-10)		In	the	analysis	
looking	at	cytokine	levels	and	risk	score	we	also	included	family	history	of	Parkinson	
disease/dementia	and	smoking	status	as	coovariates.	
	
Table	5.		Demographics	and	median	levels	of	serum	ELISA	assays	measured.	
	 control	 heterozygous	
GBA	
biallelic	GBA	 Idiopathic	
Parkinson	
disease	
GBA	
Parkinson	
disease	
n	 27	 17	 39	 19	 7	
age	median	 64	 60	 5	2	 75	 69	
%	male	 65	 55	 53	 57	 79	
IL6	median	 0.542	 0.690	 0.685	 0.716	 1.045	
IL8	median	 11.70	 11.58	 13.42	 10.67	 10.28	
TNFa	median	 1.74	 1.88	 1.87	 1.60	 2.35	
alpha	synuclein	 17599	 17077	 26188	 18167	 13969	
tau	 0.417	 0.631	 0.448	 0.985	 0.360	
		
Table	6.	Statistical	comparisons	using	biomarkers	
	 Comparison	of	GBA	group	with	
controls	
Correlation	with	combined	risk	score	
of	participants	
IL6	 OR	1.82	[95%CI	0.76-4.35]	
p=0.173	
OR	1.04	[0.865-1.27]	p=0.628		
IL8	 OR	3.51	[1.18-10.37]	p=0.023	 OR	0.90	[0.674-1.20]	p=0.488	
IL8	(subset)	 bialleic	
OR	5.45		
[1.85-16.0]	
p=0.002	
heterozygous	
OR	4.13		
[1.21-14.05]	
p=0.023	
	
TNF	alpha	 0.68	[0.14-3.34]	p=0.653	 OR	0.93	[0.479-1.81]		p=0.838	
alpha	
synuclein	
1.78	[95%CI	0.59-2.94]	p=0.109	 OR	1.4	[1.04-4.95]	p=0.025.	
tau	 OR	2.2	[1.41-3.92]	p=0.055	 OR	1.6	{0.84-2.74]	p=0.111	
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Table	7.	Correlations	of	biomarkers	with	number	of	severe	mutations	
	 OR	[95%	CI]	p	value	(<0.05)	
alpha	synuclein	 OR	5.33	[1.68	-16.85]	p=0.004	
tau	 OR	1.88	[0.79-4.5]	p=0.153	
IL6	 OR	1.29	[0.54	–	3.05]	p=0.567	
IL8	 OR	1.94	[0.775-4.85]	p=0.157	
TNF	alpha	 OR	1.87	[0.752-4.68]	p=0.177	
	
5.13	Results	(ELISA	biomarkers)	
	
Summary	statistics	for	all	analyses	undertaken	are	shown	in	tables	6	and	7.	The	ELISA	assays	
were	carried	out	on	our	behalf	by	the	laboratories	of	Prof.	Henrik	Zetterberg.	
	
5.13a	Interleukin	8	is	upregulated	in	GBA	subjects	compared	to	controls	
	
The	only	significant	increase	found	in	the	GBA	versus	control	group	was	interleukin	8.	
Subset	analysis	showed	this	was	increased	amongst	both	heterozygous	and	bi	allelic	
participants	compared	to	controls.	This	finding	is	interesting	although	what	relevance	it	has	
to	the	course	of	Parkinson’s	is	debatable.	The	primary	driver	of	this	trend	are	Gaucher	
patients	and	immune	dysregulation	has	previously	been	documented	amongst	them.	None	
the	less	the	fact	it	was	present	also	amongst	carriers	is	revealing	although	the	lack	of	
relationship	to	the	risk	score	of	prodromal	features	implies	it	may	not	correlate	with	central	
immune	dysregulation.	Such	evidence	of	immune	upregulation	in	asymptomatic	GBA	
carriers	does	imply	that	that	these	processes	are	ongoing	within	these	patients.	
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5.13b	Serum	alpha	synuclein	levels	correlate	with	severity	of	prodromal	Parkinson	disease	
features	and	number	of	severe	mutations	present		
		
There	was	a	trend	towards	an	increase	in	alpha	synuclein	amongst	the	GBA	group	(OR	1.78	
[95%CI	0.59-2.94]	p=0.109)	and	a	correlation	with	the	combined	risk	score	OR	1.4	[1.68-	
16.85]	p=0.025).	Moreover,	alpha	synuclein	levels	correlated	strongly	with	the	number	of	
severe	Gaucher	causing	mutations	possessed	by	a	participant	(OR	5.33	[1.68	-16.85]	
p=0.004,	Fig	7).			These	correlations	are	interesting	and	add	further	weight	to	the	
hypothesized	link	between	alpha	synuclein	upregulation	amongst	GBA	mutation	carriers.	
The	significance	of	alterations	in	blood	synuclein	levels	is	unclear.	Variously	serum	synuclein	
levels	have	been	shown	to	upregulated	and	downregulated	is	idiopathic	Parkinson	disease	
populations	229-232.	Given	the	increased	risk	of	Parkinson	disease	that	severe	GBA	mutations	
convey,	they	imply	a	direct	role	for	synuclein	in	the	pathogenesis	of	GBA	Parkinson	disease.		
	
There	is	no	clear	evidence	as	to	what	the	relationship	between	serum	synuclein	and	
Parkinson’s	is	or	indeed	whether	peripheral	upregulation	correlates	with	central	
upregulation.		Plausibly	increases	in	serum	synuclein	may	be	representative	of	removal	of	
the	protein	from	the	intracellular	compartment,	which	may	be	a	direct	result	of	the	failure	
of	the	autophagic	pathway	to	process	the	protein	adequately	62,65.	There	are	precedents	for	
such	findings.	Amongst	heterozygous	carriers	of	the	complete		penetrance	autosomal	
dominant	SNCA	triplication	gene,	SNCA	was	found	to	be	upregulated	in	both	serum	and	
brain	lysates,	albeit	the	brain	and	blood	samples	were	from	different	subjects	and	study	
numbers	were	low.229		In	recent	years	evidence	has	accumulated	that	alpha	synuclein	and	
oligomeric	alpha	synuclein	in	particular	transfer	directly	between	cells,	contributing	to	the	
observed	prion	like	propagation	of	the	protein.233	Alpha	synuclein	has	been	shown	to	be	
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exported	in	exosomes	and	increases	intracellularly	upon	blockage	of	lysosomal	pathway	234.	
From.	Exosomal	independent	pathways	have	also	been	implicated	in	this	process..	235,236.	
There	is	the	suggestion	that	the	aggregated	and	fibrillar	forms	are	preferentially	exocytosed	
from	the	cell,	implying	this	is	a	mechanism	to	remove	toxic	forms	of	the	protein.236	
Significantly	exocytosed	alpha	synuclein	levels	are	increased	amongst	GBA	knockout	cell	
lines	237.		
	
5.13c	GCase	activity	correlations	with	ELISA	biomarkers	
	
We	were	able	to	carry	out	GCase	activity	assays	in	a	subset	of	the	patients	who	were	part	of	
the	biomarkers	experiment.	Demographics	and	summary	statistics	of	GCase	activity	are	
shown	in	table	8	below.		
	 CTL	 HET	 BIA	
N	 5	 6	 6	
Median	age	 59	 62	 54	
%	male	 60	 50	 50	
Table	8.	Characteristics	of	participants	where	GCase	activity	was	measured	
	
A	summary	of	the	analyses	undertaken	is	presented	in	Table	9.	As	would	be	expected,	
GCase	activity	was	significantly	different	across	the	three	groups	(Kruskal	Wallis	p=0.0012,	
Fig	8)	and	followed	an	expected	pattern	in	proportion	to	the	number	GBA	mutations	
carried.	We	attempted	to	correlate	GCase	activity	with	levels	of	the	following	ELISA	
biomarkers	amongst	GBA	positive	participants	(Table	10).	The	only	significant	correlation	
seen	was	with	IL6	(p=0.026,	Fig.	9).	The	result	is	interesting	as	it	implies	reduced	GCase	
activity	may	contribute	to	an	upregulation	of	peripheral	immune	response,	although	the	
result	must	be	treated	with	significant	caution	as	there	are	no	consistent	increases	across	
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the	analyses	undertaken	with	IL6,	nor	across	the	full	range	of	cytokines	tested.	It	is	
interesting	that	no	correlation	is	present	between	leucocyte	GCase	activity	and	alpha	
synuclein.	In	vitro	inverse	correlations	have	been	observed	in	a	number	of	model	systems.		
It	may	be	this	discrepancy	is	a	result	of	variation	between	GCase	activity	levels	in	the	central	
nervous	system	and	peripheral	leucocytes	(see	chapter	8),	or	that	this	this	correlation	is	in	
fact	not	causal.		
Table	9.	Correlations	of	biomarkers	and	GCase	activity	
	 OR	[95%	CI]	p	value	(<0.05)	
IL6	 0.76	[0.60-0.96]	p=0.026	
alpha	synuclein	 1.07	[0.85-1.36]	p=0.546	
tau	 0.99	[0.81-1.21]	p=0.956	
IL8	 0.92	[0.742	-	1.16]	p=0.516	
TNF	alpha	 0.95	[0.79-1.16]	p=0.642	
	
5.14	A	hypothesis	generating	screen	of	urine	for	novel	biomarkers	of	GBA	Parkinson	disease	
conversion	
	
In	contrast	to	the	hypothesis	based	approaches	described	above	we	used	a	hypothesis	
generating	proteomics	screen	in	order	to	identify	novel	biomarkers	of	Parkinson	disease	
conversion.	Urine	was	chosen	as	the	platform	for	this	screen	because	lipid	rich	components	
of	glycosphingolipid	pathway	are	particularly	abundantly	excreted	in	acidic	conditions	of	
urine	238-240.		
We	compared	control	samples	(n=5	median	age	58,	3	Males,	2	Females),	GBA	bi-allelic	(n=	
17,	median	age	52,	10	Males,	7	Females),	GBA	heterozygotes	(n=8		median	age	58.5	,	1	
Males,	7	Females)	and	a	combined	cohort	of	GBA	samples	dichotomised		into	a	high	risk	
(risk	score	>/=	1.5,	n=	7	median	age	52,	4	Males,	3	Females)	or	a	low	risk	(risk	score	<1.5,	
n=21,	median	age	55.5,	7	Males,	11	Females).	Mutations	carried	in	these	groups	are	shown		
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in	table	11	and	their	prodromal	risk	scores	are	shown	in	table	12.	These	analyses	were	
carried	out	on	our	behalf	by	Dr.	Wendy	Heywood.	Sample	preparation	was	performed	as	
described	previously	241.	Urine	was	thawed,	centrifuged	and	filtered	using	a	3	kDa	filter	
(Millipore,	UK).	Desalted	urine	was	protein	assayed	by	BCA	(Sigma	UK).	25	mg	of	protein	
was	freeze	dried,	trypsin	digested.	Yeast	enolase	peptide	internal	standard	(Waters	Corp.	
Milford,	MA)	was	added	to	digests	to	a	final	concentration	of	50	fmol/ml	and	the	digests	
desalted	prior	to	analysis	using	C18	solid	phase	extraction	(Agilent,	UK).	Digested	peptides	
were	re-suspended	in	3%	ACN,	0.1%	TFA	and	analysed	on	a	Waters	Synapt	G2	Si	HD	mass	
spectrometer	coupled	to	a	2D	NanoAquity	UPLC.	Online	high	pH-low	pH	fractionation	was	
performed	over	2	fractions	(19	and	50%	ACN)	on	a	85	min	LC-MSe	analyses	as	described	
previously	in	our	laboratory.242	Proteins	were	identified	and	analysed	for	differential	
expression	using	Non-linear	dynamics	Progensis	QI	with	a	downloaded	UniProt	human	
reference	proteome	database	to	which	the	sequence	of	P00924	yeast	enolase	and	P00761	
porcine	trypsin	were	added	manually.	Fixed	modifications	of	carboamidomethylation	of	
cysteines,	dynamic	modifications	of	deamidation	of	asparagine/glutamine	and	oxidation	of	
methionine,	up	to	2	missed	cleavage	sites	and	false	discovery	rate	set	at	4%	mass	tolerance	
for	ion	and	fragments	were	set	to	auto.	Only	protein	identifications	with	>95%	confidence	
and	more	than	1	peptide	were	included	in	the	differential	expression	analysis.	A	two	way	
analysis	of	covariance	test	with	a	false	discovery	rate	correction	for	multiple	comparisons	
243	was	used	to	determine	differences	in	protein	expression	between	controls	vs	bi-	allelic	
carriers/heterozygous	carriers,		bi-allelic	vs	heterozygous	carriers	and	high	vs	low	risk	GBA	
carriers.	Samples	were	obtained	by	SM	and	Dr	Michelle	Beavan.	Samples	were	analysed	on	
out	behalf	by	Jenny	Hallqvist.	
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5.15	Results	(hypothesis	generating	screen)	
	
Five	proteins	were	upregulated	in	the	high	risk	versus	low	risk	groups.	These	results	are	
shown	in	table	10.		Each	of	these	candidate	proteins	is	considered	separately	below.	
	
Protein	name	 Gaucher	
disease	vs	
control	
het	vs	control	 Gaucher	
disease	vs	
het	
High	vs	low	
Ig	kappa	V-I	region	AU	 OR	3.51	
p=0.005	
OR	3.16	
p=0.002	
ns	 OR	3.35		
p=0.003	
Isoform	of	Tyrosin	protein	
phosphate	non	receptor		6		
ns	 ns	 ns	 OR	0.62	
P=0.004	
Neutrophil	defensin	1	 ns	 ns	 ns	 OR	0.03	
P=0.005	
Guanlylin	 OR	4.41		
p=0.003	
ns	 ns	 OR	2.05			
p=0.031	
Ig	kappa	V-I	region	Ni	 OR	2.79		
p=0.025	
ns	 ns	 OR	3.52		
p=0.023	
Table	10.	Summary	of	proteomics	analyses	undertaken	
	
5.15a	Ig	kappa	V-L	region	AU	and	Ni	
	
Both	proteins	are	constituent	parts	of	the	variable	region	Ig	kappa	light	chain	produced	by	B	
cells	as	part	of	the	humoral	immune	response.	This	region	determines	the	antigenic	
characteristic	of	the	resulting	immunoglobulin.		Increases	in	both	proteins	imply	the	
presence	of	these	patients	of	a	monoclonal	or	polyclonal	gammopathy.	In	Gaucher	disease	
this	has	been	described	as	has	the	increase	in	frequency	of	malignancies	associated	with	it,	
in	particular	multiple	myeloma	but	also	chronic	lymphocytic	leukemia	and	b	cell	lymphoma	
210,244.		
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Table	11.	Mutations	present	amongst	the	high	and	low	risk	GBA	groups	
low	risk	 high	risk	
L444P/F216Y	 R463C/R463C	
N370S/R120W	 N370S/R359X	
N370S/N370S	 L444P/R463C	
N370S/L105R	 N370S/N370S	
N370S/L444P	 N370S/D409H	
R469H/R359X	 595-596delCT	c.595_596delCT	
p.Leu199AspfsX62	
RecNcil/R262G	+	S271G	 N370S/wt	
N370/L444P	 	
N370S/L444P	 	
D409H/D409H	 	
595-596delCT	c.595_596delCT	
p.Leu199AspfsX62	
	
N370S/wt	 	
G250V/wt	 	
D409H/D409H	 	
N370S/wt	 	
c.1388+1	G>A	 	
N370S/wt	 	
L444P/wt	 	
L444P/wt	 	
	
	
	
Table	12.	Prodromal	risk	scores	of	high	and	low	risk	groups	at	last	assessment.	
	 Low	risk	 High	risk	
UPSIT	median	 30	 26	
MoCa	median	 27	 23.5	
UPDRS	II	median	 1	 4	
UPDRS	III	median	 5	 9	
BDI	median	 3.5	 6	
	
	
Typically	around	only	0.001%	of	plasma	immunoglobulins	cross	the	blood	brain	barrier,	
hence	it	is	unlikely	that	the	increase	in	these	light	chain	is	derived	from	the	central	nervous	
system	245.	Nonetheless,	data	derived	from	fragments	of	monoclonal	antibodies	targeted	at	
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the	A	beta	42	protein	showed	that	even	at	these	microscopic	concentrations,	fragments	of		
intravenously	administered	immunoglobulin	were	able	to	activate	glial	to	produce	a	highly	
specific	central	nervous	system		immune	response	against	the	protein	246.	In	the	case	of	one	
of	the	monoclonal	antibodies	(AN1792),	6%	of	those	administered	the	antibody	developed	a	
meningoencephalitis,	which	is	indicative	of	the	magnitude	of	the	immune	can	produce	247.		
	
The	correlation	therefore	increases	in	Ig	kappa	with	those	with	the	worst	prodromal	
features	of	Parkinson	disease	is	interesting	although	its	significance	remains	to	be	seen.	
Plausibly,	the	gammopathy	peripherally	may	be	indicative	of	a	concurrent	central	nervous	
system	immune	activation.	If	this	is	the	case	IgG	Kappa	light	chain	components	may	have	
utility	as	potential	biomarkers	of	early	Parkinson	disease	and	potentially	disease	
progression.		
	
5.15b	Neurophil	Defensin	1	
	
Neurophil	defensin	1	is	a	cytotoxic	peptide	which	is	abundant	in	granules	of	neutrophils	and	
is	widely	expressed	in	intestinal,	respiratory	and	urinary	tract	epithelia.		It	is	an	effective	
cytotoxin	against	a	variety	of	prokaryotic	and	eukaryotic	cell	types248.	In	recent	years	the	
role	of	the	microsomal	pathogens	in	Parkinson	disease	has	been	in	the	news.	The	work	of	
Braak	and	other	suggests	a	progression	of	synuclein	pathology	from	the	gut	to	the	midbrain	
via	the	vagus	nerve	and	various	other	autonomic	and	non	autonomic	nerve	ganglions	162,249.	
Synuclein	pathology	has	been	identified	decades	in	advance	of	the	development	of	motor	
Parkinson	disease	in	a	number	of	studies	250,251.		Gut	inflammation	has	been	described	in	
Parkinson	disease	patients	and	expression	of	various	cytokines	has	been	shown	to	be	
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upregulated	amongst	these	patients	252.	It	has	been	suggested	that	this	is	a	reflection	of	
aberrant	gut	flora	and	faecal	transplant	has	even	been	suggested	as	a	viable	
neuroprotective	strategy	253.	Colonic	biopsy	has	been	suggested	to	be	a	potential	
mechanism	for	diagnosis	of	the	prodromal	phase	of	Parkinson	disease.	Should	urinary	
neutrophil	defensin	in	fact	turn	out	to	be	a	correlate	of	gut	inflammation	this	could	serve	as	
a	cheap	and	non	invasive	biomarker	of	Parkinson	disease	development.	
	
5.15c	Guanylin		
	
Guanylin	is	an	endogenous	protein	hormone	which	activates	the	guanylate	cyclase	enzyme.	
Its	predominant	function	is	thought	to	be	regulation	of	intestinal	natriuretic	peptides	and	in	
turn	regulation	of	natriusis,	kaliuresis	and	diuresis	in	the	kidneys.	It	is	expressed	within	the	
central	nervous	system	but,	to	date,	has	not	been	associated	with	any	neurological	disease.	
It	is	known	to	be	implicated	in	a	number	of	diseases	including	cystic	fibrosis,	asthma,	
intestinal	cancer,	kidney	failure,	heart	failure	and	the	metabolic	syndrome	254.	It	is	unclear	
what	relevance	the	pathway	has	to	our	existing	understanding	of	Parkinson	disease	
pathogenesis.		
	
5.16	Concluding	remarks	
	
This	chapter	has	described	a	variety	of	studies	aimed	at	developing	novel	biomarkers	of	
Parkinson	disease	conversion.	Perhaps	the	most	striking	finding	is	that	PET	imaging	studies	
reveal	focal	inflammation	of	the	substantia	nigra	of	GBA	carriers	in	the	absence	of	any	
definable	dopaminergic	loss.	The	correlation	of	this	glial	activation	with	the	olfactory	deficits	
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of	the	participants	implies	that	it	is	indicative	of	glial	activation	across	a	variety	of	midbrain	
structures.	The	sample	size	here	is	small	and	so	validation	in	larger	cohorts	is	clearly	
required;	however	this	limitation	accepted,	our	results	provide	exciting	evidence	which	
suggest	it	is	feasible	to	detect	the	pathological	processes	underlying	Parkinson	disease	
development	prior	to	dopaminergic	loss	occurring.		
	
Additionally	we	attempted	to	understand	whether	a	number	of	cytokines	and	proteins	
associated	with	peripheral	inflammation	were	upregulated	in	GBA	carriers	and	whether	
they	correlated	with	the	presence	of	prodromal	Parkinson	disease	features,	number	of	
severe	GBA	mutations	and	GCase	activity.	In	truth	the	significance	of	these	findings	is	
unclear.	There	are	a	large	number	of	variables	and	assumptions	which	must	be	made	in	the	
interpretation	of	the	data.	Moreover,	the	results	are	some	what	inconsistent.	Interleukin	8	
was	upregulated	amongst	GBA	carriers	compared	to	controls	and	in	both	biallelic	and	
heterozygous	carriers,	however,	the	correlation	did	not	extend	to	prodromal	Parkinson	
disease	features.	Conversely	IL6	seemed	to	inversely	correlate	with	GCase	activity	whilst	
TNF-alpha	levels	seemed	consistently	flat	across	our	analyses.	That	said,	our	hypothesis	
generating	proteomics	screen	picked	up	two	components	of	the	Ig	kappa	light	chain	raised	
across	GBA	carriers	compared	to	controls	and	in	‘high’	vs	‘low’	risk	groups.	There	does	
therefore	appear	to	be	a	common	theme	across	these	analyses	implicating	immune	
dysregulation	peripherally	and	centrally	in	the	process	of	Parkinson	disease	conversion.	
However,	there	is	no	evidence	of	generalised	immune	upregulation	or	of	any	individual	
cytokine;	therefore	whilst	interesting,	it	is	difficult	to	draw	any	firm	conclusions	on	the	basis	
of	these	data,	although	they	do	provide	interesting	leads	which	may	be	pursued	in	larger	
cohorts.		
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Our	hypothesis	generating	screen	of	urinary	proteins	has	revealed	a	number	exciting	targets	
as	putative	urinary	biomarkers	of	Parkinson	disease	conversion.	It	also	highlights	the	utility	
of	using	prodromal	Parkinson	disease	features	as	a	potential	surrogate	of	Parkinson	disease	
conversion.	The	next	step	will	be	validation	of	these	biomarkers	amongst	idiopathic	and	
GBA	Parkinson	disease	subjects	and	this	work	is	already	ongoing.	
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Chapter	6	–	No	evidence	of	disturbance	of	calcium	homeostasis	in	N370S	embryonic	
mouse	primary	neurons		
	
The	question	of	why	neuronal	toxicity	in	Parkinson	disease	is	predominately	confined	to	
dopaminergic	cells	of	the	substantia	nigra	pars	compacta	has	attracted	much	interest	in	
recent	years.	Initial	attention	was	focused	on	whether	this	selective	toxicity	was	a	property	
of	dopamine	itself,	however	evidence	for	this	is	contradictory	87,228,255.	More	pertinently,	
this	model	fails	to	explain	why	Parkinson	disease	involves	a	minority	of	non	dopaminergic	
neurons	256	and	equally	why	many	dopaminergic	neurons	outside	the	SNc	are	spared	in	
Parkinson	disease	257,258.		
More	recently,	attention	has	focused	on	the	intrinsic	physiological	pacemaking	properties	of	
neurons	within	the	substantia	nigra	pars	compacta	and	other	parts	of	the	mesencephalon	
and	brain-	stem.	This	activity,	essential	in	the	case	of	the	dopaminergic	cells	of	the	
substantia	nigra	pars	compacta	for	maintenance	of	basal	dopamine	levels	(and	hence	
movement),	requires	rapid	spontaneous	firing	of	neurons,	which	are	highly	dependent	on	
transmembrane	calcium	currents	259,260.		
	
6.0a	Calcium	flux	as	physiological	messenging	pathway	
	
Calcium	signaling	is	a	vital	cytosolic	function.	In	addition	to	nigral	pacemaking	neurons,	it	is	
intrinsic	to	a	vast	array	of	cellular	activities	in	a	variety	of	cell	types.	For	instance	dendritic	
growth	(neurons)	261,	insulin	synthesis	and	release	(islet	cells)262,	vesicular	trafficking	
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(variety	of	cells)	263	and	oocyte	fertilization	264	are	mediated	by	cytosolic	calcium	flux.	It	
primary	advantage	is	the	versatility	of	the	signaling	it	allows.	This	can	either	be	ultra	rapid		
(mediated	through	fast	amplification	and	then	dissipation	of	intracellular	calcium	currents)	
or	slow	cell	signaling	(mediated	through	gene	transcription)	265,266.	
With	reference	to	neurons	it	is	thought	that	the	mechanism	for	this	process	is	as	follows.	
Neuronal	depolarization	stimulates	the	opening	of	voltage	gated	calcium	channels	allowing	
intracellular	entry	of	calcium	into	the	cytosolic	compartment.	As	the	cell	repolarizes	closure	
of	these	channels	is	gradual,	causing	an	influx	of	calcium	ions,	with	the	duration	of	closure	
correlated	to	the	magnitude	of	calcium	influx.	Local	calcium	current	then	are	propogated	
across	the	cytosol	causing	stimulation	of	IP3,	NAADP	and	other	receptors	within	intracellular	
organelles	such	as	the	endoplasmic	reticulum	and	lysosome.	This	causes	rapid	amplification	
and	propagation	of	these	calcium	currents.	This	intracellular	calcium	is	then	rapidly	
removed	from	the	cytosolic	compartment	back	into	the	endoplasmic	reticulum,	lysosome	
and	pertinently	the	mitochondria	and	also	through	active	efflux	via	plasma	membrane	
pumps	77.	Mitochondria	are	particularly	suited	to	such	buffering	activities	as	they	have	
negatively	polarized	matrix	which	allows	rapid	uptake	of	positively	charged	calcium	ions.	
The	mitochondrial	membrane	potential	can	then	be	repolarised	by	a	rapid	upregulation	of	
oxidative	phosphorylation	267.	
	
6.0b	Calcium	current	within	cells	affected	by	Parkinson	disease	
	
Cells	of	the	substantia	nigra	display	intrinsic	pacemaking	action	potentials	which	maintain	
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basal	neurotransmitter	tone.	This	entails	a	near	constant	broad	spiking	(slow	closing	voltage	
gates	calcium	channels)	depolarization	with	reduced	buffering	capacity	77	It	is	hypothesized	
that	because	of	the	heightened	calcium	influx	and	reduced	intrinsic	buffering	capacity,	over	
the	course	of	a	lifetime,	mitochondria	become	overloaded	by	the	perpetual	effect	of	this	
continuous	higher	level	of	calcium	buffering.	Ultimately	it	is	suggested,	this	results	in	the	
mitochondrial	incompetence	which	has	been	recognized	for	some	years	as	a	major	
component	of	the	pathogenesis	of	Parkinson	disease	268.	An	interesting	caveat	to	this	is	the	
epidemiologic	finding	that	dihydropyridines,	commonly	used	antihypertensives	that	
antagonize	L-type	calcium	channels,	seem	to	exhibit	a	protective	effect	against	Parkinson	
disease	269,270.	It	may	be	that	blocking	of	these	channels	limits	pathologic	calcium	flux,	
reducing	neuronal	toxicity	during	periods	of	enhanced	energy	demand,	slowing	the	
progression	of	Parkinson	disease.		
	
6.1	GBA	mutations	and	calcium	flux	
	
It	has	been	suggested	that	certain	genetic	forms	of	Parkinson	disease	may	lead	to	
disturbances	of	calcium	homeostasis	which	accelerate	the	process	of	mitochondrial	
overload.	In	a	fibroblast	model	of	G2019S	LRRK2,	it	was	shown	that	compared	to	controls,	
NAADP	induced	global		cytosolic	calcium	signal	was	increased	and	this	was	reversible	
through	inhibition	of	the	lysosomal	two-pore	channel	271.	In	GBA-positive	fibroblasts	
carrying	the	N370S	mutation	cytosolic	calcium	there	was	an	increased	cyclic	ADP	ribose	
induced	cytosolic	evoked	calcium	reponse.	Dissection	of	the	contributions	of	individual	
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organelles	showed	an	increase	in	endoplasmic	reticulum	and	a	decrease	in	lysosomal	
calcium	stores	272.	Moreover,	amongst	homozygous	and	some	heterozygous	GBA	carrier	
derived	induced	pluripotent	stem	cells,	basal	calcium	levels	and	calcium	flux	upon	
stimulation	of	ryanodine	receptors	with	caffeine	were	increased	compared	to	controls.	Both	
were	reversible	by	Zinc	finger	nuclease	(ZFN)	genetic	modification	of	mutant	alleles	to	the	
wild-type	273.	Mutations	of	the	GBA	gene	induce	aberrant	folding	which	compromises	the	
post	translational	modification	and	transport	of	the	of	enzyme	from	the	endoplasmic	
reticulum	to	to	lysosome	74.	Mutant	GBA	becomes	sequestered	in	the	endoplasmic	
reticulum,	resulting	in	an	unfolded	protein	response	and	in	turn	upregulation	of	calcium	
release	into	the	cytoplasm	75,76,274.	We	hypothesize	that	this	additional	calcium	release	from	
the	endoplasmic	reticulum	results	in	an	increase	of	calcium	flux,	in	turn	overloading	the	
mitochondria	and	leading	to	the	Parkinson	disease	phenotype.	
Using	a	mouse	primary	neuronal	model	carrying	the	N370S	mutation,	we	shall	investigate	
whether	deranged	calcium	homeostasis	is	present	and	dissect	the	underlying	organellar	
contributions	to	any	derangement.	We	believe	that	this	is	a	more	physiological	model	in	
which	to	test	this	hypothesis	than	the	primarily	fibroblast	based	work	that	has	preceeded	it.		
All	experiments	in	this	chapter	were	carried	out	by	SM.	
6.2	Characterisation	of	a	mouse	primary	neuronal	model		
Prior	to	commencing	experiments,	we	elected	to	test	a	number	of	the	primary	neuronal	
models	in	terms	of	their	suitability	for	these	experiments.	Two	preparations	using	wild	type	
mice	were	compared,	an	embryonic	preparation	harvested	between	day	14-18	pre	partum	
and	a	post	partum	preparation	at	between	2-5	days	gestation.	Both	preps	were	cultured	for	
5-7	days	prior	to	experiments.	We	carried	out	immunohistochemistry	to	establish	the	
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neuronal	purity	of	the	preparations	(full	protocol,	appendices	section	10.6).	Beta	three	
tubulin	(abcam	ab18207)	was	used	as	neuronal	marker	and	glial	fibrillary	acidic	protein	
(GFAP	-	abcam	ab4674)	as	a	marker	of	glia	microscopy	showed	that	the	embryonic	prep	was	
made	up	entirely	of	neurons,	whilst	the	post	partum	prep	was	substantively	glial	(Fig	1),	
with	sporadic	neurons	found	within.						
	
We	further	assessed	the	neuronal	character	of	the	two	preparations	by	measuring	cytosolic	
Ca2+		flux	upon	depolarization,	by	incubating	them	with	Fura-2AM	(2.5	uM)	and	0.005%	v/v	
pluronic	acid	(Invitrogen)	for	1	h	and	stimulating	with	52mM	KCl.	Fura-2	is	a	ratiometric	dye	
which	upon	binding	with	Ca2+	ions	changes	its	excitation	spectra	from	360nm	to	340	nm	
(full	protocol,	appendices	10.7).	By	dividing	the	intensity	of	the	emission		at	340	and	380nm,	
a		ratio	is	obtained	which	is	comparable	from	sample	to	sample	and	will	compensate	for	any	
change	in	focus	which	occurs	during	signal	recording.	The	neurons	in	the	embryonic	
preparation	(Fig	2)	consistently	underwent	a	characteristic	neuronal	depolarization	whilst	
the	evoked	calcium	signal	trace	in	the	post	partum	prep	neurons	was	heterogeneous	and	
morphologically	inconsistent	(Fig	3).	Equally	there	was	a	more	sparse	distribution	of	
neurons	amongst	the	post	partum	prep	(Fig	1),	indicative	of	a	worse	state	of	baseline	
cellular	health.	We	concluded	from	these	studies	that	the	embryonic	prep	had	a	higher	
neuronal	purity	and	represented	a	healthier	and	more	physiological	platform	upon	which	to	
base	further	functional	imaging.		
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Fig	1.	Immunohistochemistry	of	5	day	old	embryonic	neuronal	prep	(left)	and	5	day	post	partum	mixed	glial	and	neuronal	
prep	(right).	Beta	3	tubulin	(green),	GFAP	(red),	DAPI	(blue).	X20	objective.	
Stephen	Mullin	–	PhD	thesis	
	
	
162	
6.3	Optimisation	of	assessment	of	evoked	calcium	signal	through	stimulation	of	SERCA	
ATPase	inhibitor	thapsigargin	in	embryonic	primary	neuronal	prep	
	
To	quantify	endoplasmic	reticulum	Ca2+	stores,	we	carried	out	preliminary	studies	to	assess	
the	response	in	wild	type	embryonic	primary	neurons	to	the	SERCA	ATPase	inhibitor	
thapsigargin	(for	full	protocol	see	appendices).	Thapsigargin	blocks	the	active	transport	of	
Ca2+	ions	from	the	cytosol	to	the	lumen	of	the	endoplasmic	reticulum,	thus	allowing	
(through	leakage	of	calcium	ions	across	the	polarized	ER	membrane)	estimation	of	ER	
calcium	stores	by	quantification	of	the	evoked	change	in	calcium	signal	in	the	cytosol.	In	
order	to	prevent	extracellular	influx	of	calcium	ions	the	experiment	must	be	carried	out	in	
calcium-free	HBS	which	must	be	added	(in	replacement	of	normal	HBS)	just	prior	
thapsigargin	in	order	to	ensure	neurons	were	fully	equilibrated	in	terms	of	cytosolic	and	
extracellular	calcium	concentration.			
The	discernable	change	in	evoked	calcium	signal	following	administration	of	1uM	
thapsigargin	was	extremely	small	but	quantifiable	(Fig	4).	An	additional	complicating	factor	
was	the	tendency	of	the	basal	calcium	signal	to	fall	after	the	addition	of	calcium	free	HBS,	a	
well	known	phenomenon	which	tended	to	negate	the	smallest	thapsigargin-evoked	
increases	of	calcium	signal	(Fig	4).			
Stephen	Mullin	–	PhD	thesis	
	
	
163	
	
	
Fig	2.	Indicative	trace	of	Ca2+	signals	evoked	by	52mM	KCL	(red	arrow)	in	embryonic	preparation	of	mouse	primary	
neurons.	All	cell	traces	left,	average	trace	right.
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Fig	3.	Indicative	trace	of	Ca2+	signals	evoked	by	KCL	(52mM)	in	post	partum	preparation	of	mouse	primary	neurons.	
All	cell	traces	left,	average	trace	right
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6.4	Inconsistent	caffeine	evoked	calcium	signal	in	mouse	embryonic	primary	neurons	
We	attempted	to	obtain	a	more	robust	measure	of	ER	calcium:	by	stimulation	with	caffeine,	
a	ryanodine	receptor	agonist	which	has	been	shown	to	stimulate	cytosolic	ER	calcium	store	
mobilisation	(for	full	protocol	see	appendices	10.7)	275.	We	found	that	responses	to	caffeine	
were	inconsistent.	For	the	most	part	there	was	little	if	any	response,	however	in	a	few	cases	
there	was	a	more	robust	response	across	all	neurons	(Fig	5).	Unfortunately	because	of	this	
inconsistency,	we	felt	we	were	unable	to	utilize	this	paradigm	in	further	experiments.	
	
6.5	Primary	neurons	appear	to	have	minimal	lysosomal	calcium	stores	
	
We	wished	to	assess	lysosomal	stores	of	calcium.	To	do	this	we	elected	to	use	Gly–Phe–β-
naphtylamide	(GPN),	a	lysosomal	permeabiliser	which	causes	release	of	calcium	into	the	
cytosolic	compartment	(for	full	protocol	see	appendices	10.7).	Responses	of	these	neurons	
to	GPN	were	poor,	with	vast	majority	of	neurons	not	giving	rise	to	any	evoked	calcium	
response	(Fig	6).	We	used	lysotracker	red	(a	flourofore	dye	that	stains	acidic	compartments	
and	hence	localizes	to	the	lysosome)	to	confirm	that	GPN	was	permeabilising	the	lysosome	
(for	full	protocol	see	appendices).	We	found	that	the	lysotracker	signal	dissipated	in	a	
manner	consistent	with	lysosomal	permeabilisation	as	described	previously	(Fig	7).	As	such	
we	concluded	that	the	basis	for	this	was	must	be	an	innate	lack	of	lysosomal	calcium	stores.		
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6.5	GCase	activity	reduced	in	N370S	heterozygote	and	homozygote	primary	neurons	
	
Details	of	the	GCase	activity	assay	are	provided	in	the	appendices	(10.9).	We	found	
statistically	significant	in	GCase	activity	in	wildtype,	heterozygous	and	homozygous	mouse	
brain	(Kruschal	Wallis,	p0.0001,	hom	12,	het	23,	wt	13).	Results	are	presented	graphically	in	
Fig.	8.		
	
6.6	No	difference	in	basal	calcium	signal	in	N370S	compared	to	control	primary	neurons	
	
	Basal	cytosolic	calcium	levels	can	be	a	surrogate	measure	of	cellular	health	(Fig.	9).	In	an	
induced	neuronal	pluripotent	stem	cell	model	carrying	GBA	mutations,	it	has	been	reported	
basal	calcium	levels	are	raised	which	may	be	indicative	of	increased	levels	basal	of	cytosolic	
calcium	flux	273,	however	we	were	unable	show	any	difference	in	basal	calcium	levels	upon	
assessment	in	heterozygous,	homozygous	and	control	primary	neurons	(Fig	8,	15	cover	slips	
total	4	homozygous,	8	heterozygous,	3	wild	type).	Analysis	using	Kruskal-Wallis	equality-of-
populations	rank	test	showed	no	evidence	of	significant	differences	across	the	groups	
(p=0.6648).	
	
6.7	No	difference	in	KCl-evoked	calcium	signal	following	stimulation	in	N370S	primary	
neurons	compared	to	controls		
	
Next	we	attempted	to	quantify	the	KCL	evoked	calcium	signal	by	subtracting	the	peak	ratio	
from	the	basal	ratio	(Fig	11.	15	cover	slips	total	4	homozygous,	8	heterozygous,	3	wild	type).	
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Kruskal-Wallis	equality-of-populations	rank	test	showed	no	evidence	of	significant	
differences	across	the	groups	(p=0.5037)		
	
6.8	No	difference	in	thapsigargin-evoked	calcium	signal	in	N370S	primary	neurons	compared	
to	controls	
	
We	then	attempted	to	quantify	the	thapsigargin	evoked	calcium	signal.	As	previously	
discussed	in	our	optimization	experiments,	there	was	a	great	deal	of	heterogeneity	in	
thapsigargin-evoked	calcium	responses.	Kruskal-Wallis	equality-of-populations	rank	test	
showed	no	evidence	of	significant	differences	across	the	groups	(p=0.8151)	(Fig.	12)		
	
We	speculated	that	there	might	be	a	differences	in	the	character	of	thapsigargin-evoked	
calcium	signal	in	N370S	neurons	compared	to	controls.	We	did	so	qualitatively	by	
superimposing	and	comparing	averaged	(by	genotype)	traces	of	each	genotype.	Comparison	
of	the	morphology	of	traces	showed	no	discernable	qualitative	difference	(Fig	11).	We	also	
attempted	to	quantify	any	different	by	calculating	the	total	change	in	calcium	concentration	
by	calculating	the	total	area	under	curve,	but	were	unable	to	show	any	difference	between	
genotypes	(Fig	14,	Kruskal-Wallis	equality-of-populations	rank	test	p=0.2954).		
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Fig	4.	Indicative	trace	of	Ca2+	signals	following	stimulation	by	
thapsigargin 1uM		(red	arrow).	Note	fall	in	baseline	during	
trace.	All	cell	traces	top,	average	trace	bottom
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Fig	5.	Inconsistent	responses	to	stimulation	with	2mM	caffeine	(red	arrow)	followed	by	52mM	KCL	
(blue	arrow).	All	cell	traces	left,	average	trace	right	
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Fig	6.	Representative	trace	of	calcium	evoked	potential	following	stimulation	with	GPN	200uM	(red	arrow).	All	cell	
traces	left,	average	trace	right	
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Fig	7.	Fluorescence	intensity	of	lysotracker	red	(25nM)	after	addition	of	200uM	GPN	(red	arrow)	in	wild	type	primary	
neurons.	All	cell	traces	left,	average	trace	right
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Fig.	8.	GCase activity	measure	
in	brain	lysate		of	control,	
heterozygote	and	homozygote	
N370S	mice
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Basal	signal
Evoked	signal	
change
Fig	9.	Explanation	of	basal	and	evoked	calcium	signal	using	illustrative	KCL	evoked	signal
Stephen	Mullin	–	PhD	thesis	
	
	
175	
	
	
Fig.	10	Basal	calcium	signal	in	N370S	
homozygous,	heterozygous	and	wildtype	
embryonic	primary	neurons	(a)	individual	
cover	slips	with	confidence	intervals	
(S.E.M)	(b)	averages	with	confidence	
intervals	(S.E.M)
(a)
(b) ns
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Fig.	11	52mM	KCL	
evoked	calcium	signal		
signal	in	N370S	
homozygous,	
heterozygous	and	
wildtype	embryonic	
primary	neurons	(a)	
individual	cover	slips	
with	confidence	
intervals	(S.E.M)	(b)	
averages	with	
confidence	intervals	
(S.E.M)
(a)
(b) ns
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Fig.	12	Thapsigargin
evoked	calcium	signal		
signal	in	N370S	
homozygous,	
heterozygous	and	
wildtype	embryonic	
primary	neurons	(a)	
individual	cover	slips	
with	confidence	
intervals	(S.E.M)	(b)	
averages	with	
confidence	intervals	
(S.E.M)
ns
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6.9	No	deficit	in	mitochondrial	membrane	signal	of	GBA	mutation	carrying	fibroblasts	
compared	to	controls	
	
Our	hypothesis	speculated	that	aberrant	cytosolic	calcium	homeostasis	lead	to	
mitochondrial	overload	and	eventually	Parkinson	disease	in	GBA	mutations	carrying	cells.	
Previous	live	cell	imaging	of	GBA	knock	out	primary	neuronal	cultures	revealed	reduced	
basal	mitochondrial	membrane	signal	which	a	fragmented	histological	appearance	with	
evidence	to	suggest	this	was	due	to	complex	V	(ATP	synthase)	reversal	276.	In	order	to	
establish	preliminarily	whether	mitochondrial	impairment	was	present	in	cell	lines	carrying	
the	GBA	mutation	we	carried	out	an	experiment	to	measure	mitochondrial	membrane	by	
loading	with	Tetramethylrhodamine,	methyl	ester	(TMRM),	a	cell-permeant,	cationic,	
orange	fluorescent	dye	that	is	readily	sequestered	by	active	mitochondria	277.	TMRM	
localizes	to	the	mitochondrial	intermembrane	space	in	a	membrane	signal-dependent	
manner.	It	thus	provides	a	surrogate	marker	of	mitochondrial	membrane	signal	and	in	turn,	
mitochondrial	health.		Using	the	ImageXpress,	a	high	throughput	microscopy	platform	which	
assesses	individual	cells	in	a	96	well	plate	format,	we	were	able	to	quantify	the	intensity	of	
the	TMRM	signal,	
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Fig.	13	AOC	analysis	
of	1uM	thapsigargin
evoked	calcium	signal		
signal	in	N370S	
homozygous,	
heterozygous	and	
wildtype	embryonic	
primary	neurons	(a)	
individual	cover	slips	
with	confidence	
intervals	(S.E.M)	(b)	
averages	with	
confidence	intervals	
(S.E.M)
ns
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Fig	14.	(a)	Average	ratio	of	TMRM	intensity	compared	to	controls	of	control,	heterozygote,	
homozygote,	Gaucher disease	and	idiopathic	PD	fibroblasts	(b)	Individual	ratios	of	TMRM	
intensity	from	each	cell	line	
(a) (b)
ns
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thus	producing	a	surrogate	marker	of	mitochondrial	membrane	signal	across	thousands	of	
fibroblasts.	
	
Our	results	showed	no	significant	difference	between	TMRM	intensity	across	GBA	carrying	
cell	lines	compared	to	one	another	or	controls	(Fig	12a,	Kruschal	Wallis	p=0.3324)	.	There	
was	a	trend	towards	TMRM	intensity	being	reduced	amongst	idiopathic	Parkinson	disease	
cases	(Fig	12a),	implying	a	reduced	mitochondrial	membrane	signal.	Reference	to	the	
individual	measurement	shows	that	this	differences	in	predominately	driven	by	subject	
IPD2,	who	had	a	TMRM	signal	some	10%	lower	than	the	other	idiopathic	Parkinson	disease	
cases	(Fig.	12b).	Subset	pairwise	statistical	analysis	using	the	Mann	u	Whitney	(idiopathic	PD	
Parkinson	disease	vs	control)	test	confirmed	that	this	result	was	not	significant	(p=0.288).		
			
6.10		Concluding	remarks	
	
The	data	collected	reveals	no	evidence	of	either	aberrant	calcium	homeostasis	or	impaired	
mitochondrial	function	within	N370S	carrying	primary	neurons	and	fibroblasts	respectively.	
This	is	in	contrast	to	the	established	literature.	There	are	a	number	of	possible	explanations	
for	this.	The	first	is	discrepancies	in	the	disease	models	selected.	The	most	relevant	data	
collected	was	based	on	a	neuronal	induced	pluripotent	stem	cell	model	carrying	a	
combination	of	two	mutations,	L444P	and	RecNcil.	The	paper	showed	an	increase	in	basal	
cytosolic	calcium	and	of	KCl-evoked	calcium	flux	273.	Both	mutations	give	rise	to	a	severe	
form	of	Gaucher	disease105,	whilst	L444P	has	been	shown	to	cause	a	more	penetrant	
Parkinson’s	phenotype	42.	N370S	on	the	other	hand	is	associated	with	a	milder	form	of	
Gaucher	disease,	with	incomplete	penetrance	in	the	homozygous	state	and	concurrently	a	
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less	penetrant	Parkinson	disease	phenotype.105	As	such,	it	may	be	that	the	severity	of	the	
N370S	mutation	is	not	sufficient	to	cause	detectable	impairment	of	calcium	homeostasis.		
	
With	reference	to	existing	data	quantifying	mitochondrial	membrane	potential,	the	most	
pertinent	study	used	a	GBA	knockout	model	276,	once	again	it	is	likely	that	this	gives	rise	to	a	
more	severe	phenotype	than	our	N370S	model.	Moreover	our	mitochondrial	studies	were	
carried	out	in	a	fibroblast	model.	Fibroblasts	to	do	not	experience	voltage-gated	calcium	
channel	mediated	influx	of	calcium.	Without	this	influx	and	without	a	cellular	phenotype	
which	gives	rise	heightened	calcium	flux	(such	as	in	dopaminergic	nigral	neurons),	it	would	
seem	unlikely	that	such	mitochondrial	overload	would	occur.	
	
Perhaps	the	most	comparable	disease	model	tested	to	date	is	that	of	fibroblasts	carrying	
the	N370S	mutation.	In	this	paper,	an	increase	was	seen	in	thapsigargin	(ER)derived	evoked	
signal	and	a	concurrent	decrease	in	lysosomally	derived	calcium	278.	The	most	notable	
difference	between	this	model	and	the	primary	neuronal	mouse	model	we	used	was	the	
scale	of	the	evoked	signals.	Responses	to	thapsigargin	recorded	in	the	fibroblast	model,	
were	in	the	order	of	a	ratio	value	0.2	à	0.5	compared	to	an	average	change	of	0.2à0.22	in	
our	primary	neuronal	model.	This	discrepancy	was	exacerbated	by	the	declining	baseline	
calcium	signal	caused	by	the	need	to	use	calcium	free	HBS	which	caused	gradual	leakage	
calcium	ions	extracellularly.	In	terms	of	lysosomal	calcium	stores,	with	the	exception	of	a	
few	individual	neurons,	responses	to	GPN	were	not	detectable,	even	though	we	were	able	
to	demonstrate	successful	permeabilisation	of	the	lysosome.	The	implication	of	these	
findings	is	that	the	lysosomal	and	endoplasmic	reticulum	calcium	stores	are	substantially	
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reduced	in	neurons	compared	to	fibroblasts.	This	is	in	keeping	with	previous	work	which	
was	unable	to	produce	a	significant	thapsigargin	evoked	calcium	signal.		
	
Two	contrasting	conclusions	may	be	drawn.	The	first	is	that	because	of	the	small	scale	of	the	
calcium	stores	released,	our	experiments	lacked	the	sensitivity	to	detect	the	discrepancies	
in	evoked	calcium	signals,	and	as	such	that	upregulation	of	ER	derived	calcium	and	
subsequent	cytosolic	calcium	‘overload’	may	still	play	a	role	in	the	predilection	for	Parkinson	
disease	to	develop	in	the	brains	of	GBA	carriers.	Although	possible	this	conclusion	seems	
unlikely.	The	reason	for	this	is	the	scale	of	calcium	flux	brought	about	by	depolarization.	
Although	it	should	be	noted	that	52mM	KCL	is	a	concentration	does	not	represent	a	
physiological	stimulus,	it	gives	rises	to	a	change	in	calcium	ratio	of	approximately	0.2	à1.2,	
which	would	render	the	effects	of	any	additional	ER	derived	calcium	release	at	best	
marginal	and	at	worst	insignificant.	It	would	seem	unlikely	that	the	tiny	contribution	of	
these	additional	stores	would	be	the	tipping	point	which	would	overload	the	cytosolic	
calcium	buffering	capacity	of	mitochondria.		
	
It	is	interesting	therefore	that	an	increased	basal	calcium	load	and	KCl-evoked	action	signal	
have	been	demonstrated	in	an	induced	pluripotent	stem	cell	neuronal	model.	This	data	is	
compelling,	especially	the	recapitulation	of	increased	basal	and	calcium-evoked	calcium	
signal	with	zinc	finger	transgenic	modification	of	the	cell	lines	273.		If	as	suggested	previously	
the	reason	this	is	not	replicated	in	our	results	is	more	potent	phenotype	of	the	mutations	in	
question,	it	may	suggest	that	the	increased	calcium	load	results	from	upregulation	of	
calcium	entry	through	voltage	gated	calcium	channels.	One	possible	mechanism	for	this	
might	be	through	alpha	synuclein,	the	cytosolic	protein	of	unknown	aetiology	which	is	the	
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principle	component	of	Lewy	bodies.		It	has	been	shown	in	a	number	of	studies	that	alpha	
synuclein	directly	upregulates	calcium	influx	by	exerting	a	direct	effect	on	voltage	gated	
calcium	channels.	279,280.	As	mentioned	previously	there	appears	to	be	a	bidirectional	
relationship	between	GBA	activity	levels	and	alpha	synuclein,	in	which	a	reduction	in	GBA	
activity	causes	an	increase	in	alpha	synuclein	levels	and	vica	versa	36,281.	In	this	case	it	may	
be	that	the	upregulation	of	alpha	synuclein	causes	a	direct	increase	in	voltage	gated	calcium	
mediated	calcium	influx.	This	is	an	interesting	hypothesis	and	would	warrant	further	
exploration	in	a	more	potent	mutation	carrying	cell	line	such	as	L444P.	This	of	course	does	
not	explain	the	reported	rise	in	basal	calcium	signal,	although	this	may	be	purely	
representative	of	poor	cellular	health	rather	than	any	innate	dysregulation	of	calcium	
homeostasis.	Such	speculation	aside	we	are	unable	to	find	any	evidence	of	deranged	
calcium	homeostasis	in	N370S	mouse	primary	neuronal	model.	
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Chapter	7	–	Design	and	optimisation	of	AiM	PD,	a	phase	II	open	label,	non-placebo	
controlled	trial	of	ambroxol,	a	small	molecular	chaperone	of	the	GCase	protein.		
	
7.0	Introduction		
	
As	described	in	the	introduction,	there	is	substantial	interest	in	the	GCase	pathway	as	a	
potential	target	for	neurointervention	in	Parkinson’s.	Small	molecular	chaperones	offer	
perhaps	the	most	plausible	prospect	of	short	term	success	in	this	field,	primarily	because	of	
the	volume	of	research	which	has	been	undertaken	to	date	135.	Chaperones	alter	chemical	
folding	of	a	protein,	in	the	case	of	enzymes	stabilizing	the	catalysis	of	substrate.		Under	
normal	conditions	the	GCase	protein	is	bound	to	the	saposin	C,	a	physiological	chaperone	
molecule	which	is	an	intrinsic	part	of	the	ceramide	synthesis	pathway	and	is	likely	to	aid	
interactions	between	the	glucosylceramide	substrate	and	the	lipid	membrane	282.	Nuclear	
magnetic	resonance	spectroscopy	studies	show	that	it	binds	to	the	GCase	protein	61	and	
initiate	the	catalysis	of	glucosylceramide	within	the	lysosome	283.	Its	importance	is	
emphasised	by	the	finding	that	mutations	in	saposin	C	cause	a	clinical	presentation	of	
Gaucher	disease	but	with	a	normal	GCase	enzyme	activity	284.		
	
Use	of	an	external	molecule	to	change	the	conformational	properties	of	GCase	is	the	
principle	underlying	the	use	of	small	molecular	chaperones.	The	GCase	protein	upon	
translation	within	the	nucleus	is	transported	within	vesicles	to	endoplamic	reticulum.	Here	
it	is	post	translationally	modified	in	a	number	of	steps	in	order	to	enable	transport	to	the	
lysosome.	Missense	mutations	in	the	GCase	protein	appear	to	disrupt	this	folding	
mechanism	causing	the	protein	to	become	sequestered	within	the	endoplasmic	reticulum73.	
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The	consequences	of	this	are	two	fold.	Firstly,	whilst	the	active	site	of	the	mutant	GCase	
protein	is	still	suitable	for	catalysis,	it	does	not	reach	the	lysosome	and	hence	is	unable	to	
catalyse	the	pH	dependent	breakdown	of	glucosylceramide.	Secondly	the	sequestered	
protein	causes	an	unfolded	protein	response.	This	physiological	reaction	to	such	protein	
sequestration	includes	halting	of	normal	cellular	translation,	upregulation	of	molecular	
chaperones	to	aid	folding	and	upregulated	degradation	of	misfolded	porteins,	
predominately		by	the	proteasome	system	78.	Until	removed	the	sequestered	protein	gives	
rise	cellular	toxicity	mediated	predominately	by	reactive	oxygen	species	production.	If	the	
unfolded	protein	response	is	able	to	overcome	protein	sequestration	sufficiently	quickly	
then	the	cell	is	restored	otherwise	the	cell	is	marked	for	apoptosis	and	disposed	of.		
	
In	the	case	of	small	molecular	chaperones	of	the	GCase	enzyme,	the	conformational	change	
resulting	from	its	interaction	with	GCase	(rather	than	directly	assisting	substrate	catalysis)	
aids	the	physiological	folding	mechanisms	and	this	allows	transport	of	the	enzyme	away	
from	the	lysosome,	and	for	at	least	a	substantial	portion	of	the	protein,	into	the	lysosome.	
An	interesting	observed	finding	is	that	the	administration	of	small	molecular	chaperones	
causes	an	uplift	in	GCase	activity	in	wildtype	cell	lines	37,285,286.	This	presumably	is	a	
reflection	of	refolding	of	sequestered	wildtype	GCase	in	the	ER	to	the	cytosol.	The	
desirability	of	this	is	debatable.	If	this	GCase	in	question	is	functionally	competent	then	
additional	protein	reaching	the		lysosome	is	undoubtedly	a	positive.	If	on	the	other	hand	
this	sequestration	serves	as	an	intrinsic	quality	control	mechanism	for	GCase,	it	could	be	
argued	that	sending	large	amounts	of	compromised	GCase	protein	to	the	lysosome	may	be	
potentially	harmful.	
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As	discussed	in	the	introduction,	it	is	unclear	what	the	pathogenic	mechanism	of	GBA	
Parkinson	disease	is.	That	said,	whatever	this	mechanism	is,	it	seems	logical	that	
mobilisation	of	mutant	GCase	from	the	endoplasmic	reticulum	can	only	be	beneficial.	If	
GCase	were	to	have	a	direct	role	in	in	the	disposal	of	alpha	synuclein	via	autophagic	
pathways,	as	has	been	suggested	by	a	body	of	evidence	implying	a	direct	interaction	
between	the	two	62,65,66,287-289,	then	clearly	additional	functionally	active	GCase	reaching	
the	lysosome	would	remove	alpha	synuclein	and	be	protective	in	terms	of	Parkinson	
disease.	Similarly,	additional	lysosomal	GCase	would	aid	removal	of	cellular	
glucosylceramide	If	substrate	accumulation	is	the	cause.	If	sequestration	of	the	enzyme	
within	the	ER	is	the	critical	step	75,76,	then	removal	of	this	protein	by	chaperones	would	
dampen	the	unfolded	protein	response	and	reduce	cellular	toxicity.	The	only	forseeable	
negative	effect	could	be	if	the	release	of	the	sequestered	GCase	were	to	somehow	overload	
the	proteosomal	system,	mediated	by	the	chaperone	protein	LAMP2A	68,	which	is	
responsible	for	the	removal	of	compromised	cellular	GCase	136.	Such	a	mechanism	would	be	
dependent	of	overload	of	the	Lysosomal	Integral	Membrane	Protein-2	(LIMP2)	protein.	
LIMP2	is	the	mediator	of	GCase	transport	to	the	cis	and	then	trans	golgi	apparatus	290.	It	
binds	to	GCase	to	form	a	complex	which	is	supplemented	by	AP-1	protein,	allowing	uptake	
of	GCase	into	the	late	endosome.290.	This	could		in	turn	potentially	disrupt	the	removal	of	
other	proteins	which	may	be	contributory	to	Parkinson	disease,	including	alpha	synuclein,	
which	there	is	some	evidence	to	suggest	is	at	least	partially	removed	by	the	protesomal	
system	65,66.	
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7.1	Inhibitory	and	non-inhibitory	chaperones	
	
Small	molecular	chaperones	can	be	subdivided	into	inhibitory	and	non-inhibitory	subtypes	
135.The	inhibitory	tag	refers	to	the	fact	that	these	chaperones	bind	directly	to	the	active	site	
of	the	protein	in	order	to	induce	conformational	change,	in	turn	antagonising	the	binding	of	
enzyme	substrate(s)	and	hence	reducing	enzyme	activity.	Upon	reaching	the	acidic	
conditions	of	the	lysosome,	elution	of	the	chaperone	may	occur	leaving	the	active	site	
available	to	allow	enzyme	catalysis.		The	degree	of	elution	is	dependent	on	the	affinity	of	
the	chaperone	for	the	substrate;	if	the	affinity	is	too	great	or	too	high	a	dose		is	used	then	
the	active	site	will	remain	bound	to	the	chaperone	and	no	catalysis	will	occur.	The	concern	
here	is	clearly	that	far	from	aiding	enzyme	catalysis,	prolonged	binding	at	low	pH	to	the	
active	site	of	the	protein	will	in	fact	inhibit	its	action.		This	was	the	case	with	isophagamine,	
which	maintains	a	high	binding	affinity	to	the	active	site	up	to	pH	4.	Clinical	trials	of	the	
compound	in	the	context	of	Gaucher	disease	were	unsuccessful	and	it	may	be	this	enhanced	
inhibition	was	the	culprit	133,291,292.	The	majority	of	chaperones	discovered	to	date	are	
inhibitory,	hence	careful	consideration	must	be	made	of	the	choice	of	chaperone	and	the	
dose	selected.	The	latter	consideration	is	in	two	parts,	namely	whether	peripherally	
chaperone	concentration	is	sufficient	to	cause	an	inhibitory	effect	but	high	enough	to	reach	
the	central	nervous	system	and	act	as	an	effective	small	molecular	chaperone	once	it	gets	
there.	The	first	was	N-(n-nonyl)deoxynojirimycin	
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Fig	1.	GCase,	once	translated	in	the	nucleus	moves	
endoplasmic	reticulum	where	it	is	post	translationally	
modified,	and	then	translocates to	the	lysosomal	
mediated	by	LIMP2.	Small	quantities	of	aberrant	or	
misfolded	GCase is	recognised by	the	LAMP2A	
protein	and	disposed	of	by	the	proteosome
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Fig	2.	GCase,	once	translated	in	the	nucleus	moves	
endoplasmic	reticulum	where	it	is	post	translationally	
modified,	however	mutant	GCase is	misfolded	and	is	
sequestered	in	ER,	causing	an	unfolded	portein
response.	The	misfolded	recognised by	the	LAMP2A	
protein	for	disposal	by	the	proteosome,	however	the	
system	is	unable	to	handle	the	volume	protein.				
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(NN-DNJ),	an	iminosugar	which	at	10uM	concentrations	was	found	to	cause	a	x2	increase	in	
GCase	activity.		There	have	been	subsequently	a	number	of	largely	iminosugar	based	
chaperones,	however	to	date	non	have	been	found	to	be	viable	interventional	medicinal	
products.	That	said,	a	recent	study	using	an	unnamed	small	molecular	chaperone	of	GCase	
in	induced	pluripotent	stem	cells	carrying	a	number	of	GBA	mutations	showed	an	
upregulation	of	GCase	within	the	lysosomal	compartment,	increased	clearance	of	all	
synuclein	species	and	a	beneficial	effect	in	terms	of	downstream	neurotoxicity	293.	
	
7.2	Ambroxol	
	
Ambroxol	is	a	metabolite	of	bromhexine.	It	has	been	used	for	over	30	years	as	a	mucolytic	
and	in	the	treatment	of	hyaline	membrane	disease	294.	In	recent	years	it	has	also	been	
suggested	to	be	a	novel	treatment	in	acute	respiratory	distress	syndrome	295.	Interestingly	it	
has	anaesthetic	properties	which	may	be	mediated	by	blockage	of	voltage	gated	sodium	
channels	and	has	been	used	as	cough	medicine	296.	It	has	also	been	suggested	to	be		an	
inducer	of	exocytosis	of	calcium	stores	from	the	lysosome	297.	It	has	an	excellent	safety	
profile.	The	summary	of	product	characteristics	list	only	nausea	as	a	common	((≥1/100	to	
<1/10);	dyspepsia,	vomiting,	diarrhoea	and	abdominal	pain	as	uncommon	(≥1/1,000	to	
<1/100)	and	urticarial	rash	as	a	rare	(≥1/10,000	to	<1/1,000)	side	effect	298.	
	
A	screen	of	some	10,000	FDA	approved	compounds	found	that	in	fibroblast	and	
lymphoblast	cell	lines	of	a	number	of	Gaucher	disease	patients,	showed	that	ambroxol	was	
able	to	stabliise	GCase	during	thermal	denaturation,	preventing	any	reduction	in	GCase	
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activity.		Furthermore,	it	was	reported	that	ambroxol	was	a	mixed	type	inhibitor	of	GCase,	
with	high	binding	at	neutral	pH	but	almost	no	inhibitory	effect	below	pH	4.6.	This	was	in	
stark	contrast	to	isophagamine,	which	maintained	a	high	binding	affinity	to	pH	4.1	133.	Their	
data	indicated	that	a	concentration	of	60uM	was	the	threshold	at	which	concentration	
related	inhibition	occurred.	Subsequently	ambroxol	was	confirmed	to	increase	GCase	
activity	in	fibroblasts	and	mouse	models	of	Gaucher	disease	35,134	and	was	shown	to	reduce	
levels	of	alpha	synuclein	in	wildtype	and	mutant	fibroblasts,	work	which	was	later	confirmed	
in	a	neural	crest	stem	cell	model	37.	The	latter	study	also	showed	upregulation	of	a	number	
of	autophagic	pathways	in	response	to	the	ambroxol	37.		
	
7.3	Ambroxol	and	the	blood	brain	barrier	
	
In	structural	terms	small	molecular	chaperones	such	as	ambroxol	are	likely	to	cross	the	
blood	brain	barrier.	This	principle	was	first	confirmed	in	murine	model	of	GM1	
gangliosidosis	where	a	small	molecular	chaperone	molecule	of	β-galactosidase	was	able	to	
successfully	reduce	GM1	substrate	levels.	299,300	A	number	of	studies	have	confirmed	the	
brain	penetrance	of	ambroxol.	In	L444P	wildtype	and	synuclein	overexpression	mice	
respectively	activity	increased	and	in	the	latter	alpha	synuclein	levels	reduced	286.	The	
increase	in	GCase	activity	was	mimicked	in	a	wildtype	human	primate	where	GCase	activity	
was	increased	following	oral	administration	of	ambroxol	100mg	(≈	40mg/kg)	but	not	22.5mg	
(≈	10mg/kg)	301.		Moreover	a	phase	II	trial	of	ambroxol	in	5	neuronopathic	Gaucher	patients	
at	a	dose	of	approximately	1.2g/day	achieved	10-20%	of	the	serum	ambroxol		concentration	
within	the	cerebrospinal	fluid	302.	
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7.4	Safety	and	tolerability	of	ambroxol	
	
Ambroxol	 has	 a	 long	 history	 of	 use	 in	 humans,	 which	 documents	 its	 very	 low	 level	 of	
toxicity.	 	 For	 several	 decades	 ambroxol	 has	 held	 market	 authorisation	 by	 the	 European	
Medicines	 Agency	 (EMEA)	 and	 in	 several	 countries	 across	 Europe	 for	 over-the-counter	
indications	at	doses	up	to	120	mg/day.	There	have	been	a	number	of	clinical	trials	of	ambroxol	
at	a	variety	of	doses.	In	one	small	study	12	participants	with	type	I	Gaucher	disease	took	150	
mg	daily	in	two	divided	doses	for	6	months	with	minimal	side	effects	303.	A	recent	study	in	
Japan	treated	5	neuronopathic	Gaucher	disease	patients	with	ambroxol	at	an	escalating	dose	
of	3mg/kg/day	to	5mg/kg/dose	for	12-31	months	302,304.	The	only	adverse	event	reported	was	
mild	hypouricaemia	(Narita	et	al.,	2016).	Another	study	treated	12	healthy	volunteers	with	
500	mg	or	1g	twice	a	day	for	5	days	and	revealed	no	adverse	effects	305.	A	number	of	studies	
have	demonstrated	use	of	a	1g	daily	dose	on	(Intensive	Therapy	Unit)	ITU	in	participants	with	
acute	respiratory	distress	syndrome	(ARDS)	 for	short	periods.	 In	one	study	32	participants	
with	Acute	Respiratory	Distress	Syndrome	(ARDS)	were	administered	40	mg/kg	ambroxol	in	
4	 	daily	divided	doses	 for	up	 to	10	days	with	no	adverse	effects	306	whilst	a	 recent	meta-
analysis	 of	 508	 participants	 enrolled	 in	 studies	 using	 high	 dose	 ambroxol	 (15-
20mg/kg/day)	for	short	periods	(3-7	days)	to	treat	acute	respiratory	distress	syndrome	and	
acute	lung	injury	did	not	reveal	any	significant	adverse	effects	295.	A	further	trial	assesses	the	
efficacy	 of	 ambroxol	 (1g	 dose	 administered	 every	 12	 hours	 for	 a	 maximum	 of	 48	
hours)	prophylactically	 in	pregnant	women	 to	prevent	 infantile	acute	 respiratory	distresss	
syndrome.	The	study	demonstrated	its	safety	to	pregnant	woman	and	the	unborn	child	307.			
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7.5	Ambroxol	as	a	neuroprotective	agent	in	Parkinson	disease	
	
The	combination	of	its	excellent	safety	profile,	promising	in	vitro	studies	and	rationale	for	
use	along	with	its	robust	brain	penetrance	at	appropriate	doses	make	ambroxol	a	highly	
promising	neuroprotective	target	in	both	idiopathic	and	GBA	Parkinson	disease.	We	
therefore	decided	to	clarify	its	potential	application	in	a	phase	II	trial.	
	
7.6	Objectives	
	
Primary	objective	
• To	confirm	ambroxol	central	nervous	system	penetrance	and	GCase	target	
acquisition	in	a	population	of	Parkinson	disease	patients	with	and	without	GBA	
mutations	
Secondary	objectives	
• To	assess	the	safety	and	tolerability	of	the	Glucocerebrosidase	(GCase)	enhancing	
chaperone	ambroxol	in	Parkinson	disease	participants		
• To	quantify	the	effect	of	ambroxol	on	known	neurodegenerative	biomarkers		
• 	To	quantify	the	effect	of	ambroxol	on	glucosylceramide	levels	and	GCase	expression	
levels	in	cerebrospinal	fluid		
	
Exploratory	objectives	
• To	 explore	 whether	 ambroxol	 leads	 to	 improvement	 in	 cognitive	 performance,	
Montreal	Cognitive	Assessment	(MoCA)		
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• To	explore	whether	ambroxol	leads	to	improvement	in	Parkinson	Disease	non-motor	
symptom	assessment	scale	(NMSS)	and	non-motor	symptom	questionnaire		
	
7.7	Design	
	
Open	label	proof	of	principle	non-placebo	controlled	interventional	study.			
	
Briefly	participants	undergo	clinical	and	biochemical	assessments	and	have	cerebrospinal	
fluid,	serum	and	urine	samples	taken	at	baseline	prior	to	5	weekly	dose	escalations	to	a	
target	dose	of	1.24g	daily	in	three	divided	doses	which	is	administered	for	a	further	6	
months.	Following	this	there	is	3	month	washout	period	with	subsequent	reassessment	at	
the	end	of	this	period.		A	summary	of	the	assessment	and	assays	used	in	the	study	is	shown	
below	(table	1).	Study	design	was	carried	out	by	SM,	Prof.	Anthony	Schapira,	Prof.	Tom	
Foltyniea	and	Dr	Vincenzo	Libri.		
biochemical	 bl	 10d	 3m	 6m	 9m	
Leucocyte	GCase	 X	 X	 X	 X	 X	
Serum	ambroxol	 x	 	 	 x	 x	
Serum	ELISAs	 x	 	 x	 x	 x	
cerebrospinal	fluid	ambroxol	 x	 	 	 x	 x	
cerebrospinal	fluid	Glucocerebrosidase	and	Glucosylceramide	
estimation	
x	 	 	 x	 	
cerebrospinal	fluid	ELISAs	 x	 	 	 x	 x	
Proteomics,	lipidomics,	metabolimics	(cerebrospinal	fluid,	
serum,	urine)	
x	 	 	 x	 x	
clinical	 bl	 10d	 3m	 6m	 9m	
UPDRS	 (x2)	 	 x	 x	 x	
MoCa	 x	 	 	 x	 x	
NMS	 x	 	 	 x	 x	
NMSQuest	 x	 	 	 x	 x	
			Table	1.	Summary	of	clinical	and	biochemical	assessments	undertaken	at	each	visit.	
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7.8	Optimisation	and	validation	of	exploratory	assays	
GCase	assays	were	carried	out	by	SM,	Laura	Smith	or	Katherine	Lee.	Analysis	was	carried	out	
by	SM.	
	
7.9	GCase	activity		
	
The	key	assay	in	this	study	is	the	measurement	of	GCase	activity.	GCase	activity	is	measured	
using	a	fluorogenic	assay.	Briefly,	a	known	concentration	of	a	synthetic	substrate	(4-
methylumbelliferyl-D-glucopyranoside	4.8mM)	is	added	to	a	known	volume	of	leucocyte	
pellet	lysate/	cerebrospinal	fluid	and	incubated	at	38	degrees	celcius	for	a	defined	period.		
At	this	point,	a	known	volume	of	an	alkali	glycine	solution	is	added.	The	GCase	will	catalyse	
the	substrate	into	4-methylumbelliferone.	In	the	presence	of	the	alkali	pH,	the	solution	will	
fluoresce	at	450nm	following	excitation	at	365nm.	By	quantifying	the	intensity	of	the	
emitted	light	and	comparing	it	to	a	standard	containing	a	known	concentration	of	4-
methylumbelliferone	one	can	calculate	the	activity	of	the	enzyme,	normalized	in	the	case	of	
the	leucocyte	pellet	to	the	protein	concentration	of	the	pellet	and	in	the	case	of	
cerebrospinal	fluid	to	the	volume	of	cerebrospinal	fluid	used.		
	
There	are	a	number	of	limitations	of	the	GCase	assay.	Most	prominently	it	gives	only	a	
partial	estimation	of	the	catalytic	capacity	of	the	GCase	protein	because	it	takes	no	account	
of	expression	levels	of	the	GCase	protein	itself.	Moreover,	the	assay	is	extremely	sensitive	
to	a	number	of	methodological	factors	which	can	substantially	affect	the	inter	and	intra	
assay	variability.	This	is	especially	pertinent	for	cerebrospinal	fluid	GCase	because	the	
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recorded	activity	levels	are	so	low.		In	the	preparatory	work	for	this	study	it	was	vital	to	
minimize	the	variability	as	much	as	feasible	in	order	to	minimize	the	possibility	of	type	2	
error.		
	
7.9a	Previous	reports	of	GCase	activity	in	cerebrospinal	fluid		
In	our	hands	cerebrospinal	fluid	activity	were	measured	from	0.154-0.407	nmol/hr/ml	
cerebrospinal	fluid	whilst	“normal”	leucocyte	GCase	is	considered	to	be	5-15nmol/hr/mg	
protein.	Assuming	cerebrospinal	fluid	protein	concentration	to	be	around	0.45g/l,	we	
approximate	our	measured	cerebrospinal	fluid	activity	to	0.342-	0.904	nmol/hr/mg	protein,	
an	approximately	15	fold	reduced	level	of	activity.	
In	comparison	Balducci	et	al	308	found	mean	activity	in	healthy	controls	to	be	0.0312±0.0066	
nmol/hr/ml.	Parnetti	et	al	40,45	reported	0.0204-0.0966	nmol/hr/ml	in	cerebrospinal	fluid	of	
patients	undergoing	lumbar	punctures	for	other	neurological	disorders,	similar	to	our	
cerebrospinal	fluid	donors.	Persichetti	et	al	44	however,	reported	activities	between	0.0876-
0.912	nmol/hr/ml,	a	similar	range	to	those	found	in	our	results	which	probably	reflects	the	
similarity	between	the	protocols	used.	A	summary	of	the	respective	protocols	used	is	shown	
below	(Table	2).		
Stephen	Mullin	–	PhD	thesis	
	
	
198	
	
Table	2.	Summary	notes	comparing	differences	in	protocols	between	recent	
papers	
Authors	 cerebrospinal	fluid:substrate	
	
Incubation	 notes	
Balducci	wt	al.	308	 100μl:100μl	 24hrs	 3mM	substrate,	pH	4.5	
Parnetti	et	al.	40,45	 50μl:100μl	
24hrs	
	
3mM	substrate,	
pH	4.5	
Perschetti	et	al.	44	 20μl:40μl	 3hrs	
10mM	
substrate,	0.2%	
sodium	
deoxytaurochol
ate,	pH	5.0	
	
	
7.9b	Degradation	of	cerebrospinal	fluid	and	leucotye	GCase	activity	with	storage			
	
A	key	issue	during	our	design	of	the	study	was	the	observation	that	cerebrospinal	fluid	
GCase	activity	appears	to	be	affected	by	freeze	thaw	cycles	and	the	length	of	storage	at	-80	
degrees.	Persichetti	et	al.	noted	serial	reduction	of	GCase	activity	with	freeze	thaw	cycles,	
with	around	a	5-10%	loss	activity	noted	at	each	cycle	44.	They	also	note	an	almost	complete	
loss	of	GCase	activity	after	only	7	days	of	storage	at	-20°C,	whilst	at	-80°C	they	noted	an	
approximately	20%	loss	of	activity	at	4	weeks	and	an	almost	immediate	dip	around	10%	
after	thawing	compared	to	fresh	sample	44.	
	
We	wished	to	see	what	the	GCase	activity	degradation	rate	was	“in	our	hands”	and	so	
carried	out	an	experiment	to	assess	the	serial	loss	of	activity	after	long	term	storage.	Fresh	
cerebrospinal	fluid	from	control	subjects	being	investigated	for	suspected	normal	pressure	
or	idiopathic	intracranial	hypertension	hydrocephalus	were	collected	from	the	Royal	Free	
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Hospital	between	January	2016	and	November	2016.	A	cerebrospinal	fluid	GCase	assay	was	
performed	within	an	hour	of	collection.	Samples	were	aliquoted	then	frozen	at	-80	and	
thawed	respectively	at	3,	7,	10,	14,	21	and	28	days	and	GCase	assays	were	repeated.	At	each	
time	point	10	repeats	were	performed	on	5	different	cerebrospinal	fluid	samples.		
	
Our	results	showed	that	there	was	an	immediate	drop	in	cerebrospinal	fluid	GCase	activity	
of	around	20%	which	then	remained	constant	until	24	days,	at	which	point	activity	fell	to	
30%	and	then	to	40%	at	28	days	(Fig	3).	In	terms	of	leucocyte	pellet	GCase	the	immediate	
20%	drop	was	replicated,	although	over	the	four	week	course	of	the	experiment	this	fall	
remained	relatively	consistent	(Fig.	4)	.	On	the	basis	of	these	findings	we	made	the	decision	
to	process	all	samples	within	a	2	week	window,	to	avoid	variation	inactivity	measurements	
following	prolonged	storage.			
		
7.9c	Variation	in	substrate	concentration	
	
To	date	when	carrying	out	GCase	activity	measures	we	had	made	up	a	fresh	substrate	
solution.	We	realised	that	this	was	a	substantial	source	of	potential	variability	for	two	
reasons.	These	were	1)	that	the	volume	of	substrate	added	to	the	solution	was	extremely	
small,	meaning	that	margins	of	error	for	weighing	the	samples	could	cause	a	substantial	
impact	on	the	GCase	activity.	Assuming	that	at	the	stated	concentration	the	active	site	of	
the	GCase	was	not	saturated,	an	increase	in	substrate	concentration	would	equate	to	an	
increase	in	concurrent	catalytic	reactions	and	in	turn	and	increase	in	GCase	activity	(and	vica	
versa).	We	also	noted	2)	the	solubility	of	the	substrate	powder	was	not	complete	even	with	
prolonged	vortexing.	Once	again	any	variation	in	concentration	of	soluble	substrate	could	
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effect	the	GCase	activity.	The	latter	problem	was	easily	overcome	by	heating	at	25	degrees	
for	20	minutes.	We	initially	assessed	whether	any	difference	in	GCase	activity	after	a	freeze	
thaw	cycle	and	found	there	was	no	statistically	significant	differences	between	the	two	
(n=5,	10	wells	per	sample,	Wilcoxon	rank	sum	p=1.00).	We	then	compared	the	activity	
calculated	with	frozen	aliquots	of	substrate	solution	which	had	been	frozen	at	the	beginning	
of	the	experiment,	with	GCase	activity	calculated	using	a	fresh	substrate	solution	(Fig	5)	and	
found	there	was	no	significant	difference	between	the	two	(n=5,	10	well	per	sample,	week	1	
Wilcoxon	rank	sum,	p=0.386,	week	2	p=0.772,	week	3	p=1.00,	week	4	p=0.563).	On	this	
basis	we	elected	to	use	a	frozen	dissolved	substrate	solution	from	the	same	batch	for	all	
assays.		
	
7.9d	Variation	in	standard	utilised	
	
In	order	to	prevent	variation	caused	by	disprecancies	in	the	concentration	of	the	standard	
caused	by	weighing	discrepancies,	we	elected	to	use	frozen	and	aliquoted	standard	from	
one	batch	for	the	duration	of	the	study.	To	test	whether	freezing	had	any	effect	on	the	
standard	we	carried	out	a	test	assay	using	frozen	and	fresh	standard	from	the	same	batch.	
We	found	no	significant	difference	between	the	two	batches	(n=4,	10	wells	per	sample	
p=0.848).			
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7.9e	Intra-	and	inter-assay	variabilities		
The	cumulative	%	coefficient	of	variance	(CV)	for	all	the	experiments	(excluding	storage	
assays)	was	3.08%	(nsamples=5)	and	1.72%	(nplates=17)	for	the	intra-	and	inter-assay	CVs	
respectively.	Although	overall	%CVs	were	low,	there	was	a	considerable	range	for	the	intra-
assay	CV,	with	0.34%	being	the	lowest	and	13.33%	the	highest	%CV	found	across	all	the	
experiments.	In	fact	it	is	likely	the	CV	is	in	real	terms	some	what	lower	than	this,	as	we	saw	
an	improvement	in	CV	during	the	course	of	our	optimisation.	The	highest	%CV	was	from	the	
first	trial	and	0.34%	from	one	of	the	later	experiments.		
	
7.9f	Expected	effect	on	cerebrospinal	fluid	GCase	of	ambroxol	
	
	
Ambroxol	has	been	shown	consistently	to	increase	GCase	activity	in	fibroblasts,	neural	crest	
stem	cells,	mouse	brain	lysates	and	non	human	primates	35,37,286,301.	That	said,	the	effect	of	
ambroxol	binding	to	GCase	in	cerebrospinal	fluid	is	unclear.		The	rationale	for	the	observed	
increase	in	GCase	activity	in	these	various	models	is	that	chaperoning	of	GCase	to	the	
lysosomal	portion	of	the	cell	allows	pH	dependent	catalysis	to	occur.	Cell	lysis	typically	
keeps	lysosomes	intact,	hence	GCase	activity	in	these	cell	lines	is	increased	in	response	to	
cellular	incubation	of	ambroxol	because	the	lysosomes	are	enriched	for	GCase	protein.	
Conversely	cerebrospinal	fluid	is	broadly	acellular	(and	samples	are	spun	acellular	prior	to	
the	assay),	hence	the	detection	of	GCase	activity	in	it	means	that	free	GCase	protein	must	
be	present	in	the	cerebrospinal	fluid	(albeit	it	at	very	low	concentrations).	In	order	to	best	
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intepret	the	findings	of	the	AiM	PD	trial	we	carried	out	a	series	of	experiments	to	
understand	the	relationship	between	cerebrospinal	fluid	GCase	activity	and	the	presence	of	
ambroxol.	
	
7.9g	Incubation	of	cerebrospinal	fluid	with	ambroxol	causes	a	reduction	of	GCase	activity	
	
In	order	to	understand	the	effect	of	central	nervous	system		ambroxol	penetration	we	
added	ambroxol	to	control	cerebrospinal	fluid	derived	from	patients	from	the	Royal	Free	
hospital	undergoing	routine	LP	to	rule	out	normal	pressure	hydrocephalus	or	idiopathic	
intracranial	hypertension.	Ambroxol	was	added	at	a	concentration	of	500nM,	a	figure	based	
on	measured	concentrations	in	the	cerebrospinal	fluid	in	a	recent	clinical	trial	using	a	similar	
dose	302.	In	addition	we	added	isophagamine,	another	small	molecular	chaperone	of	GCase,	
again	at	a	dose	of	500nM	292.	We	also	carried	out	a	number	of	positive	controls	of	GCase	
inhibition,	namely		conduritol	B	epoxide	(CBE),	an	inhibitor	of	GCase	activity	309	and	
denatured	cerebrospinal	fluid	(by	heating	cerebrospinal	fluid	for	30min	at	80°C).	
	
Ambroxol	appeared	to	inhibit	GCase	activity	by	approximately	50%	(rank	sum,	95%CI	40.40-
52.11%,	p<0.0001)	compared	to	control	cerebrospinal	fluid.	Interestingly	isophagamine,	
which	has	been	previously	shown	to	be	a	more	inhibitory	chaperone,	reduced	activity	by	a	
further	30%	(80%	reduction	compared	to	controls)	compared	to	ambroxol	(rank	sum,	
p<0.0001)	producing	about	20%	of	the	GCase	activity	of	control	cerebrospinal	fluid	(95%CI	
18.36-20.99%].	GCase	activity	was	undetectable	in	both	CBE	treated	and	denatured	
cerebrospinal	fluid.	These	results	are	displayed	graphically	in	Fig.	6.				
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7.9h	Speculating	on	the	expected	effect	of	cerebrospinal	fluid	GCase	following	ambroxol	
administration.		
	
These	findings	are	interesting	as	they	confirm	that	ambroxol	binds	to	the	active	site	of	the	
free	GCase	protein	and	causes	direct	inhibition	of	catalysis.	As	such	any	change	other	than	
inhibition	of	GCase	activity	implies	an	upregulation	of	GCase	expression	into	the	
cerebrospinal	fluid	in	response	to	ambroxol.	This	would	not	be	a	completely	unexpected	
finding,	for	instance	the	newly	unsequestered	GCase	protein	might	be	available	in	sufficient	
quantities	as	to	be	surplus	to	the	requirements	of	the	lysosome,	meaning	it	may	be	
exocytosed	from	central	nervous	system	cells	and	eventually	into	the	cerebrospinal	fluid.	A	
sufficient	increase	in	GCase	concentration	would	be	likely	to	outweight	the	inhibitory	effect	
of	the	ambroxol.	This	emphasises	the	key	importance	of	assessment	of	GCase	and	
glucosylceramide	levels	within	the	cerebrospinal	fluid	as	these	will	allow	further	
interpretation	of	the	basis	of	ambroxol’s	mode	of	action.	For	instance	a	static	or	increased	
GCase	activity,	with	an	increase	in	cerebrospinal	fluid	GCase	levels	and	a	decrease	in	
glucosylceramide	substrate	levels	would	be	consistent	with	this	finding.	A	decrease	in	GCase	
activity	with	a	static	GCase	concentration	and	a	decrease	in	glucosylceramide	levels	would	
reveal	ambroxol	binding	to	the	substrate	and	increased	substrate	catalysis.	Even	the	
combination	of	a	reduced	GCase	concentration,	reduced	GCase	activity	and	reduced	
glucosylceramide	levels	would	imply	increased	GCase	reaching	the	lysosome	and	a	
corresponding	reduction	of	exported	GCase	into	the	cerebrospinal	fluid.	
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7.9i	Power	calculations	based	on	observed	GCase	activity	reduction	
	
Change	of	cerebrospinal	fluid	GCase	activity	is	the	primary	outcome	of	the	AiM	PD	study.	
Based	on	the	dataset	above	(mean	change	activity	50.47%,	SD	3.96%)	we	estimated	the	
number	of	participants	required	to	produce	a	statistically	significant	fall	in	GCase	activity	
(baseline	vs	6	month	ambroxol	treatment)	assuming	a	power	of	80%	and	confidence	
intervals	of	95%	(paired	student	T	test)	is	2	per	study	group,	meaning	that	to	detect	changes	
within	each	study	group	a	total	cohort	of	4	is	required.	Furthermore,	I	calculated	a	power	
curve	to	understand	the	limits	of	power	of	the	study	(Fig	7).	Using	this	curve	I	calculated	
that	given	the	proposed	number	of	participants	(N=20,	10	Parkinson	disease,	10	GBA	
Parkinson	disease),	assuming	a	50%	fall	in	activity	post	ambroxol,	a	standard	deviation	of	
50%	in	GBA	and	iParkinson	disease	groups	and	of	75%	across	all	participants	would	be	
detectable.	Based	on	these	calculations	we	felt	the	study	was	amply	powered	to	detect	
changes	in	the	primary	outcome.								
	
7.9j	Optimisation	dilution	of	leucocyte	pellet	sample	from	CPT	blood	collection	tubes		
In	order	to	standardise	the	collection	procedure	for	leucocytes	derived	from	human	blood	
we	purchased	BD	Vacutainer®	CPT™	Mononuclear	Cell	Preparation	Tube	-	Sodium	
Heparin	(catalogue	number	362753).	Briefly	the	vacutainer	tubes	collect	a	set	volume	(8ml)	
of	blood	above	an	intermediate	density	material	which	allows	blood	cells	to	pass	to	the	
bottom	of	the	tube	upon	centrifugation.	Leucocytes,	being	too	dense	to	pass	through	the	
material	are	collected	underneath	the	serum	and	can	be	removed	and	pelleted	with	a		
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pipette.	Previously	we	had	collected	blood	in	a	standard	EDTA	tube	and	pipetted	the	blood	
over	the	lysoprep,	however	this	introduced	inconsistency	in	terms	of	the	sample	volume	
“filtered”	and	produced	a	small	and	in	some	cases	insufficient	yield.					
	
Conversely,	the	principle	problem	we	encountered	was	that	the	pelleted	leucocytes	were	
too	large.	This	meant	that	in	the	case	of	the	larger	pellets	the	BCA	protein	assay	appeared	to	
underestimate	the	protein	concentration	because	the	fluorescent	substrate	was	saturated.	
Moreover	there	was	substantial	variation	between	size	of	the	pellets.	This	compounded	the	
problem	as,	for	instance,	it	meant	that	a	halving	of	the	protein	concentration	would	not	
lead	to	an	estimated	halving	of	the	calculated	protein	concentration.	In	order	to	ascertain	
the	optimal	dilution	factor	which	prevented	saturation	of	the	BCA	assay	whilst	not	overly	
diluting	the	sample	we	collected	leucocyte	pellet	samples	from	five	control	subjects	and	
serially	diluted	the	pellet	before	carrying	out	a	BCA	assay	on	the	dilutions.	The	results	are	
listed	below	(table	3)	and	are	graphed	in	Fig	8.	On	this	basis	of	these	results	a	x8	dilution	
appeared	to	represent	the	optimal	dilution	factor.			
	
Table	3.	Protein	concentration	following	serial	dilutions	of	leucocyte	pellet	
sample	
x1	
(mg/ml)	
x2		
(mg/ml)	
x4		
(mg/ml)	
x8		
(mg/ml)	
x16		
(mg/ml)	
1	 0.64	 0.57	 0.32	 0.16	 0.11	
2	 0.80	 0.63	 0.38	 0.21	 0.13	
3	 0.57	 0.40	 0.24	 0.14	 0.09	
4	 1.78	 1.28	 1.07	 0.61	 0.36	
5	 1.68	 1.34	 0.93	 0.72	 0.35	
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7.10	Liquid	chromatography	mass	spectrometry	assays	
7.10a	Ambroxol	liquid	chromatography	mass	spectrometry	assay	optomisation	
	
Optimisation	of	the	LCMS	technique	was	carried	out	on	our	behalf	by	Laboratories	of	the	
Government	Chemist	(LGC).	50ul	of	ambroxol	standard	solution	(or	methanol	in	the	case	of	
blanks)	and	ambroxol-d5	internal	standard	was	added	to	a	250uL	matrix	and	vortexed.	
Protein	was	precipitated	using	1ml	acetonitrile.	The	sample	was	then	vortexed	and	
centrifuged	(12min	13000rpm).	The	supernatant	was	diluted	50/50	and	injected	(10ul	
volume)	onto	an	ACE	Excel	2	C128-AR	column.	A	Gradient	comprised	of	of	H20	+	0.1%	
formic	acid,	15%	methanol	+	0.1%	formic	acid	and	methanol	+	5%	TetrahydroFuran	was	
used.	Flow	was	directed	to	the	mass	spectrometer	between	2-12	minutes	and	to	waster	at	
all	other	times.	Mass	spectrometry	was	performed	at	450°C,	CUR	10,	GS1:60	GS2	60	IS	
5000v.	For	ambroxol,	transitions	were	defined	at	379	à	264,	277à262,	281à266	and	for	
the	internal	standard	at	384	à	264,	382	à	262.		
	
For	the	validation	a	nine	point	calibration	was	performed	at	0.1-500ng/ml	with	six	replicate	
spikes	at	high	and	low	concentrations.	At	least	3	batches	were	prepared	on	three	separate	
days	for	each	matrix.	Triplicates	spikes	were	performed	at	the	limit	of	detection.	Two	pre-
prepared	QC	samples	were	at	stored	at	-80	degrees.	Acceptance	criteria	were	a	retention	
time	of	+/-	0.1min,	Calibration	R2	>0.995,	signal	to	noise	ratio	>	3	for	limits	if	detection	and	
>10	for	limits	of	quantification	within	ratios	of	primary	transitions	with	20%	in	both	cases.		
Spike	recovery	between	70-120%.	QC	between	70-120%.		
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In	serum	a	high	spike	at	250ng/ml	and	a	low	spike	at	5ng/ml	were	supplemented	by	an	
additional	spike	at	1500ng/ml	(diluted	1/10	post	extraction).	In	cerebrospinal	fluid	a	high	
spike	at	100ng/ml	and	a	low	spike	at	1ng/ml	were	used.	In	all	cases	acceptance	criteria	were	
met.	In	the	case	of	the	QC	samples	(50ng/ml	in	serum	and	cerebrospinal	fluid)	samples	were	
run	initially	in	duplicate.	Initially	in	both	cerebrospinal	fluid	and	serum	the	acceptance	
criteria	were	not	met	in	2	batches	(batch	1	and	2	cerebrospinal	fluid,	batch	2	and	3	serum).	
It	was	discovered	that	standard	degraded	upon	storage	at	-80	degrees.	The	QC	samples	
were	repeated	with	fresh	standards	and	all	samples	met	acceptance	criteria.	This	
modification	was	incorporated	into	the	final	protocol.	For	both	samples	the	limit	of	
detection	was	0.5ng/ml	(1.3nmol)	and	limit	of	quantification	was	1ng/ml	(2.6	nmol).	This	is	
well	below	the	anticipated	concentrations	of	ambroxol	found	by	found	by	Narita	et	al.	at	an	
equivalent	dose	(cerebrospinal	fluid	60-830	nmol,	serum	41–424nmol)	302.		
	
7.10b	Quantification	of	Glucosylceramide	and	Glucocerebrosidase	cerebrospinal	fluid	protein	
levels	by	mass	spectrometry	
	
In	order	to	measure	glucosylceramide	and	GCase	concentration	within	cerebrospinal	fluid	it	
was	necessary	to	develop	novel	assays.	We	carried	out	a	number	of	validation	experiments	
to	ensure	these	assays	had	sufficient	sensitivity	and	specificity	to	detect	and	quantify	the	
proteins/lipids.	These	were	performed	on	our	behalf	by	Jenny	Hallqvist	of	the	Centre	for	
Translational	Omics	UCL	Great	Ormond	Street	Institute	of	Child	Health.		
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7.11c	Glucocerebrosidase	
	
The	samples	were	prepared	in	the	following	manner.	10g	whole	protein	yeast	enolase	were	
added	to	300	µL	cerebrospinal	fluid.	900	µL	ice	cold	acetone	was	added	whereupon	the	
samples	were	vortexed	and	left	at	-20	°C	overnight.	The	samples	were	centrifuged	at	16	900	
x	g,	+4	°C	for	10	minutes.	Supernatant	was	taken	off	and	the	pellet	was	washed	twice	with	
ice	cold	80%	acetone.	The	samples	were	freeze-dried	overnight.	The	freeze-dried	
cerebrospinal	fluid	was	re-suspended	in	60	µL	digest	buffer	(100	mM	Tris,	pH	7.8,	6M	urea,	
2M	thiourea,	2%	ASB14)	and	shaken	for	30	minutes.	4.5	µL	DTE	solution	were	added	and	
the	samples	were	left	shaking	for	1	hour.	9	µL	of	IAA	solution	were	added,	the	samples	were	
shaken	and	left	to	incubate	in	darkness	for	45	minutes.	496.5	µL	of	MilliQ	water	were	
added.	3	µg	trypsin	were	added	and	the	samples	were	incubated	at	+37	°C	for	16	hours.	The	
samples	were	cleaned	of	salts	using	C18	cartridges.	Peptides	were	eluted	with	70%	acetone.	
Solvents	were	evaporated	and	the	samples	were	reconstituted	in	100	µL	3%	ACN,	0.1%	TFA	
prior	to	analysis	by	mass	spectrometry.	Mass	spectrometry	was	performed	at	450°C,	CUR	
10,	GS1:60	GS2	60	IS	5000v.	
	
The	calibration	curve	consisted	of	a	set	of	pooled	cerebrospinal	fluid	samples	spiked	with	
known	amounts	of	analyte.	Samples	were	analysed	on	Waters	Cortecs	UPLC	C18+,	1.6	µm,	
2.1	x	50	mm	(with	a	VanGuard	pre-column).	A	solution	of	MilliQ	water	with	0.1%	formic	acid	
was	added	and	acetone	with	0.1	formic	acid	was	slowly	added	to	a	target	gradient	of	40%	
over	7	minutes	whereupon	the	flow	was	increased	to	100%	acetone.	Quantifier	and	qualifier	
transitions	were	measured	respectively	at	731>1100	and	731>1199.	The	transition	for	the	
internal	standard	was	measured	at	790>805.	The	duplicate	points	for	each	calibrant	in	the	
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calibration	curve	consist	of	one	measurement	from	a	20	µL	injection,	and	one	from	a	10ul	
injection.	The	lowest	point	used	for	calculations	in	the	calibration	curve	was	0.5	ng/µL	
spiked	in	pooled	cerebrospinal	fluid.	Unfortunately	GCase	quantification	in	five	
cerebrospinal	fluid	samples	were	below	the	limits	of	quantification.	In	order	to	broaden	the	
limits	of	quantification	we	increased	the	sample	volume	used	to	500	µL	cerebrospinal	fluid.	
We	also	simplified	the	purification	procedure	in	order	to	increase	the	sample	yield,	omitting	
the	acetone	cleaning	step	before	reconstitution	in	50	µL	and	injection.	Following	these	
changes	it	was	possible	to	detect	GCase	with	a	revised	limit	of	detection	/quantification	of	
1nM	respectively.		In	the	pooled	QC	sample	a	concentration	of	84ng/ml	(58nM)	was	
detected,	whilst	within	the	five	sample	tested	concentrations	ranged	from	53-169	ng/ml	
(36-116nM).		
	
7.11d	Glucosylceramide	
	
550uL	ice	cold	CHCl3:MeOH	[2:1,	v/v]	containing	the	internal	standards	(IS)	d3-C16-Gb1	and	
dimethylpsychosine	were	added	to	100	µL	cerebrospinal	fluid.	The	concentration	of	the	
internal	standards	in	the	extraction	mixture	were	as	follows;	[D3]-C16:0-Gb1	:	4	ng/mL,	
Dimethylpsychosine:	0.05	ng/mL.		The	samples	were	shaken	in	room	temperature	at	7	x	g	
for	20	minutes	and	thereafter	left	for	1	h	at	room	temperature.	The	samples	were	
centrifuged	at	+4	°C,	16	900	x	g	for	5	minutes.	The	organic	phase	lower	phase	was	
transferred	to	glass	vials	and	dried	under	N2.	A	calibration	curve	was	created	by	spiking	a	set	
of	pooled	samples	with	known	amounts	of	Gb1.	The	samples	were	reconstituted	in	50	µL	
MeOH	prior	to	analysis	by	mass	spectrometry.	Mass	spectrometry	was	performed	at	450°C,	
CUR	10,	GS1:60	GS2	60	IS	5000v.	
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Detection	of	glucosylceramide	is	complicated	by	the	existence	of	a	number	of	isoforms	of	
the	lipid.	Transitions	are	listed	below:	
	
Isoform	 Monitored	transitions	
[D3]-C16:1	(internal	standard)	 725.67	>	563.67	
Dimethyl	psychosine	(internal	standard)	 490.46	>	310.44	
Lyso-Gb1	 462.46	>	264.3/282.0	
C16:0-CMH	 722.7	>	542.6/560.6	
C16:0-CMH-OH	 738.6	>	264.3	
C18:1-CMH	 748.6	>	586.6		
C18-CMH	 750.6	>	588.6		
C18:0-OH	 766.6	>	264.3	
C20-CMH	 778.6	>	616.7		
C20-CMH-OH	 794.6	>	264.3	
C22:1-CMH	 804.7	>	642.7		
C22-CMH	 806.7	>	644.7		
C22-CMH-OH	 820.7	>	658.8	
C24:1-CMH	 832.7	>	670.7		
C24-CMH	 834.7 >	672.7		
Table	4.	Mass	spectrometry	transitions	used	for	detect	glycosphingolipid	isoforms	
	
The	Gb1	standard	(Matreya	ID	1521)	consisted	of	a	mixture	of	Gb1	isoforms.	Gb1	is	present	
in	isoforms	due	to	the	varying	fatty	acids	attached	to	it.	For	calculation	of	the	total	Gb1	
content	in	the	samples,	a	calibration	curve	with	the	sum	of	all	isoforms’	analyte/[D3]C16:0	
ratios	against	total	the	Gb1	concentration	was	constructed.	When	estimating	precision	and	
limit	of	detection,	the	C16:0	isoform	was	used.	We	also	attempted	to	detect	lyso	Gb1	a	
derivative	of	Gb1	in	which	the	fatty	acid	group	has	been	cleaved.	This	required	a	separate	
internal	standard	(Matreya	1306).	The	lipid	is	not	normally	detectable	in	bodily	fluids,	
however	it	is	found	in	Gaucher	and	Krabbe	patients	and	is	thought	to	be	produced	as	a	
breakdown	product	of	acid	ceramidase	mediated	catalysis	(when	high	levels	of	Gb1	are	
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present	in	these	conditions).	The	QC	samples	consisted	of	non-spiked	pooled	cerebrospinal	
fluid	samples	measured	on	two	different	days.	Acceptance	criteria	were	spikes	at	expected	
transitions	(+/-	0.1min),		linear	increase	in	signal	with	increase	in	standard	concentration,	a	
signal	to	noise	ratio	of	X3	for	limits	of	detection	and	x10	for	limits	of	quantification.		
Additionally	we	carried	out	further	QC	samples	on	cerebrospinal	fluid	from	five	(non	pooled)	
subjects	to	estimate	endogenous	levels	of	the	lipids.		
	
For	total	Gb1	the	limit	of	detection/quantification	was	0.04ng/ml	(0.05nM)	and	40ng/ml	
(51nM)	respectively.		Spikes	of	all	isoforms	were	detected	with	standard	alone,	standard	
spiked	in	matrix	and	in	QC	samples.	For	our	five	additional	QC	samples	total	Gb1	levels	were	
quantified	at	≈	120-190ng/ml	(153	-	242	nM).	A	breakdown	of	individual	concentrations	of	
Gb1	isoforms	is	available	in	the	appendices.	Unfortunately,	although	we	were	able	to	detect	
the	spiked	standard	in	solvent	and	within	the	matrix,	we	were	unable	to	detect	lyso	Gb1	
within	the	pooled	or	separate	QC	samples.		
	
7.12	Concluding	remarks	
	
In	this	chapter	we	have	presented	the	design	and	optimisation	work	necessary	to	
commence	the	AiM	PD	trial.	Most	of	this	work	revolved	around	the	frailties	and	pitfalls	of	
the	GCase	assay.	Clearly	being	able	to	reproducibly	quantify	this	activity	will	be	of	critical	
importance	to	the	success	of	the	study	and	through	the	studies	we	have	carried	out	we	
believe	that	in	our	hands	the	study	is	robust	with	excellent	intra	and	inter	assay/plate	
variability	demonstrated.	We	have	also	carried	out	in	vitro	experiments	which	have	allowed	
us	to	predict	the	effect	of	ambroxol	on	central	nervous	system	GCase	(although,	as	we	have	
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described,	we	would	not	be	surprised	if	the	predicted	fall	in	GCase	activity	did	not	occur,	
which	would	point	to	additional	nuances	to	ambroxol’s	biological	effect	of	GCase).	In	this	
case	the	metabolomics,	proteomics	and	lipidomics	screen	in	serum,	cerebrospinal	fluid	and	
urine	will	be	of	key	importance	as	it	will	hopefully	highlight	pathways	(and	potentially	off	
target	effects)	of	the	drug.	Moreover	we	have	shown	the	successful	optimisation	of	LCMS	
assays	to	detect	ambroxol,	glucosylceramide	and	GCase	levels	within	the	cerebrospinal	
fluid.	The	former	will	establish	central	nervous	system	penetration	whilst	the	latter	two	will,	
as	described,	aid	our	definition	of	the	precise	mode	of	action	of	the	drug.			
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Chapter	8	-	Preliminary	results	from	the	AiM	PD	clinical	trial	
	
8.0	Characterisation	of	participants	
	
We	attempted	to	match	participants	in	the	GBA	and	idiopathic	Parkinson	disease	group	in	
terms	of	age,	sex	and	Hohn	and	Yahr	clinical	staging.	Details	of	the	demographics	are	listed	
in	table	1	together	with	significance	tests	between	the	two	groups	(Spearman	rank	unless	
otherwise	stated)	whilst	the	mutations	of	the	GBA	Parkinson	disease	group	are	listed	in	
table	2.		In	terms	of	the	individual	mutations	we	opted	to	enrol	a	range	of	Parkinson	disease	
causing	mutations.	These	included	four	‘severe’	mutations,		two	non	severe	(N370S)	
mutation	carriers,	three	Parkinson	disease	associated	variants	(E326K)	and	one	biallelic	
participant	who	carried	the	T369M	polymorphism	together	with	a	null	stop	codon	which	
gives	rise	to	a	non	coding	GCase	protein.	By	including	a	diverse	selection	of	mutations	we	
hoped	to	establish	the	effect	on	a	mix	of	categories	of	genotype	in	order	to	understand	the	
potential	scope	of	recipients	for	the	treatment.	Subjects	were	recruites	by	SM.	Leucocyte	
GCase	assays	were	carried	out	by	Rob	Baker.	CSF	GCase	assats	were	carried	out	by	SM	or	
Laura	Smith.	Data	analysis	was	carried	out	by	SM.
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	 GBA	
Parkinson	
disease	
Idiopathic	
Parkinson	
disease	
significance	 combined	
Age,	median	(yr)	 61	 60	 p=1.000	 60.5	
Male	(%)	 90	 80	 p=1.000	 85	
Age	of	onset	(yr)	 47	 54	 p=0.1661	 53	
Duration	(yr)	 10	 5.5	 p=0.2576	 7	
H&Y	(%	stage	I	/	%	
stage	II)	
10/90	 10/90	 p=1.000	 10/90	
UPDRS(off),	
median	
64	 51	 p=0.3151	 56	
MoCa,	median	 26	 25	 p=0.7506	 25	
NMS,	median	 67	 31	 p=0.1692	 34	
NMSQuest,	
median	
11.5	 8	 p=0.1024	 10	
Table	1	Demographics		
Table	2.	GBA	mutations	of	GBA	Parkinson	disease	participants	
IVS	2+1	 N370S	
E326K	 N370S	
E326K	 RecNcil	(L444P/A456P/V460V)	
E326K	 R463C	
T369M/W362STOP	 R463C	
*	denotes	Fishers	exact	test	
	
8.1	cerebrospinal	fluid	and	leucocyte	GCase	activity	are	strongly	correlated.		
	
As	a	potential	biomarkers	of	Parkinson	disease	progression	or	Parkinson	disease	
development,	the	correlation	between	central	nervous	system	and	peripheral	blood	
leucocyte	GCase	activity	is	of	interest.	Clearly	if	the	correlation	is	strong	then	there	is	no	
need	to	subject	a	patient	to	the	expense	and	potential	complications	of	a	lumbar	puncture	
as	the	biomarker	can	be	measured	in	peripheral	blood.	To	date	no	studies	have	looked	at	
the	correlation.	Spearman’s	rank	showed	a	strong	correlation	between	cerebrospinal	fluid	
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and	leucocyte	GCase	(p=0.001).	A	scatter	graph	of	the	correlation	is	shown	in	Figure	1.	As	
would	be	expected	there	were	statistically	significant	differences	in	GCase	activity	in	both	
leucocytes	(Spearman	coef	-0.67,	p<0.0001)	and	cerebrospinal	fluid	(Spearman	oef	=-0.689,	
p<0.0001).	Box	plots	of	both	are	displayed	in	Fig	2.		
	
8.2	cerebrospinal	fluid	GCase	does	not	correlate	with	markers	of	Parkinson	disease	severity	
	
We	explored	whether	cerebrospinal	fluid	GCase	activity	was	associated	with	clinical	markers	
of	Parkinson	disease	severity	namely	age	of	Parkinson	disease	onset,	duration	of	disease,	
UPDRSscore,	NMS,	NMSQuest,	MoCa	and	GBA	mutations	severity	(GBA	group	only).		In	
order	to	minimise	the	risk	of	type	1	error	caused	by	multiple	comparisons	we	initially	tested	
for	correlations	within	the	whole	cohort,	carrying	out	pairwise	analyses	only	when	a	
significant	result	was	obtained.	A	summary	of	these	tests	is	presented	in	table	3.	
	
	The	NMSQuest	was	the	only	assessment	where	correlations	were	observed	across	the	
whole	cohort	and	this	was	duplicated	in	the	GBA	Parkinson	disease	group	only.	A	scatter	
graph	of	the	correlation	is	shown	in	Fig	3.	Trends	were	observed	for	the	NMS	(p=0.0991).	It	
seems	strange	that	correlations	exist	between	the	non	motor	features	of	Parkinson	disease	
and	cerebrospinal	fluid	activity,	but	not	in	terms	of	any	other	measures.	This	may	be	a	
question	of	power.	Slight	trends	could	be	said	to	exist	for	UPDRS	(coef.	-0.2650,	p=0.3039),	
disease	duration	(coef.	-0.2741,		p=0.3042)	and	age	of	onset	(coef.	0.3004,	p=0.2582),	
although	they	are	far	from	convincing.	Given	a	few	of	the	participants	had	relatively	mild	
Parkinson	disease	(e.g	UPDRS23	and	29),	non-motor	features	may	provide	a	more	
prominent	phenotype	to	correlate	to.		Nonetheless	this	data	does	add	some	weight	to	the		
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GBA	PD
Idiopathic	PD
Fig	1.	scatter	graph	of	CSF	(x)	and	leucocyte	GCase (y)	in	GBA	PD	(red)	and	idiopathic	PD	(blue)	
subjects	
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Fig	2.	Box	plots	of	CSF	(left)	and	leucocyte	GCase activity	in	GBA	PD	and	idiopathic	PD	subjects	
Stephen	Mullin	–	PhD	thesis	
	
	
224	
	
	
	
	
	
Table	3.	Correlation	of	cerebrospinal	fluid	GCase	activity	with	clinical	markers	of	
Parkinson	disease	severity	
	 Combined	
Parkinson	disease	
group	
GBA	Parkinson	
disease	
Idiopathic	
Parkinson	disease	
AAO	 p=0.2582	 -	 -	
duration	 P=0.3042	 -	 -	
UPDRS	 p=0.3039	 -	 -	
NMS	 p=0.0991	 -	 -	
NMSQuest	 p=0.0464	 p=0.0017	 p=0.1802	
MoCa	 p=0.7889	 -	 -	
Mutation	severity	 p=1.000*	 	 	
*	denotes	Fishers	exact	test	
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GBA	PD
Idiopathic	PD
Fig	3.	scatter	graph	of	CSF	GCase activity	(x)	and	NMSQuest score	(y)	in	GBA	PD	(red)	and	
idiopathic	PD	(blue)	subjects	
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hypothesis	that	GCase	is	a	potential	biomarker	of	Parkinson	disease,	although	the	result	is	
far	from	conclusive.					
	
8.3	Preliminary	data	shows	ambroxol	is	tolerable	at	1.26g/day	
	
At	the	time	of	writing	16	participants	had	reached	the	target	dose	of	1260mg.	Reported	
adverse	events	related	to	the	IMP	were	nausea	and	burning	at	the	back	the	throat	when	the	
tablets	were	not	taken	with	food	as	advised	(2	participants).	One	of	these	participants	
withdrew	from	the	study,	primarily	on	account	of	illness	in	the	family,	although	dyspepsia	
was	cited	as	a	contributing	factor.	Another	subject	withdrew	because	the	tablet	burden	(7	
tablets	3	times	a	day)	was	too	high.	Otherwise	participants	have	tolerated	the	ambroxol	
well	with	minimal	side	effects.			
		
8.4	Ambroxol	delivers	a	dose	dependent	increase	in	GCase	activity	in	GBA	Parkinson	disease	
cases		
	
Compared	to	baseline,	ambroxol	administration	delivered	a	median	63%	and	109%	increase	
in	GCase	activity	at	10	days	(120mg	TID)	and	3	months	1260mg	TID	respectively,	both	of	
which	reached	statistical	significance	(Fig	4	and	5).	For	idiopathic	Parkinson	disease	
participants	the	median	increase	was	7%	and	15%,	although	this	failed	to	reach	significance	
(Tables.	4	and	5).		A	graph	of	these	results	is	shown	in	Fig	4.		
	
It	is	unsurprising	that	the	percentage	GCase	activity	increases	more	prominently	amongst	
GBA	mutations	carriers.	Ambroxol’s	putative	mode	of	action	is	to	mobilise	mutant	ER	
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sequestered	GCase	to	the	lysosome.	In	idiopathic	Parkinson	disease	subjects	the	degree	of	
such	sequestration	is	likely	to	be	substantially	less,	hence	the	potential	to	increase	GCase	
activity	is	reduced.	None	the	less	in	vitro	studies	do	suggest	a	lesser,	although	still	
detectable	increase	in	GCase	activity	35,37.	We	would	expect	to	see	this	effect	mirrored	in	
the	idiopathic	Parkinson	disease	group.	There	is	a	small,	non	significant	increase	detected	
amongst	the	idiopathic	Parkinson	disease	group.	Our	recruitment	strategy	initially	recruited	
GBA	Parkinson	disease	cases	and	matched	them	with	idiopathic	Parkinson	disease	subjects.	
As	such	the	number	of	participants	who	had	reached	3	months	on	the	IMP	was	a	reflection	
of	this	(GBA	Parkinson	disease	5,	idiopathic	Parkinson	disease	2).	Accordingly	it	is	likely	that	
as	numbers	increase	this	trend	will	reach	significance.						
	
8.5	Concluding	remarks	
	
We	have	presented	here	preliminary	data	from	the	AiM	PDtrial.	The	baseline	result	are	of	
interest	in		themselves.	In	the	first	case	they	confirm	that	peripheral	GCase	activity	is	a	good	
correlate	of	central	nervous	system	GCase	activity,	alleviating	(if	in	future	GCase	is	advanced	
as	a	Parkinson	disease	biomarker)	the	need	for	collection	of	cerebrospinal	fluid.	We	have	
also	presented	some	limited	data	supporting	at	least	some	correlation	with	Parkinson	
disease	disease	severity,	although	as	we	have	discussed	the	results	are	not	conclusive.	
Finally	we	have	shown	dose	dependent	increases	of	GCase	activity	in	peripheral	blood	
leucocytes	following	ambroxol	administration.	Of	course,	the	primary	outcome	of	the	study	
is	to	establish	ambroxol’s	penetrance	and	target	engagement	within	the	central	nervous	
system	,	but	nonetheless	these	results	are	highly	promising,	
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baseline 180mg	
day	10
1260mg
month	3
Fig	4.	Graph	of	change	in	leucocyte	GCase activity	pre	and	post	dose	in	GBA	PD	(red)	and	idiopathic	PD	(blue)	
patients	
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Table	4.	statistical	tests	
GCase	activity	pre	and	post	
dose	
Day	10	(120mg	TID)	 3	month	(1260mg	TID)	
GBA	Parkinson	disease	 N=8		Z=-2.731	p=0.0063	 N=5	Z=-3.646	p=0.0003	
Idiopathic	Parkinson	
disease	
N=8		Z=0.00		p=1.0000	 N=2	Z=0.000	p=1.000	
	
GBA	
baseline	
GCase	
nmol/mg/hr	
GCase	at	day	
10	(120mg)	
nmol/mg/hr	
GCase	at	3	
months	
(1260mg)	
nmol/mg/hr	
%	change	
GCase	at	
day	10	
(120mg)		
%	change	
GCase	at	3	
months	
(1260mg)		
baseline	
cerebrospinal	
fluid	GCase	
nmol/ml/hr	
IPD	mean	 13.65	 13.45	 14.95	 -1.50	 15.35	 0.49	
IPD	median	 13.35	 13.1	 14.3	 7.28	 15.36	 0.42	
GBA	PD	mean	 8.65	 13.85714	 14.38	 63.41	 129.2234	 0.26	
GBA		median	 7.30	 12.10	 14.30	 60.87	 109.52	 0.26	
Combined		
mean	 11.51	 13.64	 14.54	 28.79	 96.69	 0.39	
combined	
median	 11.70	 12.70	 14.30	 23.93	 104.29	 0.36	
Table	5.	descriptive	statistics	of	GCase	activity	pre	and	post	dose
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Chapter	9	-	Conclusion	
	
9.0	Two	complementary	disease	models	caused	by	the	same	genetic	mutations		
	
It	is	a	unique	and	not	fully	exploited	privilege	for	researchers	examining	the	GBA	gene,	that	
two	human	disease	models,	one	which	is	rare	with	a	young	onset	and	very	debilitating	
course	and	one	which	is	common,	phenotypically	heterogeneous	and	a	disease	of	old	age,	
coexist	and	are	caused	by	mutations	in	the	same	gene.	For	Parkinson’s	researchers,	twenty	
years	of	research	and	the	proven	therapeutic	strategies	Gaucher	researchers	have	devised	
and	demonstrated	have	doubtless	advanced	the	field	by	years	if	not	decades.	The	major	
question	that	remains	unanswered	is	whether	the	disease	mechanism	underlying	the	two	
diseases	the	same.	In	chapter	2	we	presented	data	showing	that	many	of	the	prodromal	
features	present	in	Parkinson	disease	are	also	present	in	asymptomatic	GBA	carriers	and	
Gaucher	patients.	Moreover	in	chapter	4	we	showed	that	amongst	GBA	carriers	(which	
includes	a	substantial	number	of	Gaucher	patients)	serum	alpha	synuclein	levels	are	
upregulated	in	those	with	the	most	prominent	evidence	of	these	Parkinson	disease	
prodromal	features	and	that	there	is	a	good	correlation	between	serum	alpha	synuclein	
levels	and	the	number	of	severe	mutations	carried.	We	have	already	discussed	the	
commonalities	of	the	clinical	presentations	of	so	called	neuronopathic	Gaucher	disease	and	
aspects	of	Parkinsonian	disorders.	These	comparisons	are	brought	further	into	focus	by	the	
finding	that	the	mutations	associated	with	neuronopathic	Gaucher	features	are	also	those	
with	the	highest	risk	of	Parkinson	disease.		The	fact	that	penetrance	of	GBA	Parkinson	
disease	and	neuronopathic	Gaucher	disease	are	both	variable	highlights	further	these	
striking	commonalities.	It	is	the	responsibility	of	researchers	from	both	fields	to	fully	exploit	
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the	outstanding	opportunities	that	spawn	from	the	appropriate	investigation	of	these	
diseases,	in	tandem.	
	
9.1	A	common	but	heterogenous	genetic	cause	of	Parkinson’s	
	
The	neurogenetics	community	has	to	date	been	extremely	adept	at	identifying	very	rare	and	
highly	penetrant	Parkinson	disease	causing	gene	mutations	and	conversely	very	common	
variants	associated	with	marginal	odds	ratios	of	Parkinson	disease.	What	is	particularly	
remarkable	about	GBA	is	that	it	lies	in	between	these	two	exemplars,	namely	it	is	a	
reasonably	common	genetic	risk	factor	associated	with	an	incomplete	but	none	the	less	
highly	significant	risk	of	developing	Parkinson	disease.		Such	intermediate	frequency,	
intermediate	penetrance	alleles	are	perhaps	the	most	pertinent	because	they	mimic	the	
inheritance	of	idiopathic	Parkinson	disease,	in	that	a	family	history	of	Parkinson	disease	is	
the	single	greatest	genetic	risk	factor	for	it,	although	most	Parkinson	disease	is	not	inherited	
in	a	mendelian	manner.		GBA	allele	frequencies	amongst	the	Parkinson	disease	population	is	
around	0.05	(5%)	and	this	makes	GBA	by	some	way	the	most	significant	genetic	risk	factor	
for	Parkinson	disease.	Thus	GBA	(and	LRRK2)	are	the	only	examples	of	a	genetic	risk	factors	
which	have	significance	to	a	large	number	of	Parkinson	disease	patients.	It	may	be	that	the	
GBA	gene	is	even	more	important	to	our	understanding	of	Parkinson	disease,	as	only	now	
has	full	exome	sequencing	(as	opposed	to	targeted	analysis	of	SNPs)	becoming	the	norm.	
The	very	onerous	practical	difficulties	of	sequencing	the	GBA	gene	also	mean	that	the	
identification	of	a	number	of	very	significant	alleles	(such	as	the	splice	variant	IVS	2+1)	are	
often	not	carried	out.	Another	hugely	promising	but	as	yet	largely	unexplored	area	is	the	
role	of	the	autonomous	pseudogene	in	the	pathogenesis	of	Parkinson	disease.	It	has	been	
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said	that	the	pseudogene	is	non	coding,	however	there	is	evidence	of	protein	transcription	
and	it	is	known	that	there	are	high	levels	of	variability	associated	with	it	310-312.	If	variants	in	
the	GBA	pseudogene	were	implicated	in	Parkinson	disease	then	this	would	be	likely	to	
broaden	the	scope	of	the	involvement	of	GBA	in	Parkinson	disease	still	further.		
	
On	a	practical	level	the	ubiquitous	frequency	and	involvement	of	GBA	in	Parkinson	disease	
pathogenesis	provides	a	stable	platform	to	understand	the	genetics	of	a	complex	polygenic	
disease	such	a	Parkinson	disease.	In	chapter	2	using	the	work	of	Ziv	Gan-Or	and	other	as	a	
prototype,	we	were	able	to	demonstrate	the	epidemiological	principle	of	ascribing	a	
quantification	“Parkinson	disease	risk”	to	individual	GBA	mutations.	The	stark	variation	
demonstrated	here	between,	for	example,	polymorphisms	such	as	E326K	and	severe	
disease	causing	alleles	such	as	L444P	or	84GG,	speak	to	the	complexity	of	the	genetics	that	
underlie	GBA	Parkinson	disease,	but	moreover	that	stratification	of	the	risk	to	an	individual	
mutation	carrier	may	be	tangible.	The	fact	that	such	a	vast	array	of	GBA	mutations	have	
been	described	in	the	context	of	Gaucher	disease	makes	this	process	all	the	more	tantalising	
because	much	of	the	leg	work	of	deciphering	which	variants	convey	significant	
pathogenicity	has	been	done	(assuming	that	all	Gaucher	causing	alleles	also	cause	Parkinson	
disease	which	may	well	be	an	assumption	which	lacks	nuance).	The	most	pertinent	take	
home	message	is	the	scale	required	to	undertake	this	kind	of	analysis.	Sample	sizes	in	the	
tens	of	thousands	are	required	and	this	makes	conventional	means	of	clinical	assessment,	
such	as	those	described	in	chapter	3	largely	redundant.	Big	data,	collected	in	a	sustainable	
and	cost	effective	manner	will	be	the	key	to	these	analyses	and	we	provide	a	blue	print	for	
such	assessment	in	chapter	4.		
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9.2	Towards	a	comprehensive	stratified	risk	model	accounting	for	the	variable	penetrance	of	
GBA	Parkinson	disease	
	
In	chapter	3	we	described	work	which	shows	consistently	that	the	prodromal	Parkinson	
disease	features	of	cognitive	impairment	and	hyposmia	seem	to	be	worse	amongst	
asymptomatic	GBA	carriers	than	age	adjusted	controls.	We	also	show	that	these	symptoms	
together	with	depression	appear	to	cluster	together	in	a	number	of	“higher	risk	subjects”	in	
a	prototype	model	for	disease	stratification.	Quite	what	the	significance	of	such	symptoms	
or	clustering	is	unclear,	nonetheless	is	seems	plausible	that	they	may	be	markers	of	the	
same	ongoing	neurodegeneration	which	ultimately	leads	to	Parkinson	disease	in	a	subset	of	
these	patients.	A	screening	approach	by	which	sensitivity	is	progressively	narrowed	by	
successive	more	focussed	methodologies	seems	a	plausible	and	realistic	possibility.	With	
genetic	classifications	of	Parkinson	disease	risk	(such	as	the	prototype	described	in	chapter	
2)	a	starting	point	of	simple	clinical	assessments	could	be	augmented	with	imaging	and	
biochemical	tests	to	achieve	this	end.	A	number	of	pilot	approaches	have	been	described	in	
chapter	5	of	which	PET	imaging	using	the	PK11195	ligand	appears	to	be	the	most	promising.	
In	all	cases	further	development	is	required,	necessitating	once	again	the	establishment	of	
large	cohorts	which	have	been	reliably	and	accurately	phenotyped.	Once	again	this	requires	
enlarging	of	cohorts	using	mechanisms	such	as	the	rapsodi	platform	described	in	chapter	4.	
In	this	chapter	we	describe	the	validation	of	a	number	of	novel	instruments	for	collecting	
clinical	data	as	well	as	the	adaptation	of	some	established	ones	using	questionnaires	or	
smell	identification	kits.	The	numbers	here	are	relatively	small	but	do	provide	tantalising	
evidence	that	it	may	be	feasible	to	detect	these	symptoms	using	an	internet	based	platform.	
The	assessments	in	question	are	by	no	means	the	finished	product	and	will	require	not	only	
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optimisation	and	improvement,	but	also	maintenance	of	enough	continuity	to	take	full	
advantage	of	the	prospective	nature	of	the	assessments.	Such	a	platform	will	rise	and	fall	on	
its	ability	to	maintain	the	attention	of	participants	without	the	motivating	factor	of	an	
assessor	present.	It	will	require	innovation	in	terms	of	approach	and	technology	(like	for	
instance	the	integration	of	touch	screen	technologies	into	future	portals),	but	will	provide	
insights	into	the	genetic,	epigenetic	and	epidemiological	cofactors	which	may	or	may	not	
contribute	to	penetrance	of	GBA	Parkinson	disease.	The	end	product,	of	course,	of	such	a	
complicated	an	involved	process	of	disease	stratification	will	(hopefully)	be	the	targeting	of	
bespoke	therapies	to	GBA	pathway,	such	ambroxol,	in	vivo	human	studies	of	which	are	
described	in	chapter	8.	
	
9.3	The	structural,	biochemical	and	biological	basis	for	GBA	mediated	Parkinson	disease	
pathogenesis		
	
The	pathological	basis	of	GBA	Parkinson	disease	remains	unclear.	In	this	thesis	we	have	
carried	out	experiments	using	a	variety	of	methodologies	which	contribute	to	our	
understanding	of	the	field.	In	chapter	5	used	PET	imaging	to	estimate	whether	there	was	
evidence	of	glial	activation	amongst	asymptomatic	GBA	carriers.	Small	numbers	accepted,	
these	experiments	found	that	nigral	PK11195	signal	is	upregulated	in	the	substantia	but	not	
in	other	brain	regions.	Moreover	the	signal	correlated	with	evidence	of	hyposmia,	a	well	
described	prodromal	Parkinson	disease	feature	occurring	decades	in	advance	of	Parkinson	
disease	onset.	The	fact	that	there	is	no	correlation	between	this	signal	and	the	DAT	signal	
recorded,	implied	that	in	advance	of	dopaminergic	loss	some	form	of	targeted	inflammation	
may	occur	in	Parkinson	disease	affected	brain	regions,	although	whether	this	is	a	pathogenic	
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or	protective	mechanism	is	unclear.	This	data	coincides	with	slightly	inconsistent	findings	
(also	described	in	chapter	5)	showing	variously	that	biomarkers	of	peripheral	immune	
activation	are	upregulated	and	together	fit	in	with	a	prevailing	literature	related	to	
neuroinflammation	and	Parkinson	disease.		
	
Equally	in	chapter	6	we	tested	a	hypothesis	that	sequestered	GCase	protein	gives	rise	to	a	
disruption	of	intracellular	calcium	signalling,	but	were	not	able	to	produce	any	evidence	to	
corroborate	it	(this	may	be	because	of	a	poor	choice	of	disease	model).		Finally	across	the	
thesis	we	have	carried	out	various	experiments	that	provide	insights	into	the	often	
presumed	mode	of	action	of	Parkinson	disease	conversion,	namely	GCase	activity	levels.	In	
chapter	2	we	correlated	the	generated	odds	ratios	of	the	Parkinson	disease	risk	of	individual	
mutations	with	peripheral	blood	spot	GCase	measurements	and	found	no	evidence	of	a	
correlation.	In	chapter	2	the	failure	of	GCase	activity	to	correlate	with	prodromal	risk	scores	
or	in	chapter	5	the	fact	that	no	correlation	of	serum	alpha	synuclein	levels	with	GCase	
activity.	Finally	in	Chapter	8,	we	showed	no	correlation	of	cognitive	impairment,	Parkinson	
disease	severity,	mutation	severity,	age	of	onset	or	any	other	measures	of	Parkinson	disease	
symptoms	severity	with	leucocyte	or	cerebrospinal	fluid	GCase	activity.	There	was	however	
a	strong	correlation	between	cerebrospinal	fluid	and	leucocyte	GCase,	activity,	confirming	
that	peripheral	leucocyte	measures	are	a	stable	representation	of	central	nervous	system		
GCase	activity.	On	balance	these	findings	disfavour	the	hypothesis	that	impaired	GCase	
activity	is	the	driving	factor	behind	the	pathogenesis	of	GBA	Parkinson	disease,	although	
there	are	hints	to	the	contrary,	such	as	the	fact	that		in	the	same	chapter	we	showed	that	
non	motor	Parkinson	disease	features	did	seem	to	correlate	with	this	cerebrospinal	fluid	
GCase	.		
Stephen	Mullin	–	PhD	thesis	
	
	
236	
	
A	recurring	theme	is	the	utility	of	epidemiological	and	clinical	studies	to	inform	in	terms	of	
the	basic	mechanisms	of	GBA	Parkinson	disease	pathogenesis.	There	is	no	more	prescient	
example	of	this	than	the	fact	that	astute	clinical	observation	(and	for	that	matter	not	on	the	
part	of	neurologists)	highlighted	the	initial	link	between	the	two	conditions.	As	such	the	
importance	of	appropriately	scaled	and	designed	clinical	and	cohort	based	research	is	once	
again	emphasised.	
	
9.4	The	realisation	and	promise	of	targeted	therapies	for	Parkinson	disease	and	Gaucher	
disease		
	
For	Parkinson’s	investigators	the	field	of	GBA	research	is	enhanced	significantly	by	the	large	
number	of	therapeutic	strategies	which	have	been	devised	and	(in	some	cases	proven)	in	
the	context	of	Gaucher	disease.	In	Chapters	7	and	8	I	have	described	preparatory	work	and	
preliminary	results	of	a	phase	II	clinical	trial	of	the	mixed	type	inhibitory	chaperone	of	
GCase,	ambroxol.	The	preliminary	data	is	encouraging	and	shows	that	as	expected	the	drug	
is	able	to	upregulate	GCase	activity	in	leucocytes	in	a	dose	dependent	manner.		There	are	
moreover	Parkinson	disease	clinical	trials	underway	of	substrate	reduction	therapies	for	
GBA	Parkinson	disease	and	together	they	hint	at	a	beckoning	era	of	medication	targeted	at	
the	GBA	pathway.	This	emphasises	the	importance	of	the	proposed	system	of	risk	
stratification	of	GBA	carriers	to	successfully	deliver	neuroprotective	drugs	prior	to	the	onset	
of	Parkinson	disease	symptoms.		
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9.5	GBA:	a	prototype	for	idiopathic	Parkinson	disease	
	
The	single	greatest	promise	of	the	GBA	paradigm	is	that	not	only	is	there	the	realistic	
promise	of	neurotherapeutics	targeted	at	GBA	mutation	carriers,	but	that	these	same	
strategies	may	be	applied	to	idiopathic	Parkinson	disease	patients	as	a	whole.	In	chapter	2	
we	discussed	at	length	about	the	shared	pattern	of	inheritance	of	GBA	and	idiopathic	
Parkinson	disease	and	highlighted	the	potential	(given	the	huge	number	of	documented	
Gaucher	causing	mutations	and	Gaucher	associated	polymorphism)	that	GBA	may	plausibly	
account	for	as	much	as	10%	of	UK	idiopathic	Parkinson	disease	cases	(in	addition	to	the	25%	
of	Israeli	Parkinson	disease	cases	are	already	known	to	be	GBA	positive).	It	is	reasonable	to	
speculate	that	other	variants	within	the	GBA	gene	may	account	for	even	more	of	the	
missing	inheritance	of	GBA	Parkinson	disease.		
	
Although	this	correlation	between	GCase	activity	and	many	of	the	biochemical,	clinical	and	
epidemiological	markers	of	Parkinson	disease	is	not	absolute	and	has	been	interrogated	
throughout	this	thesis,	it	is	established	that	compromise	of	the	GCase	enzyme	is	part	of	the	
pathological	process	underlying	Parkinson	disease	development.	At	a	cellular	level	
autophagy	is	an	established	and	well	studied	paradigm	in	Parkinson	disease	research.	A	
number	of	studies	have	shown	that	at	a	population	level	peripheral	and	central	GCase	
activity	is	lower	in	idiopathic	Parkinson	disease	subjects.	In	chapter	5	we	also	highlighted	a	
role	for	neuroinflammation	in	GBA	Parkinson	disease,	another	well	described	association	
with	the	pathogenesis	of	idiopathic	Parkinson	disease.	There	are	therefore	multiple	
rationales	to	lead	us	to	believe	that	GBA	targeted	neurotherapeutic	strategies,	such	as	those	
highlighted	in	chapters	7	and	8,	may	be	applicable	to	idiopathic	Parkinson	disease	as	a	
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whole.		Moreover,	the	data	collected	in	terms	of	the	prodromal	course	of	Parkinson	disease	
which	may	be	present	amongst	GBA	carriers	(chapter	3)	has	already	informed	us	as	to	how	
we	might	target	such	drugs	in	idiopathic	and	GBA	Parkinson	disease	alike,	whilst	the	
promise	of	enlarged	datasets	such	as	those	proposed	in	chapter	4	may	provide	a	practical	
mechanism	to	allow	us	to	do	so.	The	promise	of	the	GBA	gene	in	term	of	Parkinson	disease	
is	substantial.	In	the	author’s	opinion,	it	is	the	most	relevant	of	the	various	genetic	forms	of	
Parkinson’s	to	idiopathic	Parkinson	disease	as	whole	and	may	provide	substantive	
neuroprotective	therapies	and	screening	strategies	for	targeting	of	these		drugs	within	the	
near	future.	
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Appendices	
	
Chapter	1	
	
10.0		Supplementary	Methods		
	
Forty	one	studies	were	identified	and	included	in	the	final	analysis.	Mutations/variants	were	
included	if	they	were	found	in	two	or	more	separate	studies.	For	all	variants,	please	refer	to	
Tables	1	and	2,	Figures	2-4,	Supplementary	table	1	and	Supplementary	figures	1-6.	We	
excluded	two	studies	31,313	from	the	L444P/RecNcil	analyses	because	it	was	unclear	whether	
the	methodology	was	able	to	distinguish	between	L444P	as	a	lone	mutation	or	as	part	of	the	
RecNcil	haplotype.	
	
Although	pertinent	meta-analyses	of	the	role	of	N370S,	L444P	and	all	GD-causing	GBA	
mutations	in	Parkinson	disease105,106	already	exist	30,42,140,141,	we	attempted	to	carry	out	all	
three	analyses	on	these	mutations/pooled	data	to	validate	our	methods	in	a	context	where	
established	estimates	were	available.		
	
10.1	Supplementary	Results	
	
10.1a	All	GD-causing	mutations	
	
Meta-analysis	of	all	detected	Gaucher	disease	causing	GBA	alleles	(Fig	2.	Supp.	Fig	1	and	6)	
revealed	an	OR	of	3.53	(95%CI	3.14-3.97,	p=3.61x10-99),	however		Woolf’s	test	revealed	a	
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highly	heterogeneous	sample		(I2=	71.1,	p=1.60x10-12),	an	effect	which	has	been	
demonstrated	in	other	meta-analysis	30	Use	of	a	random	effects	model	did	not	resolve	this	
heterogeneity		(I2=	71.1,	p=1.60x10-12),	We	explored	through	meta-regression	the	influence	
of	ethnicity	(p=0.498),	the	portion	of	familial/early	onset	cases	(p=0.755)	and	the	screening	
methodology	(p=0.278)	used;	however	we	failed	to	show	a	significant	contribution	of	these	
co-covariates.	We	considered	whether	the	heterogeneity	could	be	caused	by	publication	
bias,	however	Begg’s	test	was	not	significant	(p=0.180).	Joint	analysis	revealed	an	OR	of	2.45	
(95%CI	2.18-2.73,	p=3.88x10-55).	We	attempted	to	carry	out	the	meta	analysis	amongst	
studies	individual	ethnicities.	Interestingly	the	Caucasian	(OR	3.55	[95%CI	2.37-5.30]	
p=3.0x10-10,	heterogeneity	I2	=	73.7	p=	8.07x10-9)	cohort	remained	heterogeneous	and	
Ashkenazi	cohorts	showed	a	strong	trend	towards	heterogenicity	(OR	4.46	[95%CI	3..07-
6.49]	p2.25x10-15,	heterogeneity	I2	=	58.8	p=	0.063);	however	the	East	Asian	(OR	10.16	
[95%CI	5.42-19.03]	p2.08x10-13,	heterogeneity	I2=3.9	p=0.469),	Hispanic	(OR	21.12	[95%CI	
3.74-119.28]	p=0.0002,	heterogeneity	I2=0.0	p=0.917)	and	North	African	cohorts	did	not	(OR	
5.15	[95%CI	1.30-20.32]	heterogeneity	I2			=	0.0	p=0.947).	
	
The	joint	analysis	revealed	an	odds	ratio	of	2.44	(95%CI	2.18-2.73,	p=3.64x10-56).	
	
10.1b	N370S	and	L444P	
	
In	the	case	of	joint	analyses	of	L444P	and	N370S	we	excluded	Ashkenazi	cohorts	to	prevent	
skewing	of	results	on	the	basis	of	the	higher	Ashkenazi	allele	frequency	of	these	21,314	in	the	
(disproportionately	large)	control	groups	in	two	of	these	studies	(respectively	Parkinson	
disease/control	groups	were	1,000/3,805	and	99/1,543).	Furthermore	we	confined	the	
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N370S	joint	analysis	to	Caucasians,	as	N370S	is	largely	specific	to	these	and	Ashkenazi	
populations	19,314-317.	This	allowed	us	to	augment	N370S	data	with	66,666	subjects	from	the	
ExAc	database.	Because	L444P	is	found	amongst	all	ethnicites,	we	were	not	able	to	generate	
an	adequately	matched	control	group	from	the	ExAc	database.		
	
N370S	meta-analysis	(Fig	2,	Supp	Fig.	2	and	6)		gave	rise	to	an	OR	of	3.11	(95%CI	2.60-3.72,	
p=1.84x10-35,	Woolf’s	p=0.078,	Begg	p=0.385).	Joint	analysis	(Fig.	2)	revealed	an	OR	of	3.85		
(95%CI	2.63-5.63,	p=	5.1x10-12)	and	4.24	(95%CI	3.52-5.11,	p=7.2x10-52)	including	control	
subjects	from	the	ExAc	database.		
	
L444P	meta-analysis	(Fig.	2,	Supp	Fig	2	and	6)	revealed	an	OR	of	8.76	(95%CI	6.01-12.76,	
p=1.2x10-29,	Woolf	p=0.997,	Begg	p=0.691).	Joint	analysis	(Fig.	2)	produced	an	OR	of	13.91	
(95%CI	8.58-22.54,	p=1.0x10-26).			
	
10.1c	RecNcil	(L444P;	A456P;	V460V)	
	
RecNcil	gives	rise	to	a	severe	form	of	Gaucher	diseaseand	after	N370S,	L444P,	E326K	and	
T369M	was	the	most	frequent	mutation	identified	in	our	analysis.	It	is	present	across	the	
spectrum	of	ethnicities	(apart	from	Ashkenazi	studies	which	did	not	screen	for	the	
mutation),	although	proportionately	it	appears	over	represented	in	East	Asian	populations.			
	
Meta-analysis	(Fig.	2,	Supp.	Fig	3	and	6)	revealed	an	OR	of	3.08	(95%CI	1.65-5.76,	p=8.0x10-
4,	Woolf	p=0.907,	Begg	p=0.921).	Joint	analysis	(Fig	2.)	showed	an	OR	of	3.63	[95%CI	1.68-
7.87]	of	developing	Parkinson	disease	associated	with	mutation	(p=0.002).	Because	RecNcil	
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is	a	haplotype	consisting	of	3	mutations	the	ExAc	database	did	not	include	control	data	to	
augment	the	dataset.		
	
10.1d	84GG	
	
84GG	is	a	null	mutation	caused	by	a	glycine	duplication	leading	to	a	frameshift	and	a	
premature	stop	codon	18	amino	acids	downstream.318	Our	study	confirms	previous	findings	
that	it	is	predominately	an	Ashkenazi	mutation	149	in	that	65.8%	of	Parkinson	disease	
(25/38)	and	90%	of	control	(9/10)	84GG	alleles	identified	were	in	Ashkenazi	cohorts	even	
though	they	accounted	for	10.5%	(1,100/7,021)	of	Parkinson	disease	subjects	and	56.7%	
(5,348/9,430)	of	control	subjects	surveyed.		
	
Meta-analysis	(Fig.	2,	supp.	Fig.	3	and	7)	revealed	a	combined	OR	of	13.47	(95%CI	7.75-23.44	
p=2.26x10-20,	Woolf	p=0.907,	Begg	p=1.00)	
	
Because	84GG	is	overwhelmingly	an	Ashkenazi	mutation	(65.8%	of	case	and	90%	of	control)	
we	excluded	non-Ashkenazi	studies	in	our	joint	analysis	in	order	not	to	unduly	skew	the	case	
and	control	groups	(lower	allele	frequency	amongst	other	populations).	Joint	analysis	(Fig.	
2)	concluded	that	84GG	increased	Parkinson	disease	risk	with	an	OR	of	14.42	(95%CI	6.96-
29.88	p=1.94x10-12).	Although	ExAc	data	was	available	it	was	not	included	due	to	an	absence	
of	Ashkenazi	participants.		
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10.1e	R120W	
	
R120W	is	a	severe	GD-causing	mutation.	It	was	disproportionately	prevalent	amongst	East	
Asian	populations	(89.3%	of	mutations	were	found	within	these	populations)	and	in	
particular	in	Japan	where	two	studies	accounted	for	24/28	mutations.	Meta-analysis	(Fig.	2,	
supp.	Fig.	3	and	7)	revealed	an	OR	of	8.85	(95%CI	2.51-31.11,	p=0.002,	Woolf	p=0.403,	Begg	
p=0.221).	The	joint	analysis	(Fig.	2)	derived	OR	of	the	risk	of	Parkinson	disease	was	51.92	
(95%CI	3.15-853.3,	p=0.016).	ExAc	control	data	was	not	available	for	this	mutation.		
	
10.1f	H255Q	
	
H255Q	causes	as	a	severe	GD-causing	mutation.	It	was	solely	found	amongst	Caucasians	and	
interestingly	all	these	were	within	Greek	cohorts.	Meta-analysis	(Fig.	2	supp.	Fig.	3	and	6)	
revealed	an	OR	of	4.58	(95%CI	0.80-26.27,	p=0.260,	Woolf	p=0.916	Begg	p=0.296).	The	joint	
analysis	(Fig.	2)	showed	a	significance	effect	with	(OR	4.71	[95%CI	2.06	–	10.63]	p=0.0007)	
but	not	without	(OR	9.38	[95%CI	0.53-164.39],	p=0.375)	the	addition	of	Caucasian	66,702	
control	subjects	from	the	ExAc	database.		
	
10.1g	E326K	
	
E326K	is	a	mild	mutation	and	causes	Gaucher	diseaseonly	in	combination	with	more	severe	
GD-causing	mutations.150	This	mutation	has	been	shown	to	reduce	enzyme	activity.23,35	Our	
meta-analysis	(Fig	3.,	sup	Fig.	3	and	6)		revealed	an	OR	of	(1.51	[95%CI	1.15-1.99]	p=0.006,	
Woolf		p=0.589,	Begg	p=0.855).	It	was	found	almost	exclusively	in	Caucasian	populations	
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(146/148	Parkinson	disease,	66/68	control),	and	accordingly	for	our	pooled	analysis	(Fig.	3)	
we	excluded	studies	in	non-Caucasian	groups	(OR	1.78	[95%CI	1.33-2.38],	p=2.4x10-4)	and	
then	augmented	the	control	group	with	66,406	Caucasian	controls	from	the	ExAc	database	
(OR	1.78	[95%CI	1.50-2.11],	p=1.6x10-11).		
		
10.1h	T369M	
	
T369M	is	classified	as	a	mild	GD-causing	mutation	and	is	pathogenic	only	in	conjunction	
with	a	severe	GD-causing	allele.	It	was	found	predominately	amongst	Caucasian	populations	
(59/61	and	23/24	amongst	case	and	control	group	respectively).	Meta-analysis	(Fig.	3,	supp.	
Fig.	3	and	8)	failed	to	show	a	significant	effect	(OR	1.69	95%CI	1.10-2.60,	p=0.051,	Woolf	
p=0.402,Begg	p=0.087).	Joint	analysis	(Fig.	3)	of	Caucasian	subjects	showed	an	OR	of	1.39	
(95%CI	0.86-2.25,	p=0.516)	and	1.06	(95%CI	0.81-1.28	p=0.99)	with	the	addition	of	64196	
Caucasian	controls	from	the	ExAc	database		
	
10.1i	D409H	
D409H	is	classified	as	a	severe	GD-causing	mutation.	It	is	found	amongst	Caucasian	and	
Asian	populations	within	our	study,	with	the	latter	being	relatively	over	represented	(6/14	in	
East	Asian	studies	in	the	Parkinson	disease	group).	Meta-analysis	(Fig.	4,	supp	Fig.	5	and	8)	
revealed	an	OR	of	2.58	(95%CI	1.04-6.39,	p=0.123,	Woolf	test	p=0.99,	Begg’s	test	p=0.876)	
and	joint	analysis	(Fig.	3)		(OR	6.89	95%CI	1.3-36.6	p=0.072)	failed	to	reveal	a	significant	
effect	although	a	further	joint	analysis	which	included	63,400	Caucasian	and	East	Asian	
control	subjects	from	the	ExAc	database	did	(OR	10.47	95%CI	4.71-23.3	p=1.4x10-8	).		
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10.0j	D409H;H255Q	
D409H;H255Q	is	classified	as	a	severe	GD-causing	mutations.	It	was	only	found	within	
Caucasian	studies	in	our	dataset.	Meta-analysis	(Fig.	3,	supp.	Fig.	5	and	8)	revealed	an	OR	of	
3.99	(95%CI	1.12-14.2,	p=0.066,	Woolf	p=0.990,	Begg	p=0.466)	and	of	(OR	2.75	95%CI	0.84-
8.93,	p=0.27,	Fig.	3	in	our	joint	analysis.		ExAc	data	was	not	available	for	this	haplotype.	
	
10.0k	R463C	
	
R463C	is	a	severe	GD-causing	mutation.	It	was	found	only	within	Caucasian	populations.		
Meta-analysis	(Fig.	3,	supp.	Fig.	4	and	8)	failed	to	reveal	a	significant	effect	(OR	3.87	95%CI	
0.87-17.29,	p=0.228,	Woolf’s	test	p=0.874	,Begg’s		test	p=0.734).		This	was	replicated	in	joint	
analyses	(Fig.	3)	with	(OR	1.63	95%CI	0.54-4.93,	p=0.999]	and	without	(OR	2.10	95%CI	0.85-
51.65,	p=0.999)	the	inclusion	of	66,728	ExAc	controls.	
	
	
Supp	table	1.	Summary	of	individual	study	characteristics	
Study	 year	 country	 ethnicity	 Mutations	
screened	
familial	 Total	
Parkinson	
disease	
Total	
CTL	
Asselta	et	
al.19	
2014	 Italy	 Caucasian	 Exons	8-11	
Y	
2,766	 1,111	
Bras	et	
al.319	
2009	 Portugal	 Caucasian	 sequencing	
N	
230	 430	
Choi	et	
al.320	
2012	 Korea	 E.	Asian	 sequencing	
Y	
277	 291	
Clark	et	
al.321	
2007	 USA	 Ashkenazi	 sequencing	
N	
278	 179	
Duran	et	
al.16	
2013	 UK	 Caucasian	 sequencing	
Y	
185	 283	
De	Marco	
et	al.322	
2008	 Italy	 Caucasian	 N370S,	L444P	
N	
395	 483	
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Emelyanov	
et	al.323	
	
2012	 Russia	 Caucasian	 N370S	
L444P	
Y	
320	 240	
Gan-Or	et	
al.22	
2015	 Israel	 Ashkenazi	 84GG,	N370S,	
L444P	 N	
1,000	 3,805	
Guo	et	
al.324	
2015	 China	 E.	Asian	 L444P	
N	
1,061	 1,066	
Han	et.	
Al.325	
2015	 Canada	 Caucasian	 sequencing	
N	
225	 110	
Hu	et	al.	 2010	 China	 E.	Asian	 N370S	 N	 328	 300	
Huang	et	
al.326	
2011	 China	 E.	Asian	 R120W,D409H,	
L444P,		 N	
967	 780	
Kalinderi	
et	al.327	
2009	 Greece	 Caucasian	 sequencing	
N	
172	 132	
Kumar	et	
al.328	
2013	 Serbia	 Caucasian	 sequencing	
N	
360	 348	
Lesage	et	
al.18	
2011	 France	 Caucasian	 sequencing	
Y	
1,391	 391	
Lesage	et	
al.329	
2011	 Tunisia	 N.African	 sequencing	
y		
194	 177	
Li	et	al.330	 2014	 Japan	 E.	Asian	 sequencing	 Y	 147	 100	
Mao	et	
al.331	
2010	 China	 E.	Asian	 L444P	
N	
616	 411	
Mata	et	
al.31	
2008	 USA	 Caucasian	 N370S,	L444P	
N	
721	 554		
Mitsui	et	
al.332	
2009	 Japan	 E.	Asian	 sequencing	
Y	
534	 544	
Moritau	et	
al.333	
2011	 Greece	 Caucasian	 N370S,	D409H,	
H255Q,	L444P,	
R120W	 N	
205	 206	
	
Neumann	
et	al.334	
2009	 UK	 Caucasian	 sequencing	
Y	
790	 257	
Nichols	et	
al.335	
2009	 USA	 Caucasian	 sequencing	
Y	
1,325	 359	
Nishioka	
et	al.317	
2010	 Tunisia	 N.African	 sequencing	
Y	
240	 372	
Noreau	et	
al.336	
2011	 Canada	 Caucasian	 sequencing	
N	
212	 189	
Peretz	et	
al.21	
2004	 Israel	 Ashkenazi	 84GG,	N370S,	
L444P	 N	
99	 1,543	
Rincon	et	
al.316	
2013	 Mexico	 Latino	 N370S,	L444P	
Y	
128	 252	
Ran	et	
al337	
2016	 Sweden	 Caucasian	 N370S,	L444P,	
E326K	 N	
1,872	 1,450	
Sato	et	
al.338	
2005	 Canada	 Caucasian	 84GG,	N370S,	
L444P	 Y	
88	 122	
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Seto	Salvia	
et	al.	339	
2012	 Spain	 Caucasian	 sequencing	
Y	
225	 182	
Spitz	et	
al.340	
2007	 Brazil	 Latino	 N370S,	L444P	
Y	
65	 267	
Tan	et	
al.341	
2007	 Singapore	 East.	
Asian	
N370S,	L444P	
N	
331	 347		
Toft	et	
al.342	
2006	 Norway	 Caucasian	 N370S,	L444P	
N	
311	 474	
Vaz	dos	
Santos	et	
al.343	
2010	 Brazil	 Latino	 RecNcil,	
N370S,	L444P	
Y	
110	 155	
Wu	et	
al.344	
2007	 Taiwan	 E.	Asian	 RecNcil,	
R120W	 N	
518	 339	
Yu	et	al.345	 2015	 China	 E.	Asian	 sequencing	 N	 184	 130	
Zhang	et	
al.140	
2012	 China	 E.	Asian	 R120W,	
N370S,	L444P	 Y	
195	 443	
CTL-	control,	Parkinson	disease	–	Parkinson	disease	
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Supp.	table	2.		Mutation/Variant	characteristics	and	summary	of	count	data	
Mutation/Variant	 exon	 type	 cDNA	 severe/mild	
/null	(GD)	
Parkinson	
disease+	
Parkinson	
disease-	
CTL+	 CTL-	 CTL+	
(Exac)	
CTL-	
(Exac)	
84GG	(Meta)	 2	 Insertion/	
frameshift	
1910Ggdup	 null	 30	 1,347	 9	 5,518	 -	 -	
84GG	(Joint)	 	 	 	 	 30	 1,347	 9	 5,518	 -	 -	
R120W	(Meta)	 5	 missense	 475C>T	 severe	 28	 2,840	 0	 1,553	 	 	
R120W	(Joint)	 	 	 	 	 25	 2,797	 0	 2,627	 -	 -	
H255Q	(Meta)	 7	 missense	 882T>G	 severe	 5	 9,553	 0	 3,949	 	 	
H255Q	(Jpint)	 	 	 	 	 5	 4,068	 0	 2,501	 24	 73,332	
H255Q;D409H	
(Meta)	
7,9	 complex	 882T>G	
1342G>C	
severe	 12	 553	 3	 551	 -	 -	
H255Q;D409H	
(Joint)	
	 	 	 	 12	 5,597	 3	 3,946	 -	 -	
E326K	(Meta)	 8	 missense	 1093G>A	 mild	 148	 5,698	 67	 4,185	 -	 -	
E326K	(Joint)	 	 	 	 	 146	 7,267	 66	 5,123	 798	 66,406	
T369M	(Meta)	 8	 missense	 1223	C>A	 mild	 58	 4,016	 23	 1,758	 	 	
T369M	(Joint)	 	 	 	 	 59	 5,334	 23	 2,837	 627	 63,569	
N370S	(Meta)	 8	 missense	 1226	A>G	 mild	 360	 13,112	 350	 13,262	 -	 -	
N370S	(Joint)	 	 	 	 	 208	 11,623	 32	 7,981	 242	 58,286	
D409H	(Meta)	 9	 missense	 1342G>C	 severe	 14	 4,405	 0	 2,657	 	 	
D409H	(joint)	 	 	 	 	 14	 9,328	 0	 5,840	 8	 63,392	
L444P	(Meta)	 9	 missense	 1448T>C	 severe	 299	 17,139	 20	 16,472	 -	 -	
L444P	(Joint)	 	 	 	 	 292	 15,441	 18	 12,155	 -	 -	
L444P;A456P;	
V460V(RecNcil)	
(Meta)	
9,10	 complex	 1448T>C	
1483G>C	
1497G>C	
severe	 45	 7,433	 7	 4,334	 -	 -	
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L444P;A456P;	
V460V(RecNcil)	
(Joint)		
	 	 	 	 45	 11,045	 7	 6,480	 -	 -	
R463C	(Meta)	 10	 missense	 1504C>T	 severe	 11	 2,715	 0	 1,279	 -	 -	
R463C	(Joint)	 	 	 	 	 11	 5,999	 0	 4,204	 4	 66,724	
CTL-	control,	cDNA	–	complementary	DNA,	Joint	–	Joint	analysis,	Meta	–	meta-analysis,	Parkinson	disease	–	Parkinson	
disease,	Gaucher	disease-	Gaucher	disease		
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Sup	Fig.	1.	Effect	size	(OR)	with	95%	CI	of	PD	risk	associated	with	H255Q;D409H,	
and	R463C	mutations
R463C
H255Q;D409H
H255Q
Mutation
Joint Analysis + Exac
Joint Analysis
Meta Analysis
Joint Analysis
Meta Analysis
Joint Analysis + Exac
Joint Analysis
Meta Analysis Analysis
Effect (95% CI)
2.10 (0.85, 51.65)
1.63 (0.54, 4.93)
3.87 (0.87, 17.29)
1.95 (0.66, 5.75)
3.99 (1.12, 14.20)
9.38 (0.53, 164.39)
4.71 (2.06, 10.63)
4.58 (0.80, 26.27)
p_value
.999
.999
.228
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.066
.375
7.0x10-4
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Supplementary	Fig.	2.	Forest	plot	of	risk	of	PD	(with	95%CI)	associated	with	L444P	and	N370S	mutations	
N370S and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 7.08 (2.58,19.45) Asselta   4.3
 3.16 (0.75,13.36) Bras et al   1.6
 5.29 (1.56,17.89) Clark et al   2.6
 8.62 (0.44,167.44) Dr Marco et al.   0.3
 7.83 (0.91,67.60) Duran et al.   0.6
 5.14 (0.26,99.98) Emelyanov et al.   0.4
 2.40 (1.91,3.01) Gan Or et al.  62.9
 2.47 (0.12,51.93) Han et al   0.5
 2.78 (0.56,13.86) Hu et al.   1.6
 14.79 (0.84,259.91) Kumar   0.4
 6.06 (1.46,25.13) Lesage   2.3
 4.61 (0.22,96.69) Lesage et al.   0.4
 4.28 (0.94,19.37) Mata et al.   1.7
 2.62 (0.33,21.04) Neumann   1.2
 0.54 (0.13,2.17) Nichols et al.   3.6
 0.18 (0.01,3.70) Noreau et al.   2.0
 5.62 (3.43,9.21) Peretz et al.   6.3
 5.02 (1.10,22.95) Ran et al   1.5
 1.39 (0.09,22.54) Sato et al.   0.6
 9.10 (0.50,165.74) Seto Salvia et al.   0.4
 0.87 (0.25,2.99) Toft et al   4.2
 7.17 (0.34,150.74) Vaz dos Santos   0.3
 3.04 (2.53,3.65) Overall (95% CI)
L444P and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 6.38 (1.98,20.55) Asselta et al.  14.7
 5.29 (0.25,110.69) Choi et al.   1.7
 3.25 (0.15,68.00) Clark et al   2.1
 9.96 (1.24,80.01) Dr Marco et al.   3.1
 7.72 (0.37,161.82) Duran et al.   1.4
 4.43 (0.53,37.01) Emelyanov et al.   4.0
 2.86 (0.64,12.80) Gan-or et al   5.8
 26.75 (3.62,197.51) Guo et al.   3.4
 4.49 (0.24,84.14) Han et al   2.3
 22.38 (3.03,165.03) Huang et al   3.8
 3.89 (0.18,81.62) Kalinderi et al   1.9
 1.94 (0.17,21.48) Kumar et al.   3.5
 10.55 (0.63,175.40) Lesage et al.   2.7
 2.75 (0.11,67.99) Lesage et al.   1.8
 18.54 (1.09,316.88) Li et al   1.9
 13.76 (1.84,102.92) Mao et al.   4.0
 7.60 (0.45,129.38) Neumann et al.   2.6
 4.64 (0.27,80.56) Nichols et al.   2.7
 4.67 (0.19,115.01) Nishioka et al.   1.4
 4.54 (0.53,39.22) Noreau et al.   3.6
 15.05 (4.62,49.04) Ran et al.   9.0
 31.17 (1.77,550.28) Rincon et al.   1.1
 4.20 (0.17,104.32) Sato et al.   1.4
 17.78 (1.04,305.57) Seto Salvia et al.   1.8
 21.06 (1.00,444.16) Spitz et al.   0.7
 18.26 (1.05,317.65) Tan et al   1.7
 4.61 (0.48,44.49) Toft et al   2.7
 14.58 (0.59,361.20) Tsuang et al   0.6
 7.17 (0.34,150.74) Vaz dos Santos   1.4
 4.34 (0.97,19.34) Wu et al.   8.2
 3.58 (0.17,75.09) Yu et al.   2.0
 30.42 (1.71,542.79) Zhang et al.   1.0
 9.22 (6.23,13.66) Overall (95% CI)
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RecNcil and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 0.68 (0.04,10.97) Li et al   8.5
 5.68 (0.70,46.27) Huang et al   7.9
 0.65 (0.09,4.66) Wu et al.  17.3
 2.44 (0.10,60.22) Seto Salvia et al.   3.9
 2.91 (0.12,71.63) Kumar et al.   3.6
 1.63 (0.08,34.12) Neumann et al.   5.4
 10.87 (0.56,211.75) Duran et al.   2.8
 1.41 (0.07,29.40) Lesage et al.   5.6
 4.26 (0.17,105.56) Vaz dos Santos   2.9
 7.30 (1.65,32.26) Mitsui et al  13.8
 1.08 (0.12,9.73) Nichols et al.  11.3
 1.94 (0.08,47.90) Clark et al   4.3
 1.48 (0.06,36.54) Han et al   4.8
 5.03 (0.26,98.27) Yu et al.   4.1
 4.61 (0.22,96.69) Lesage et al.   3.7
 3.08 (1.65,5.76) Overall (95% CI)
84GG and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 13.58 (5.47,33.74) Gan-Or et al  72.2
 21.61 (4.77,97.96) Peretz et al.  10.2
 7.22 (0.40,131.36) Clark et al  17.6
 13.29 (5.86,30.14) Overall (95% CI)
R120W and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 1.94 (0.08,47.90) Clark et al  20.0
 1.41 (0.07,29.40) Lesage et al.  25.8
 13.79 (0.79,239.63) Li et al et al.  18.4
 32.49 (1.94,544.42) Mitsui et al  15.9
 1.97 (0.08,48.45) Wu et al.  19.9
 8.85 (2.52,31.12) Overall (95% CI)
H255Q and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 3.03 (0.12,74.80) Moritau et al.  47.3
 7.08 (0.38,132.62) Kalinderi et al.  52.7
 5.16 (0.61,43.77) Overall (95% CI)
Supplementary	
Fig	3.	Forest	
plots	of	risk	of	
PD	(with	
95%CI)	
associated	with	
84GG,	R120W,	
H255Q	and	
L444P;A456P;V
460V		(RecNcil)	
mutations
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E326K and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 0.77 (0.05,12.36) Kalinderi et al   1.6
 1.25 (0.21,7.53) Bras et al   2.9
 1.50 (0.35,6.35) Noreau et al.   4.3
 3.23 (1.28,8.16) Duran   7.1
 1.45 (0.68,3.13) Lesage  16.8
 0.83 (0.42,1.66) Nichols et al.  23.4
 0.64 (0.04,10.34) Clark et al   1.7
 0.48 (0.12,1.96) Han et al   7.3
 2.13 (0.09,52.79) Yu et al.   0.8
 0.91 (0.06,14.69) Lesage et al.   1.4
 2.06 (1.28,3.33) Ran et al.  32.8
 1.53 (1.13,2.07) Overall (95% CI)
T369M and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 1.62 (0.15,18.05) Seto Salvia et al.   3.8
 1.63 (0.54,4.96) Noreau et al.  17.8
 1.13 (0.38,3.40) Kumar et al.  21.0
 4.83 (0.64,36.37) Lesage et al.   5.4
 0.67 (0.21,2.16) Nichols et al.  21.9
 0.97 (0.16,5.84) Clark et al.   8.5
 1.36 (0.42,4.38) Han et al.  17.9
 1.83 (0.16,20.39) Lesage et al.   3.6
 1.39 (0.85,2.27) Overall (95% CI)
R463C and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 2.91 (0.12,71.63) Kumar et al.  20.9
 2.29 (0.12,44.46) Neumann et al.  31.0
 10.87 (0.56,211.75) Duran et al.  16.0
 2.54 (0.14,47.27) Lesage at al.  32.1
 3.87 (0.87,17.29) Overall (95% CI)
Supplementary	Fig	4.	Forest	plots	of	risk	of	
PD	(with	95%CI)	associated	with	E326K,	
T369M	and	R463C	mutations/variants
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D409H and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 3.03 (0.12,74.80) Moritau et al   9.5
 6.30 (0.34,118.38) Li et al.  11.1
 2.32 (0.09,57.35) Kalinderi et al  10.7
 5.63 (0.23,138.69) Bras et al.   6.6
 4.04 (0.19,84.31) Huang et al.  10.6
 4.08 (0.19,85.58) Seto Salvia et al.  10.5
 0.98 (0.04,24.09) Neumann et al.  14.4
 0.84 (0.03,20.78) Lesage et al.  14.9
 1.94 (0.08,47.90) Clark et al.  11.6
 2.96 (1.05,8.29) Overall (95% CI)
D409H;H255Q and PD risk
Odds ratio
.1 1 10
Study  % Weight
 Odds ratio
 (95% CI)
 6.18 (0.74,51.80) Moritau et al  32.6
 2.93 (0.59,14.63) Kumar  67.4
 3.99 (1.12,14.20) Overall (95% CI)
Supplementary	Fig	5.	Forest	plot	of	risk	of	PD	(with	95%CI)	associated	with	D409H;H255Q	and	D409H	
mutations
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Begg plot of studies estimating L444P PD risk
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Supplementary	Fig.	
6.	Begg plots	of	
N370S,	L444P,	
RecNcil and	all	GD	
causing	mutations	
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Begg plot of studies estimating 84GG PD risk
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s.e. of: logor
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Begg plot of studies estimating R120W PD risk
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Begg plot of studies estimating H255Q PD risk
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Begg plot of studies estimating E326K PD risk
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Supplementary	Fig.	
7.	Begg plots	of	
84GG,	H255Q,	
R120W	and	E326K	
mutations/variants
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Begg plot of studies estimating T369M PD risk
log
or
s.e. of: logor
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Begg plot of studies estimating D409H PD risk
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Begg plot of studies estimating R463C PD risk
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Begg plot of studies estimating H255Q;D409H PD risk
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Supplementary	Fig.	
8.	Begg plots	of	
T369M,	D409H	
R463C	and	
H255Q;D409H	
mutations/variants
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Chapter	3	
	
10.2	Supplementary	Methods	
10.2a	Participants	
Type	1	Gaucher	patients	between	over	40	years	of	age	were	recruited	from	the	Royal	Free	
London	Hospital	in	2010,	heterozygous	GBA	mutation–positive	relatives	were	recruited	
from	their	kindred	(see	supplementary	materials	for	genotyping	details).	Controls	were	
unrelated.	All	participants	were	free	of	any	neurological	symptoms	or	signs	at	
inclusion111,112		participants	were	assessed	longitudinally	from	baseline	(2010/2011),	with	
target	assessments	in	2012/13	(timepoint	1)	and	2014/15	(timepoint	2).	It	should	be	noted	
that	previous	studies	referred	to	age	matched	populations	whilst	the	present	analysis	
encompasses	these	and	additional	cases	drawn	from	our	longitudinal	database.	The	study	
was	approved	by	the	Hampstead	Research	Ethics	Committee	(10/H0720/21).	All	participants	
provided	written	informed	consent.		
	
10.2b	Follow-up	Evaluation		
	
At	each	timepoint		a	standardised	clinical	history	and	neurological	assessment	was	
conducted,	including	the	Unified	Parkinson’s	Disease	Rating	Scale	parts	II	and	III,	the	
University	of	Pennsylvania	Smell	Identification	Test	(UPSIT),	the	Montreal	Cognitive		
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Supplementary	table	3.	Trimmed	mean	(	+	exact	confidence	intervals)	and	median	scores	of	prodromal	features	of	Parkinson	disease	
amongst	control,	homozygous,	bi-allelic	and	combined	group	of	GBA	carriers		
	 	 baseline	
Timepoint		
1	
Timepoint		
2	 		 		 baseline	
Timepoi
nt		1	
timepoint		
2	
UPSIT	ctl	
trimmed	mean	
[95%CI]	
34.6	[33.6-
35.7]	
34.2	[32.9-
35.5]	
33.1	[31.6-
34.6]	
UPDRS	II	
ctl	
trimmed	mean	
[95%CI]	 0.0	
0.4	[0.1-
0.7]	
0.7	[0.0-
1.3]	
		 median	 35.0	 35.0	 32.0	 		 median	 0.0	 0.0	 0.0	
UPSIT	
hom	
trimmed	mean	
[95%CI]	
32.8	[31.4-
34.2]	
31.2	[29.3-
33.0]	
29.8	[2.7-
31.9]	
UPDRS	II	
hom	
trimmed	mean	
[95%CI]	
0.6	[0.1-
1.2]	
2.1	[1.1-
3.0]	
4.8	[2.0-
7.5]	
		 median	 34.0	 32.0	 32.0	 		 median	 0.0	 1.0	 3.0	
UPSIT	het	
trimmed	mean	
[95%CI]	
31.6	[29.8-
33.4]	
30.6	[29.0-
32.2]	
29.1	[27.0-
31.2]	
UPDRS	II	
het	
trimmed	mean	
[95%CI]	
0.5	
[0.13-
0.8]	
1.3	[0.8-
1.7]	
2.1	[1.0-
3.2]	
		 median	 33.5	 32.0	 30.0	 		 median	 0.0	 1.0	 1.0	
UPSIT	
gba	
trimmed	mean	
[95%CI]	
32.2	[31.1-
33.5]	
31.1	[30.1-
32.1]	
29.7	[28.2-
31.2]	
UPDRS	II	
gba	
trimmed	mean	
[95%CI]	
0.5	(0.1-
0.9)	
1.6	[1.0-
2.1]	
3.3	[1.8-
4.8]	
		 median	 34.0	 32.0	 30.0	 		 median	 0.0	 1.0	 2.0	
MOCA	ctl	
trimmed	mean	
[95%CI]	
27.9	[27.3-
28.4]	
28.0	[27.5-
28.7]	
28.3	[27.7-
29.0]	
UPDRS	III	
ctl	
trimmed	mean	
[95%CI]	
0.0	[0.0-
0.2]	
1.9	[0.4-
3.3]	
2.5	[1.0-
4.0]	
		 median	 28.0	 28.0	 28.5	 		 median	 0.0	 0.0	 1.0	
MOCA	
hom	
trimmed	mean	
[95%CI]	
26.6	[25.8-
27.4]	
26.9	[25.8-
28.0]	
25.8		[24.5-
27.0]	
UPDRS	III	
hom	
trimmed	mean	
[95%CI]	
1.9	[0.2-
3.6]	
6.4	[3.0-
9.7]	
8.5	[4.8-
12.2]	
		 median	 27.0	 28.5	 26.0	 		 median	 0.0	 3.0	 5.0	
MOCA	
het	
trimmed	mean	
[95%CI]	
26.1	[25.1-
27.1]	
26.5	[25.4-
27.6]	
26.3	[24.9-
27.7]	
UPDRS	III	
het	
trimmed	mean	
[95%CI]	
2.4	[0.9-
3.8]	
8.0	[5.4-
10.6]	
6.5	[3.7-
9.2]	
Stephen	Mullin	–	PhD	thesis	
	
	
260	
		 median	 27.0	 27.0	 26.5	 		 median	 0.0	 8.0	 7.0	
MOCA	
gba	
trimmed	mean	
[95%CI]	
26.4	[25.8-
27.1]	
26.8	[26.0-
27.5]	
26.0	[25.1-
26.9]	
UPDRS	III	
gba	
trimmed	mean	
[95%CI]	
1.9	[0.9	-	
3.0]	
6.8	[4.7-
8.9]	
7.6	[5.2-
9.9]	
		 median	 27.0	 27.0	 26.0	 		 median	 0.0	 4.0	 5.0	
BDI	ctl	
trimmed	mean	
[95%CI]	
0.72	[0.0-
1.77]	
2.1		[0.0-
5.0]	
3.44	[1.8-
5.1]	
UMSARS	
ctl	
trimmed	mean	
[95%CI]	
0.1	[0.0-
0.2]	
0.1	[0.1-
0.2]	
0.3	[0.0-
0.5]	
		 median	 0.0	 0.0	 3.5	 		 median	 0.0	 0.0	 0.0	
BDI	hom	
trimmed	mean	
[95%CI]	 1.24	[0.3-2.2]	
5.3	[3.1-
7.5]	
9.3	[6.5-
12.0]	
UMSARS	
hom	
trimmed	mean	
[95%CI]	
0.3	[0.1-
0.5]	
0.6	[0.3-
0.9]	
1.3	[0.7-
1.8]	
		 median	 0.0	 0.0	 8.0	 		 median	 0.0	 0.0	 1.0	
BDI	het	
trimmed	mean	
[95%CI]	 1.41	[0.1-2.7]	
3.8	[2.5-
5.1]	
6.0	[4.5-
7.4]	
UMSARS	
het	
trimmed	mean	
[95%CI]	
0.4	[0.2-
0.5]	
0.5	[0.1-
0.9]	
0.6	[0.3-
1.0]	
		 median	 0.0	 3.0	 5.0	 		 median	 0.0	 0.0	 1.0	
BDI	gba	
trimmed	mean	
[95%CI]	 1.3	[0.5-2.0]	
4.4	[3.0-
5.7]	
7.5	[5.7-
9.3]	
UMSARS	
gba	
trimmed	mean	
[95%CI]	
0.6	[0.3-
0.9]	
0.5	[0.3-
0.8]	
1.0	[0.6-
1.3]	
		 median	 0.0	 4.0	 7.5	 		 median	 0.0	 0.0	 1.0	
RBDQS	
ctl	
trimmed	mean	
[95%CI]	 0.1		[0.0-0.3]	
1.0	[0.3-
1.6]	
1.8	[1.1-
2.5]	
RBDSQ	
het	
trimmed	mean	
[95%CI]	
0.6	[0.1-
1.0]	
2.1	[1.2-
3.0]	
2.4	[1.6	
3.1]	
		 median	 0.0	 0.0	 2.0	 		 median	 0.0	 1.5	 2.5	
RBDSQ	
hom	
trimmed	mean	
[95%CI]	 0.6	[0.1-1.2]	
2.8	[1.9-
3.6]	
2.5	[1.8-
3.1]	
RBDSQ	
gba	
trimmed	mean	
[95%CI]	
0.5	[0.2-
0.9]	
2.4	[1.8-
3.0]	
2.4	[1.9-
2.9]	
		 median	 0.0	 2.0	 2.0	 		 median	 0.0	 2.0	 2.0	
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Supplementary	table	4		-	full	breakdown	of	analyses	for	cohort	study	
Ordinal	logistic	regression	model	looking	for	associations	between	GBA	group	and	prodromal	features	
(compared	to	controls)	taking	into	account	age,	sex,	education,	smoking	history	and	history	of	Parkinson	
disease	or	dementia		(p<0.05)		 	
GBA	vs	controls	 OR	[95%CI]	bl	 p	bl	 KEY	
UPSIT	 4.0	[1.6-10.4]	 p=0.003	 bia:	bia-allelic	
MOCA	 6.0	[2.3-15.2]	 p<0.001	 bl:	baseline	
BDI	 1.0	[0.1-9.0]	 p=0.977	 Chi	2:	Chi	squared	
RBDSQ	 1.5	[0.1-1.9]	 p=	0.729	 ctl:	control	
GBA	vs	controls	 OR	[95%CI]	tp1	 p	tp1	
GBA:	glucocerebrosidase	
mutation	
UPSIT	 7.6	[2.7-21.8]	 p<0.001	 hom:	homozygous	
MOCA	 7.3	[2.1-24.9]	 p=0.002	 OR:	odds	ratio	
BDI	 2.2	[0.0-440]	 p=0.997	 tp1:	timepoint	1	
RBDSQ	 5.0	[0.9-41.2]	 p=0.139	 tp2:	timepoint	2	
GBA	vs	controls	 OR	[95%CI]	tp2	 p	tp2	 	
UPSIT	 6.8	[2.0-23.1]	 p=0.002	 	
MOCA	 4.0	[1.2-13.6]	 p=0.024	 	
BDI	 10.6	[1.3-90.0]	 p=0.029	 	
RBDSQ	 2.2	[0.21-20.0]	 p=0.486	 	
Ordinal	logistic	regression	model	looking	for	associations	between	bi-allelic/homozygous	groups		and	prodromal	features	(compared	to	
controls)	taking	into	account		taking	into	account	age,	sex,	education,	smoking	history	and	history	of	Parkinson	disease/dementia(p<0.05)		
vs	controls	 OR	[95%CI]	bl	bia	 p	bl	bia	 	
UPSIT	[95%CI]	 4.2	[1.8	-	12.2]	 p=0.006	 	
MOCA		[95%CI]	 5.0	[0.9-14.4]	 p=0.003	 	
BDI	 		 		 KEY	
RBDSQ	 		 		 bia:	bia-allelic	
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vs	controls	 OR	[95%CI]	bl	het	 p	bl	het		 bl:	baseline	
UPSIT	[95%CI]	 4.3	[	1.5	-	12.2]	 p=0.011	 Chi	2:	Chi	squared	
MOCA		[95%CI]	 6.8	[2.5-19.1]	 p<0.001	 ctl:	control	
BDI	 		 		
GBA:	glucocerebrosidase	
mutation	
RBDSQ	 		 		 hom:	homozygous	
		 		 		 OR:	odds	ratio	
		 		 		 tp1:	timepoint	1	
		 		 		 tp2:	timepoint	2	
vs	controls	 OR	[95%CI]	tp1	bia	 p	tp1	bia		 	
UPSIT	[95%CI]	 6.3	[2.0	-	19.7]	 p=0.002	 	
MOCA		[95%CI]	 2.9	[0.9-9.6]	 p=0.069	 	
BDI	 		 		 	
RBDSQ	 		 		 	
vs	controls	 OR	[95%CI]	tp1	het	 p	tp1	het	 	
UPSIT	[95%CI]	 9.0	[2.8	-	28.8]	 p<0.001	 KEY	
MOCA		[95%CI]	 2.9	[0.9-9.6]	 p=0.072	 bia:	bia-allelic	
BDI	 		 		 bl:	baseline	
RBDSQ	 		 		 Chi	2:	Chi	squared	
vs	controls	 OR	[95%CI]	tp2	bia	 p	tp2	bia		 ctl:	control	
UPSIT	[95%CI]	 6.8	[1.8	-	26.0]	 p=0.005	
GBA:	glucocerebrosidase	
mutation	
MOCA		[95%CI]	 5.9	[1.5	-	23.3]	 p=0.011	 hom:	homozygous	
BDI	 18.5	[1.9	-	169.0]	 p=0.010	 OR:	odds	ratio	
RBDSQ	 		 		 tp1:	timepoint	1	
vs	controls	 OR	[95%CI]	tp2	het	 p	tp2	het	 tp2:	timepoint	2	
UPSIT	[95%CI]	 7.2	[1.8-	27.4]		 p=0.004	 	
MOCA		[95%CI]	 2.6	[0.65-10.4]		 p=0.175	 	
BDI	 4.8	[0.5	-	44.7]	 p=0.173	 	
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RBDSQ	 		 		 	
Repeated	measures	regression	model	looking	for	associations	between	combined	GBA	group	and	
prodromal	features	(compared	to	controls)	taking	into	account	age,	sex,	education,	smoking	history	and	
history	of	Parkinson	disease/dementia(p<0.05)	 KEY	
repeated	measures	 OR	[95%CI]	GBA	 p	GBA	 bia:	bia-allelic	
UPSIT	 5.0	[1.6-16.1]	 p=0.006	 bl:	baseline	
MOCA	 5.7	[1.5-20.0]	 p=0.007	 Chi	2:	Chi	squared	
BDI	 2.3	[0.7	-	7.4	]	 p=0.158	 ctl:	control	
RBDSQ	 3.2	[0.7-13.4]	 p=0.120	
GBA:	glucocerebrosidase	
mutation	
		 		 		 hom:	homozygous	
		 		 		 OR:	odds	ratio	
		 		 		 tp1:	timepoint	1	
		 		 		 tp2:	timepoint	2	
repeated	measures	 OR	[95%CI]	bia	 p	bia	 	
UPSIT	 4.7	[1.3-5.3]	 p=0.020	 	
MOCA	 7.1	[1.69-29.3]	 p=0.007	 	
BDI	 		 		 	
RBDSQ	 		 		 	
repeated	measures	 OR	[95%CI]	het	 p	het	 	
UPSIT	 5.3	[1.6-17.5]		 p=0.008	 	
MOCA	 4.4	[1.1-18.4]		 p=0.042	 	
BDI	 		 		 	
RBDSQ	 		 		 	
Ordinal	logistic	regression	model	looking	for	associations	between	individual	risk	scores	of	prodromal	
features	amongst	GBA	carriers	taking	into	account	age,	sex,	education,	smoking	history	and	history	of	
Parkinson	disease/dementia(p<0.05)(p<0.05)		 	
high	risk	model	 OR	[95%CI]	GBA	 p	GBA	 	
MOCA	 1.5	[1.03-2.3]	 p=0.033	 KEY	
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BDI	 1.3	[1.02-1.8]		 p=0.030	 bia:	bia-allelic	
high	risk	model	 OR	[95%CI]	bia	 p	bia	 bl:	baseline	
MOCA	 2.2	[1.3	-	4.0]	 p=0.006	 Chi	2:	Chi	squared	
BDI	 1.2	[0.8	-	1.7]	 p=0.333	 ctl:	control	
high	risk	model	 OR	[95%CI]	het	 p	het	
GBA:	glucocerebrosidase	
mutation	
MOCA	 0.9	[0.4	-	1.7]	 p=0.750	 hom:	homozygous	
BDI	 1.3	[	1.2	-	0.3]	 p=0.249	 OR:	odds	ratio	
		 		 		 tp1:	timepoint	1	
Ordinal	logistic	regression	model	looking	for	associations	between	individual	risk	scores	of	prodromal	
features	amongst	controls	(p<0.05)		 tp2:	timepoint	2	
high	risk	model	 OR	[95%CI]		 p	GBA	 	
MOCA	 0.25	[0.0-2.8]	 p=0.259	 	
BDI	 1.3	[0.6-2.8]	 p=0.435	 	
		 	 	 	
		 	 	 	
Fishers	exact	test	of	ctl	vs	combined	GBA	
group	(p<0.05)		 	 	 	
		 p	value	bl	 	 KEY	
UMSARS	 p=0.040	 	 bia:	bia-allelic	
RBD	 p=0.376	 	 bl:	baseline	
UPDRS	II	 p=0.490	 	 Chi	2:	Chi	squared	
UPDRS	III	 p=0.407	 		 ctl:	control	
		 p	value	tp1	 		
GBA:	glucocerebrosidase	
mutation	
UMSARS	 p=0.096	 		 hom:	homozygous	
RBD	 p=0.493	 		 OR:	odds	ratio	
UPDRS	II	 p=0.201	 		 tp1:	timepoint	1	
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UPDRS	III	 p=0.020	 		 tp2:	timepoint	2	
		 p	value	tp2	 		 	
UMSARS	 p=0.292	 		 	
RBD	 p=0.546	 		 	
UPDRS	II	 p=0.022	 		 		
UPDRS	III	 p=0.593	 		 		
Fishers	exact	test	of	ctl	vs	bia	(p<0.05)		 	 		 		
		 p	value	bl	 		 		
UMSARS	 p=0.028	 		 		
RBD	 		 		 	
UPDRS	II	 		 		 	
UPDRS	III	 		 		 KEY	
		 p	value	tp1	 		 bia:	bia-allelic	
UMSARS	 		 		 bl:	baseline	
RBD	 		 		 Chi	2:	Chi	squared	
UPDRS	II	 		 		 ctl:	control	
UPDRS	III	 p=0.003	 		
GBA:	glucocerebrosidase	
mutation	
		 		 		 hom:	homozygous	
		 		 		 OR:	odds	ratio	
		 		 		 tp1:	timepoint	1	
		 		 		 tp2:	timepoint	2	
		 p	value	tp2	 		 	
UMSARS	 		 		 	
RBD	 		 		 	
UPDRS	II	 p=0.006	 		 	
UPDRS	III	 		 		 	
Fishers	exact	test	of	ctl	vs	het	(p<0.05)		 		 		 	
		 p	value	bl	 		 KEY	
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UMSARS	 p=0.036	 		 bia:	bia-allelic	
RBD	 		 		 bl:	baseline	
UPDRS	II	 		 		 Chi	2:	Chi	squared	
UPDRS	III	 		 		 ctl:	control	
		 p	value	tp1	 		
GBA:	glucocerebrosidase	
mutation	
UMSARS	 		 		 hom:	homozygous	
RBD	 		 		 OR:	odds	ratio	
UPDRS	II	 		 		 tp1:	timepoint	1	
UPDRS	III	 p=0.004	 		 tp2:	timepoint	2	
		 p	value	tp2	 		 	
UMSARS	 		 		 	
RBD	 		 		 	
UPDRS	II	 p=0.030	 		 KEY	
UPDRS	III	 		 		 bia:	bia-allelic	
Fishers/Chi	squared	test	bia	vs	het	(p<0.05)		 		 		 bl:	baseline	
		 p	value	bl	 		 Chi	2:	Chi	squared	
UMSARS	 p=0.035	 		 ctl:	control	
RBD	 		 		
GBA:	glucocerebrosidase	
mutation	
UPDRS	II	 		 		 hom:	homozygous	
UPDRS	III		 		 		 OR:	odds	ratio	
		 p	value	tp1	 		 tp1:	timepoint	1	
UMSARS	 		 		 tp2:	timepoint	2	
RBD	 		 		 	
UPDRS	II	 		 		 	
UPDRS	III	(chi2)*	 p=0.279	 		 	
		 p	value	tp2	 		 	
UMSARS	 		 		 	
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RBD	 		 	 	
UPDRS	II	 p=0.989	 	 	
UPDRS	III		 		 	 	
Ordinal	regression	model		taking	into	account	age,	sex,	education,	family	history	of	dementia/Parkinson	
disease	and	smoking	history,		looking	for	associations	between	putative	biomarkers	and	risk	score	 	
		 OR	[95%	CI]	 p	value	 	
alpha	synuclein	 1.4	[1.0-1.9]		 p=0.025	 	
Tau	 1.6	[0.9-2.9]	 p=0.111	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 	
		 	 	 KEY	
ANOVA	with	FDR	correction	for	multiple	comparisons	of	levels	of	urine	Ig	Kappa	light	chain	 bia:	bia-allelic	
		 bia	v	ctl	 		 bl:	baseline	
		 p	value	 Fold	change	 Chi	2:	Chi	squared	
Ig	kappa	chain	V-I	region	AU	 p=0.005	 3.5	 ctl:	control	
Ig	kappa	chain	V-I	region	Ni	 p=0.025	 2.8	
GBA:	glucocerebrosidase	
mutation	
		 het	v	ctl	 		 hom:	homozygous	
		 p	value	 Fold	change	 OR:	odds	ratio	
Ig	kappa	chain	V-I	region	AU	 p=0.028	 3.2	 tp1:	timepoint	1	
Ig	kappa	chain	V-I	region	Ni	 ns	 ns	 tp2:	timepoint	2	
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		 bia	v	het	 		 	
		 p	value	 Fold	change	 	
Ig	kappa	chain	V-I	region	AU	 ns	 ns	 		
Ig	kappa	chain	V-I	region	Ni	 ns	 ns	 	
		 High	risk	v	Low	risk	(GBA)	 		 	
		 p	value	 Fold	change	 	
Ig	kappa	chain	V-I	region	AU	 p=0.003	 3.4	 	
Ig	kappa	chain	V-I	region	Ni	 p=0.020	 3.5	 	
Sensitivity	analysis:	ordinal	regression	model:	
taking	into	account	age,	sex,	education,	
family	history	of	dementia/Parkinson	disease	
and	smoking	history,		looking	for	associations	
with	dependent	variables	and	whether	
participant	record	contains	any	missing	data.	
Across	three	timepoints	 		 		 	
		
baseline	(OR	[95%CI]	p	
value)	 tp1		(OR	[95%CI]	p	value)	 tp2		(OR	[95%CI]	p	value)	
UPSIT	 1.9	[0.7	-	4.9]	p=0.207	 1.9	[0.6	-	6.2]	p=0.321	 2.0	[0.4	-	10.1]	p=0.416	
MOCA	 0.6	[0.2	-1.8]	p=0.366	 1.1	[0.3-4.4]	p=0.858	 0.6	[0.1-4.3]	p=0.574	
BDI	 3.9	[0.2-6.7]	p=0.344	 2.8	[0.3-30.4]	p=0.395	 1.4	[0.4-5.4]	p=0.586	
RBDSQ	 0.9	[0.1-13.4]	p=0.965	 1.1	[0.15	-	7.8]	p=0.941	 2.4	[0.3-19.5]	p=0.418	
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Assessment	(MOCA),	the	Rapid	Eye	Movement	Behaviour	Disorder	Sleep	Questionnaire	
(RBDSQ),	the	Beck’s	Depression	Inventory	(BDI),	and	a	Unified	Multiple	System	Atrophy	
Rating	Scale	(UMSARS)	subscale.	Participants	were	examined	independently	by	a	physician	
trained	in	movement	disorders	(A.M,	M.B	or	S.M).	A	blinded	senior	neurologist	and	expert	
in	movement	disorders	(A.H.V.S.)	evaluated	participants	upon	deterioration	in	UPDRSscores.		
	
10.2c	Standardization	of	UPDRStesting	
	
To	ensure	consistency	in	UPDRSpart	III	scoring	a	standardized	approach	to	administration	of	
testing	was	carried	out.	To	test	this	approach	investigators	carried	out	a	blinded	assessment	
of	patients	with	a	clinical	diagnosis	of	Parkinson	disease	and	compared	scores.	Scores	
respectively	for	each	participant	showed	a	deviation	of	0	points,	1	point,	2	points	and	4	
points	out	of	33.		
	
10.2d	Risk	stratification	procedure	
To	produce	an	indicator	of	overall	worse/deterioration	of	performance,	we	devised	a	risk	
stratification	system.	From	the	first	to	last	timepoint,	for	each	half	standard	deviation	fall	in	
the	assessment	score	of	each	prodromal	feature,	one	point	was	scored	(maximum	of	four).	
For	each	half	standard	deviation	that	the	average	score	was	below	the	trimmed	mean	of	the	
combined	GBA	group	a	point	was	scored	(maximum	of	four).	The	combined	risk	score	out	of	
eight	was	then	produced.		
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10.3	Statistical	analysis	
10.3a	Clinical	data	
Data	was	analysed	using	Stata	version	v.14.1	(StataCorp,	Texas).	Graphs	were	plotted	using	
Stata	and	Microsoft	excel	v.15.17.	Outliers	with	disproportionately	poor	scores	in	GBA	
carrier	groups	caused	a	non	parametric	distribution.	To	compensate	trimmed	means	with	
exact	confidence	intervals	were	derived	by	excluding	participants	with	scores	more	than	
two	standard	deviations	from	the	mean	(and	recalculating).	Primary	analysis	was	carried	out	
on	the	combined	GBA	vs	controls	groups.	In	the	event	of	a	significant	association	we	carried	
out	secondary	analyses	comparing	bi-allelic/heterozygous	groups	with	controls.		
	
We	assessed	the	confounding	effect	of	study	covariates	and	differences	of	groups	
demographics	with	descriptive	statistics	and	a	Kruskal–Wallis	test.	
	
Non-parametrically	distributed	raw	data	precluded	analyses	taking	into	account	covariate	
risk	factors,	therefore	where	possible	(MOCA,	BDI,	UPSIT,	RBDSQ)	data	was	categorised	
according	to	clinically	validated	thresholds:	
UPSIT:	<19	anosmia,	20-24	severe	microsmia,	25-29	microsmia,	30-33	mild	microsmia	169		
	
MOCA:	<25	dementia,	25-26	mild	cognitive	impairment	170	
	
RBDSQ:	>5	REM	sleep	disorder	172	
	
BDI:		9-19	mild	depression,	20-29	moderate	depression,	>	29	severe	depression	171	
	
Ordinal	logistic	regression	was	used	to	determine	associations	between	the	combined	GBA	
cohort	and	controls	adjusted	for	sex,	education	(university/non	university	educated),	family	
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history	of	Parkinson	disease	and/or	dementia,	significant	past	smoking	history	(>1	pack	
year)	and	age	(henceforth	be	referred	to	as	study	covariates).		
Repeated	measures	logistic	regression	was	used	to	determine	associations	between	the	
change	of	prodromal	features	and	study	group,	adjusted	for	study	covariates	using	clinically	
validated	thresholds:	
UPSIT:	<30	microsmia	169	
MOCA:	<27	Mild	cognitive	impairment	170	
RBDSQ	>5	REM	sleep	disorder	172	
BDI	>8	mild	depression	171	
	
Fisher’s	exact	test	was	used	to	compare	dependent	variables	which	were	not	amenable	to	
stratification	(UMSARS	subscale,	UPDRS	II/III)		
	
Prodromal	feature	risk	scores	were	entered	into	an	ordinal	regression	model	examining	
potential	associations	between	the	UPSIT	and	other	risk	scores,	taking	into	account	study	
co-variates.	Successively	the	least	statistically	significant	risk	score	was	removed	until	only	
significant	associations	(p<0.05)	remained.	This	model	was	then	tested	in	heterozygous/bi-
allelic	carriers	and	the	control	group.	
	
10.3b	Missing	data	
	
We	carried	out	a	sensitivity	analysis	within	the	dataset	to	assess	the	impact	of	missing	data.	
To	do	this	we	constructed	a	regression	model	which	included	the	dependent	variable	in	
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questions	at	each	timepoint,	GBA	carriers	status	(ctl/het/bia),	all	other	study	coovariates	
and	whether	data	was	missing	for	the	participant	and	dependent	variable	in	question.	We	
concluded	that	missing	data	did	not	impact	on	any	dependent	variable	and	hence	that	data	
was	missing	at	random	(see	supplementary	table	1	for	details).		
	
Where	appropriate	(cross	sectional	and	repeated	measures	analyses)	we	used	multiple	
imputation	using	chained	equations	(m=50)	to	impute	missing	values.	Because	dependent	
variables	were	not	parametrically	distributed	we	were	only	able	to	impute	variables	which	
were	amenable	to	transformation	into	ordinal	datasets	(MOCA,	BDI,	RBDSQ	and	UPSIT	–	see	
above).	Dependent	variables	were	included	in	the	regression	model	if	respectively	there	
was	a	missing	data	rate	in	excess	of	5%.	This	included	at	baseline	UPSIT	and	BDI	and	at	
timepoints	1/2	UPSIT,	BDI,	MOCA	and	RBDSQ.	All	study	covariates	were	included	in	the	
chained	regression	model	in	order	to	calculate	these	imputed	values.		
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Chapter	4	
10.4		Supplementary	results	
Supplementary	table	5	–	descriptive	statistics	of	cogtrack	validation	assisted/unassisted	
experiments		
	 Choice	
reaction	
time	
Spatial	
working	
memory	
Numeric	
working	
memory	
Picture	
recognition	
Digit	
Vigilance	
reaction	time	(msec)	assisted	
median	 544.4	 1139.4	 1005.3	 1123.8	 508.1	
IQR	
512.2-576.7	
952.0-
1326.9	
811.8-
1198.85	
1038.0-
1209.6	 498.2-518.0	
reaction	time	(msec)	unassisted	
median	 512.4	 1175.25	 898.9	 1164.85	 518.04	
IQR	
443.4-581.4	
977.1-	
1373.4	
727.7-
1070.2	
727.7-
1349.4	
498.9-
537.14	
accuracy	(%)	assisted	
median	 96.3	 93.8	 96.7	 100	 100	
IQR	
92.95-99.65	
87.55-
100.05	
92.25-
101.15	 97.5-102.5	 98.9-101.1	
accuracy	(%)	unassisted	
median	 100	 100	 96.7	 100	 98.9	
IQR	 100-100	 100-100	 83.3-110.0	 100-100	 96.7-101.1	
False	alarms	(#)	assisted	
	 -	 -	 -	 -	 3	
	 -	 -	 -	 -	 4.5-1.5	
False	alarms	(#)	assisted	
	 -	 -	 -	 -	 1	
	 -	 -	 -	 -	 1.5-0.5	
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Supplementary	table	6	–	Descriptive	statistics	of	cogtrack	outputs.	
group	 		 SRT	(msec)	 SRTM	(msec)	
SRTSD	
(msec)	 SRTCV	(%)	
VIGACC	
(%)	
VIGRT	
(msec)	 VIGFA	(#)	
VIGSD	
(msec)	
VIGCV	
(msec)	
control	 mean	 367.68	 340.33	 122.25	 32.83	 95.29	 453.54	 3.12	 63.75	 14.05	
		 median	 348.77	 333.90	 102.16	 26.15	 97.78	 456.89	 3.00	 65.94	 14.71	
carrier	 mean	 495.96	 432.31	 340.23	 62.11	 95.35	 503.33	 3.25	 80.58	 15.90	
		 median	 404.78	 353.40	 151.77	 35.91	 97.78	 509.43	 3.00	 77.06	 14.65	
biallellic	 mean	 455.74	 392.46	 255.92	 45.99	 96.15	 473.42	 2.44	 71.24	 14.93	
		 median	 426.14	 373.80	 115.86	 30.65	 97.78	 476.11	 1.50	 70.75	 14.38	
Parkinson	
disease	 mean	 431.46	 380.35	 210.97	 42.92	 95.26	 497.62	 5.24	 79.05	 15.78	
		 median	 382.79	 333.35	 111.79	 28.69	 97.78	 490.72	 4.00	 77.65	 15.67	
	
group	
		
CRTACC	
(%)	 CRT	(msex)	
CRTM	
(msec)	
CRTSD	
(msec)	
CRTCV	
(%)	
control	 mean	 95.52	 545.26	 525.05	 186.35	 32.38	
		 median	 96.00	 562.86	 561.10	 108.77	 22.38	
carrier	 mean	 96.36	 633.19	 579.85	 329.72	 38.83	
		 median	 98.00	 597.14	 587.70	 112.33	 18.79	
biallellic	 mean	 96.08	 580.03	 548.33	 198.31	 28.39	
		 median	 98.00	 543.84	 535.00	 107.61	 19.12	
Parkinson	
disease	 mean	 95.16	 628.46	 575.06	 313.48	 43.51	
		 median	 96.00	 533.56	 526.90	 117.79	 19.44	
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group	 		 SPMOACC	(%)	 SPMNACC	(%)	 SPMORT	(msec)	
SPMNRT	
(msec)	
SPMRT	
(msec)	
SPMORTM	
(msec)	
SPMNRTM	
(msec)	
SPMRTM	
(msec)	
SPMSD	
(msec)	
SPMCV	
(%)	
control	 mean	 93.50	 86.40	 1020.18	 1081.51	 1065.38	 847.13	 1010.61	 895.74	 667.00	 54.02	
		 median	 100.00	 100.00	 864.15	 1015.49	 954.49	 859.50	 888.00	 868.00	 279.65	 26.49	
carrier	 mean	 86.82	 87.82	 1369.96	 1556.69	 1483.40	 1213.60	 1264.74	 1232.76	 959.80	 55.47	
		 median	 93.75	 100.00	 1287.76	 1436.08	 1362.29	 1147.80	 1226.70	 1154.50	 553.83	 38.21	
biallellic	 mean	 87.14	 84.23	 1213.60	 1415.29	 1323.90	 1056.40	 1225.60	 1141.14	 670.14	 47.81	
		 median	 93.75	 95.00	 1141.22	 1371.90	 1294.75	 910.10	 1063.50	 1065.40	 518.40	 44.98	
Parkinson	
disease	 mean	 82.89	 85.79	 1332.26	 1530.98	 1440.51	 1175.38	 1241.36	 1124.55	 1139.98	 69.74	
		 median	 93.75	 95.00	 1122.30	 1216.60	 1217.17	 1086.50	 981.90	 998.60	 476.60	 44.45	
	
group	 		 NWMOACC	(%)	
NWMNACC	
(%)	
NWMORT	
(msec)	
NWMNRT	
(msec)	
NWMRT	
(msec)	
NWMORTM	
(msec)	
NWMNRTM	
(msec)	
NWMRTM	
(msec)	
NWMSD	
(msec)	
NWMCV	
(%)	
control	 mean	 94.40	 94.93	 839.13	 972.26	 904.42	 798.92	 936.14	 854.66	 248.73	 26.63	
		 median	 100.00	 100.00	 843.86	 939.53	 909.52	 804.50	 916.30	 888.00	 234.94	 25.19	
carrier	 mean	 91.27	 94.91	 981.09	 1110.77	 1044.30	 894.69	 973.27	 933.07	 453.02	 38.33	
		 median	 93.33	 100.00	 972.36	 1054.60	 1008.10	 903.00	 901.80	 923.90	 300.52	 33.21	
biallellic	 mean	 94.61	 93.59	 907.81	 1031.96	 969.11	 825.22	 923.82	 866.87	 352.64	 35.08	
		 median	 100.00	 100.00	 914.50	 984.36	 954.04	 846.90	 916.25	 880.10	 307.26	 32.54	
Parkinson	
disease	 mean	 92.81	 95.26	 1002.82	 1161.58	 1081.77	 899.24	 1072.87	 1015.23	 361.94	 31.73	
		 median	 100.00	 100.00	 937.71	 1006.47	 1004.08	 842.05	 953.10	 948.35	 318.54	 31.56	
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group	 		 DPICOA	(%)	 DPICNA	(%)	 DPICORT	(msec)	 DPICNRT	(msec)	
DPICRT	
(msec)	
DPICORTM	
(msec)	
DPICNRTM	
(msec)	
DPICRTM	
(msec)	
DPICSD	
(msec)	
DPICCV	
(%)	
control	 mean	 92.20	 65.00	 1385.45	 1709.29	 1499.26	 1163.58	 1529.28	 1260.83	 695.87	 44.14	
		 median	 90.00	 70.00	 1395.15	 1572.60	 1366.60	 1134.50	 1302.60	 1240.90	 676.38	 40.56	
carrier	 mean	 88.91	 62.00	 1475.09	 1841.32	 1599.90	 1220.69	 1477.54	 1283.55	 995.26	 57.13	
		 median	 90.00	 65.00	 1323.27	 1679.11	 1477.71	 1172.20	 1429.20	 1242.70	 732.27	 47.31	
biallellic	 mean	 88.85	 58.75	 1318.37	 1754.44	 1460.27	 1091.08	 1441.26	 1173.81	 797.32	 50.69	
		 median	 90.00	 65.00	 1140.44	 1717.53	 1297.92	 996.65	 1302.50	 1042.70	 598.66	 46.41	
Parkinson	
disease	 mean	 91.32	 59.47	 1333.96	 1653.58	 1446.88	 1149.69	 1457.03	 1263.11	 622.33	 40.57	
		 median	 95.00	 62.50	 1152.31	 1606.39	 1381.64	 1106.70	 1401.25	 1167.90	 499.44	 40.99	
	
Supplementary	table	7.	Schapiro	Wilks	tests	for	normality	
	
control	 heterozygote	
Variable	 		 Obs	W	 V	 z	 Prob>z	 Variable	 Obs	 W	 V	 z	 Prob>z	
SRT1	 	25	 0.93095	 1.919	 1.332	 0.0914	 SRT1	 55	 0.53129	 23.769	 6.795	 0	
SRTM1	 	25	 0.95061	 1.372	 0.647	 0.25874	 SRTM1	 55	 0.51863	 24.411	 6.852	 0	
SRTSD1	 	25	 0.87971	 3.343	 2.467	 0.00682	 SRTSD1	 55	 0.76329	 12.004	 5.33	 0	
SRTCV1	 	25	 0.85040	 4.157	 2.913	 0.00179	 SRTCV1	 55	 0.77828	 11.244	 5.19	 0	
VIGACC1	 	25	 0.61153	 10.794	 4.863	 0	 VIGACC1	 55	 0.81881	 9.188	 4.757	 0	
VIGRT1	 	25	 0.91318	 2.412	 1.8	 0.03591	 VIGRT1	 55	 0.97214	 1.413	 0.741	 0.22929	
VIGFA1	 	25	 0.99471	 0.147	 -3.921	 0.99996	 VIGFA1	 55	 0.94261	 2.91	 2.291	 0.01098	
VIGSD1	 	25	 0.92359	 2.123	 1.539	 0.06189	 VIGSD1	 55	 0.97837	 1.097	 0.198	 0.42156	
VIGCV1	 	25	 0.92011	 2.22	 1.63	 0.05153	 VIGCV1	 55	 0.95502	 2.281	 1.768	 0.03849	
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CRTACC1	 	25	 0.87974	 3.342	 2.466	 0.00683	 CRTACC1	 55	 0.85399	 7.404	 4.294	 0.00001	
CRT1	 	25	 0.92132	 2.186	 1.599	 0.05491	 CRT1	 55	 0.77858	 11.228	 5.187	 0	
CRTM1	 	25	 0.91449	 2.376	 1.769	 0.03843	 CRTM1	 55	 0.96515	 1.768	 1.222	 0.11095	
CRTSD1	 	25	 0.49242	 14.104	 5.41	 0	 CRTSD1	 55	 0.3782	 31.533	 7.401	 0	
CRTCV1	 	25	 0.43843	 15.604	 5.617	 0	 CRTCV1	 55	 0.45582	 27.596	 7.115	 0	
SPMOACC1	 	25	 0.52882	 13.093	 5.258	 0	 SPMOACC1	 55	 0.75547	 12.401	 5.4	 0	
SPMNACC1	 	25	 0.34355	 18.241	 5.936	 0	 SPMNACC1	 55	 0.61337	 19.607	 6.382	 0	
SPMORT1	 	25	 0.62048	 10.546	 4.816	 0	 SPMORT1	 55	 0.92764	 3.669	 2.788	 0.00265	
SPMNRT1	 	25	 0.87576	 3.25	 2.397	 0.00827	 SPMNRT1	 55	 0.90562	 4.786	 3.358	 0.00039	
SPMRT1	 	25	 0.77599	 6.225	 3.738	 0.00009	 SPMRT1	 55	 0.95082	 2.494	 1.96	 0.025	
SPMORTM1	 	25	 0.96691	 0.92	 -0.171	 0.56808	 SPMORTM1	 55	 0.89145	 5.505	 3.658	 0.00013	
SPMNRTM1	 	25	 0.88985	 2.881	 2.152	 0.01571	 SPMNRTM1	 55	 0.97642	 1.196	 0.383	 0.3507	
SPMRTM1	 	25	 0.96371	 1.008	 0.017	 0.49327	 SPMRTM1	 55	 0.94956	 2.558	 2.014	 0.02199	
SPMSD1	 	25	 0.54543	 12.631	 5.185	 0	 SPMSD1	 55	 0.66717	 16.878	 6.061	 0	
SPMCV1	 	25	 0.53648	 12.88	 5.224	 0	 SPMCV1	 55	 0.65628	 17.431	 6.13	 0	
SPMSI1	 	25	 0.53473	 12.928	 5.232	 0	 SPMSI1	 55	 0.66371	 17.054	 6.083	 0	
NWMOACC1	 	25	 0.86808	 3.666	 2.655	 0.00396	 NWMOACC1	 55	 0.78892	 10.705	 5.084	 0	
NWMNACC1	 	25	 0.72069	 7.761	 4.189	 0.00001	 NWMNACC1	 55	 0.5673	 21.943	 6.623	 0	
NWMORT1	 	25	 0.96255	 1.04	 0.081	 0.46767	 NWMORT1	 55	 0.96646	 1.701	 1.139	 0.12733	
NWMNRT1	 	25	 0.91742	 2.295	 1.698	 0.04476	 NWMNRT1	 55	 0.85668	 7.268	 4.254	 0.00001	
NWMRT1	 	25	 0.95965	 1.121	 0.234	 0.40752	 NWMRT1	 55	 0.90578	 4.778	 3.354	 0.0004	
NWMORTM1	 	25	 0.89147	 3.016	 2.256	 0.01202	 NWMORTM1	 55	 0.97124	 1.459	 0.809	 0.20914	
NWMNRTM1	 	25	 0.83199	 4.668	 3.15	 0.00082	 NWMNRTM1	 55	 0.89437	 5.357	 3.599	 0.00016	
NWMRTM1	 	25	 0.93661	 1.761	 1.157	 0.12356	 NWMRTM1	 55	 0.95818	 2.121	 1.612	 0.05345	
NWMSD1	 	25	 0.91572	 2.342	 1.74	 0.04097	 NWMSD1	 55	 0.55092	 22.774	 6.703	 0	
NWMCV1	 	25	 0.87747	 3.405	 2.505	 0.00613	 NWMCV1	 55	 0.65624	 17.433	 6.13	 0	
NWMSI1	 	25	 0.85398	 4.057	 2.863	 0.0021	 NWMSI1	 55	 0.65239	 17.628	 6.154	 0	
DPICOACC1	 	25	 0.98613	 0.386	 -1.948	 0.97432	 DPICOACC1	 55	 0.95849	 2.105	 1.596	 0.05522	
DPICNACC1	 	25	 0.95569	 1.231	 0.425	 0.3354	 DPICNACC1	 55	 0.97344	 1.347	 0.639	 0.2615	
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DPICORT1	 	25	 0.94168	 1.621	 0.987	 0.16184	 DPICORT1	 55	 0.93693	 3.198	 2.493	 0.00633	
DPICNRT1	 	25	 0.77218	 6.33	 3.772	 0.00008	 DPICNRT1	 55	 0.80842	 9.715	 4.876	 0	
DPICRT1	 	25	 0.90601	 2.612	 1.962	 0.02486	 DPICRT1	 55	 0.90647	 4.743	 3.339	 0.00042	
DPICORTM1	 	25	 0.94203	 1.611	 0.974	 0.16491	 DPICORTM1	 55	 0.91327	 4.398	 3.177	 0.00075	
DPICNRTM1	 	25	 0.65905	 9.474	 4.597	 0	 DPICNRTM1	 55	 0.8651	 6.841	 4.124	 0.00002	
DPICRTM1	 	25	 0.97212	 0.775	 -0.522	 0.69923	 DPICRTM1	 55	 0.9529	 2.388	 1.867	 0.03095	
DPICSD1	 	25	 0.89084	 3.033	 2.268	 0.01166	 DPICSD1	 55	 0.70172	 15.126	 5.826	 0	
DPICCV1	 	25	 0.96883	 0.866	 -0.294	 0.61553	 DPICCV1	 55	 0.70286	 15.069	 5.817	 0	
DPICSI1	 	25	 0.96191	 1.058	 0.116	 0.45388	 DPICSI1	 55	 0.96406	 1.822	 1.287	 0.09902	
biallelic	 Parkinson	disease	
Variable	Obs	 W	 V	 z	 Prob>z	
		
Variable	Obs	 W	 V	 z	 Prob>z	
		
SRT1	 52	 0.7832	 10.516	 5.03	 0	 SRT1	 38	 0.76007	 9.118	 4.637	 0	
SRTM1	 52	 0.83827	 7.845	 4.403	 0.00001	 SRTM1	 38	 0.67935	 12.185	 5.245	 0	
SRTSD1	 52	 0.62416	 18.231	 6.206	 0	 SRTSD1	 38	 0.54367	 17.341	 5.986	 0	
SRTCV1	 52	 0.78038	 10.653	 5.057	 0	 SRTCV1	 38	 0.56	 16.721	 5.909	 0	
VIGACC1	 52	 0.64181	 17.375	 6.103	 0	 VIGACC1	 38	 0.84296	 5.968	 3.748	 0.00009	
VIGRT1	 52	 0.98354	 0.798	 -0.481	 0.6848	 VIGRT1	 38	 0.98414	 0.603	 -1.062	 0.85591	
VIGFA1	 52	 0.86543	 6.528	 4.01	 0.00003	 VIGFA1	 38	 0.87593	 4.715	 3.253	 0.00057	
VIGSD1	 52	 0.97717	 1.107	 0.218	 0.41371	 VIGSD1	 38	 0.94391	 2.132	 1.588	 0.05615	
VIGCV1	 52	 0.97117	 1.398	 0.717	 0.23673	 VIGCV1	 38	 0.97953	 0.778	 -0.527	 0.70083	
CRTACC1	 52	 0.94125	 2.85	 2.239	 0.01259	 CRTACC1	 38	 0.97838	 0.822	 -0.412	 0.65975	
CRT1	 52	 0.63763	 17.578	 6.128	 0	 CRT1	 38	 0.72139	 10.588	 4.95	 0	
CRTM1	 52	 0.82163	 8.652	 4.612	 0	 CRTM1	 38	 0.69863	 11.453	 5.115	 0	
CRTSD1	 52	 0.41479	 28.387	 7.152	 0	 CRTSD1	 38	 0.63388	 13.913	 5.523	 0	
CRTCV1	 52	 0.52371	 23.104	 6.712	 0	 CRTCV1	 38	 0.64193	 13.607	 5.477	 0	
SPMOACC1	 52	 0.80242	 9.584	 4.831	 0	 SPMOACC1	 38	 0.59977	 15.209	 5.71	 0	
SPMNACC1	 52	 0.73149	 13.025	 5.487	 0	 SPMNACC1	 38	 0.82863	 6.512	 3.931	 0.00004	
Stephen	Mullin	–	PhD	thesis	
	
	
279	
SPMORT1	 52	 0.84035	 7.744	 4.375	 0.00001	 SPMORT1	 36	 0.6535	 12.635	 5.304	 0	
SPMNRT1	 51	 0.87567	 5.939	 3.804	 0.00007	 SPMNRT1	 38	 0.71019	 11.013	 5.033	 0	
SPMRT1	 52	 0.86133	 6.726	 4.074	 0.00002	 SPMRT1	 38	 0.82067	 6.815	 4.026	 0.00003	
SPMORTM1	 52	 0.90302	 4.704	 3.31	 0.00047	 SPMORTM1	 36	 0.62633	 13.626	 5.462	 0	
SPMNRTM1	 51	 0.85181	 7.079	 4.179	 0.00001	 SPMNRTM1	 38	 0.50741	 18.719	 6.146	 0	
SPMRTM1	 52	 0.80235	 9.587	 4.832	 0	 SPMRTM1	 38	 0.79405	 7.826	 4.316	 0.00001	
SPMSD1	 52	 0.69523	 14.783	 5.758	 0	 SPMSD1	 38	 0.72359	 10.504	 4.934	 0	
SPMCV1	 52	 0.81039	 9.197	 4.743	 0	 SPMCV1	 38	 0.72851	 10.317	 4.896	 0	
SPMSI1	 52	 0.81994	 8.734	 4.633	 0	 SPMSI1	 38	 0.73594	 10.035	 4.838	 0	
NWMOACC1	 52	 0.72422	 13.377	 5.544	 0	 NWMOACC1	 38	 0.77187	 8.669	 4.531	 0	
NWMNACC1	 52	 0.5597	 21.358	 6.544	 0	 NWMNACC1	 38	 0.4103	 22.409	 6.523	 0	
NWMORT1	 52	 0.92888	 3.45	 2.647	 0.00406	 NWMORT1	 38	 0.69527	 11.58	 5.138	 0	
NWMNRT1	 52	 0.96239	 1.824	 1.285	 0.09938	 NWMNRT1	 38	 0.62825	 14.127	 5.555	 0	
NWMRT1	 52	 0.97282	 1.319	 0.591	 0.27723	 NWMRT1	 38	 0.65347	 13.169	 5.408	 0	
NWMORTM1	 52	 0.95945	 1.967	 1.446	 0.07406	 NWMORTM1	 38	 0.85637	 5.458	 3.56	 0.00019	
NWMNRTM1	 52	 0.96181	 1.853	 1.318	 0.09375	 NWMNRTM1	 38	 0.69251	 11.685	 5.157	 0	
NWMRTM1	 52	 0.95954	 1.963	 1.441	 0.07474	 NWMRTM1	 38	 0.73177	 10.193	 4.871	 0	
NWMSD1	 52	 0.85184	 7.187	 4.216	 0.00001	 NWMSD1	 38	 0.59873	 15.249	 5.716	 0	
NWMCV1	 52	 0.85082	 7.236	 4.23	 0.00001	 NWMCV1	 38	 0.93138	 2.608	 2.011	 0.02217	
NWMSI1	 52	 0.69273	 14.905	 5.775	 0	 NWMSI1	 38	 0.87237	 4.85	 3.313	 0.00046	
DPICOACC1	 52	 0.95822	 2.027	 1.51	 0.06551	 DPICOACC1	 38	 0.93868	 2.33	 1.775	 0.03796	
DPICNACC1	 52	 0.95128	 2.363	 1.838	 0.03302	 DPICNACC1	 38	 0.91721	 3.146	 2.405	 0.0081	
DPICORT1	 52	 0.90505	 4.606	 3.265	 0.00055	 DPICORT1	 38	 0.8532	 5.579	 3.606	 0.00016	
DPICNRT1	 52	 0.92562	 3.608	 2.743	 0.00305	 DPICNRT1	 38	 0.94182	 2.211	 1.665	 0.04799	
DPICRT1	 52	 0.90534	 4.592	 3.258	 0.00056	 DPICRT1	 38	 0.89893	 3.841	 2.823	 0.00238	
DPICORTM1	 52	 0.87294	 6.164	 3.887	 0.00005	 DPICORTM1	 38	 0.93131	 2.61	 2.013	 0.02206	
DPICNRTM1	 52	 0.91334	 4.203	 3.069	 0.00107	 DPICNRTM1	 38	 0.87092	 4.905	 3.336	 0.00042	
DPICRTM1	 52	 0.86609	 6.496	 4	 0.00003	 DPICRTM1	 38	 0.93272	 2.557	 1.969	 0.02446	
DPICSD1	 52	 0.81967	 8.747	 4.636	 0	 DPICSD1	 38	 0.92238	 2.95	 2.269	 0.01162	
DPICCV1	 52	 0.86771	 6.417	 3.974	 0.00004	 DPICCV1	 38	 0.93609	 2.429	 1.862	 0.03133	
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DPICSI1	 52	 0.95535	 2.166	 1.652	 0.04927	 DPICSI1	 38	 0.96827	 1.206	 0.393	 0.34734	
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Supplementary	Fig	9	.	Validation	data	showing	power	of	attention	
cogtrack task	variation	with	sex.	Picture	sensitivity	index	and	
speed.	
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Supplementary	Fig	10	..	Validation	data	for	internet	based	version	of	cogtrack (CDR)	battery.	Power	of	Attention	(left)	and	Continuity	of	attention	(right).	Study	
run	over	12	months	2011-2012.	Four	tests	from	a	computer	based	cognitive	methodology,	the	CDR	System,	were	internet	enabled:	simple	reaction	time,	choice	
reaction	time,	digit	vigilance	and	delayed	picture	recognition.	5	language	versions	were	available:	English,	Greek,	Hungarian,	Portuguese	&	Spanish.	120,171
individuals	logged	on	to	a	website,	entered	their	age	and	gender,	and	performed	the	tests	on-line.	Male	to	female	ratio	41%	v	59%
Continuity	of	attention.	
LSmeans with	95%	confidence	intervals.	(n=97,441)
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Chapter	6	
	
10.5	Mice	
Mice	were	treated	in	accordance	with	local	ethical	committee	guidelines	and	the	UK	
Animals	(Scientific	Procedures)	Act	of	1986.	All	procedures	were	carried	out	in	accordance	
with	Home	Office	guidelines	(United	Kingdom).	B6129SF1/J	(101043)	mice	expressing	wild-
type	GBA1	(wild-type	mice)	and	mice	expressing	the	N370S	mutation346		
All	mice	were	10	to	12	weeks	of	age	at	sacrifice.	
	
Genotyping	of	N370S	alleles	in	primary	mouse	neurons	was	performed	on	brain	samples	
samples	from	respective	mouse	embryos	as	previously	described.	286	Briefly	brains		were	
extracted	and	digested	in	15ml	of	extraction	buffer	+	15uL	of	proteinase	K		(55	degree	for	5	
hours,	99	degrees	for	10minutes).	Transgenic	mice	containing	heterozygous/homozygous	
N370S	mutation	were	identified	by	polymerase	chain	reaction	(PCR)	of	ear	genomic	DNA	
using	forward	primer	F:	5’CACAGATGTGTATGGCCATCGG-3	and	reverse	primer	R:	5’-
CTGAAGTGGCCAAGATGGTAG-3’.	
	
10.6	Immunohistochemistry	
	
Cells	were	fixed	in	3.7%	paraformaldehyde	(pH	7.4),	permeabilised	with	methanol	for	10min	
at	-20°C,	blocked	in	2%	(v/v)	goat	serum	in	PBS	with	0.1%	(v/v)	Triton	X-100	(PBST)	for	1h	at	
RT,	and	then	incubated	with	chicken	polyclonal	anti	GFAP	(abcam	ab4674)		or	rabbit	
polyclonal	anti	beta	3	tubulin		(abcam	ab18207)	antibodies	overnight	at	4°C.	Following	
Stephen	Mullin	–	PhD	thesis	
	
	
284	
washing	of	cover	slips	with	PBS,	cells	were	incubated	with	green	goat	anti	chicken	(abcam	
ab150173)	or	red	goat	anti	rabbit	(ab6719)	antibody	for	1h	at	37 °C	in	PBST	with	2%	goat	
serum.	Coverslips	were	then	washed	three	times	with	PBS	and	mounted	in	citifluor	
containing	DAPI.	
	
	
10.7	Live-cell	imaging		
Ca2+	imagingCells	were	loaded	with	the	ratiometric	fluorescent	Ca2+	indicator	Fura-2	after	
incubation	with	Fura-2	AM	(2.5μM)	and	0.005%	(v/v)	pluronic	acid	(Invitrogen)	for	1	hour	at	
room	temperature	in	HEPES-buffered	saline	(HBS)	consisting	of	10	mM	HEPES,	2	mM	
MgSO4,	156	mM	NaCl,	3	mM	KCl,	2	mM	CaCl2,	1.25	mM	KH2PO4	and	10	mM	glucose	(pH	
7.4).		
Following	three	washes	in	HBS,	cells	were	stimulated	with	either	GPN	(200	μM;	glycyl-L-
phenylalanine-naphthylamide;	SantaCruz	Biotech),	thapsigargin	(1	μM;	Merck),	or	KCL	(52	
mM;	Sigma).	Where	indicated	(thapsigargin),	extracellular	Ca2+	was	removed	using	a	
modified	HBS	solution	containing	1	mM	EGTA	(ethylene	glycol	tetraacetic	acid)	instead	of	
CaCl2.		
	
10.8	Lysotracker	imaging		
Fibroblasts	were	incubated	with	100	nM	Lysotracker	red	(Invitrogen)	for	30	minutes	in	HBS.	
After	loading,	cells	were	washed	three	times	in	HBS	and	imaged	after	stimulation	with	GPN.		
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10.9	GCase	activity	assay	(brain	lysate)	
	
Brain	samples	were	homogenized	in	5mM	ethylenediaminetetraacetic	acid,	750mM	sodium	
chloride,	50mM	Tris	(pH 7.4),	10%	Triton	X-100.	Homogenate	was	centrifuged	to	remove	
insoluble	materials,	and	protein	concentration	was	determined	using	a	Pierce	BCA	Protein	
Assay.	Resulting	lysate	was	diluted	to	2mg/ml	in	distilled	water	and	sonicated.	
GCase	activity	was	measured	in	lysate	(20 μg	protein)	using	5mM	4-methylumbelliferyl	β-D-
glucopyranoside	substrate	in	McIlvaine	buffer	(pH 5.4)	supplemented	with	22mM	sodium	
taurocholate	hydrate	at	37 °C	for	1	hour.	The	reaction	was	stopped	by	adding	0.25M	glycine	
(pH 10.4),	and	substrate	fluorescence	was	measured	at	excitation	of	365nm,	emission	of	
450nm	with	a	PerkinElmer	(Waltham,	MA)	fluorescence	spectrometer.	All	GCase	assays	
were	performed	in	duplicate.	GCase	activity	was	expressed	as	nanomoles	of	substrate	
catalysed	per	milligram	protein	per	hour.	
	
10.10	GCase	activity	assay	(fibroblasts)	
	
Fibroblast	pellets	were	lysed	in	10%	Triton	X-100.	protein	concentration	was	determined	
using	a	Pierce	BCA	Protein	Assay.	Resulting	lysate	was	diluted	to	2mg/ml	in	distilled	water	
and	sonicated.	GCase	activity	was	measured	in	lysate	(20 μg	protein)	using	5mM	4-
methylumbelliferyl	β-D-glucopyranoside	substrate	in	McIlvaine	buffer	(pH 5.4)	
supplemented	with	22mM	sodium	taurocholate	hydrate	at	37 °C	for	1	hour.	The	reaction	
was	stopped	by	adding	0.25M	glycine	(pH 10.4),	and	substrate	fluorescence	was	measured	
Stephen	Mullin	–	PhD	thesis	
	
	
286	
at	excitation	of	365nm,	emission	of	450nm	with	a	PerkinElmer	(Waltham,	MA)	fluorescence	
spectrometer.	All	GCase	assays	were	performed	in	duplicate.	GCase	activity	was	expressed	
as	nanomoles	of	substrate	catalysed	per	milligram	protein	per	hour.	
	
	
10.11	GCase	activity	brain	(homogenates)	
	
Brain	samples	were	homogenized	in	5mM	ethylenediaminetetraacetic	acid,	750mM	sodium	
chloride,	50mM	Tris	(pH 7.4),	10%	Triton	X-100,	unless	stated	otherwise.	Homogenate	was	
centrifuged	to	remove	insoluble	materials,	and	protein	concentration	was	determined	using	
a	Pierce	BCA	Protein	Assay.	Resulting	lysate	was	diluted	to	2mg/ml	in	distilled	water	and	
sonicated.	GCase	activity	was	measured	in	lysate	(20 μg	protein)	using	5mM	4-
methylumbelliferyl	β-D-glucopyranoside	substrate	in	McIlvaine	buffer	(pH 5.4)	
supplemented	with	22mM	sodium	taurocholate	hydrate	at	37 °C	for	1	hour.	The	reaction	
was	stopped	by	adding	0.25M	glycine	(pH 10.4),	and	substrate	fluorescence	was	measured	
at	excitation	of	365nm,	emission	of	450nm	with	a	PerkinElmer	(Waltham,	MA)	fluorescence	
spectrometer.	All	GCase	assays	were	performed	in	duplicate.	GCase	activity	was	expressed	
as	nanomoles	of	substrate	catalysed	per	milligram	protein	per	hour.	
	
10.12 	Demographics	of	fibroblast	cell	lines	
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	 Supplementary	table	8.	Characterstics	of	fibroblast	lines	TMRM	
experiments	
	 mutation	 disease	 age/sex	 passage	
	 wt	 -	 70F	 9	
	 wt/wt	 -	 52M	 9	
	 wt/wt	 -	 54M	 7	
	 wt/wt	 -	 65M	 9	
	 N370S/wt	 -	 75F	 7	
	 N370S/wt	 -	 45M	 8	
	 N370S/wt	 -	 52M	 7	
	 N370S/wt	 -	 71F	 8	
	 N370S/wt	 Parkinson	
disease	
78F	 7	
	 N370S/wt	 Parkinson	
disease	
57M	 9	
	 N370S/wt	 Parkinson	
disease	
63M	 7	
	 N370S/wt	 Parkinson	
disease	
57M	 8	
	 N370S/203insc	 GD	 61M	 8	
	 N370S/c1263del55	 GD	 50M	 8	
	 N370S/N370S	 GD	 70M	 7	
	 N370S/R359X	 GD	 54M	 8	
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10.13 TMRM	image	express	methods	
	
Cells	were	plated	on	96	well	glass	bottomed	plates	in	DMEM,	10%	FBS,	pen/strep,	NEAA,	
pyruvate	48	hours	prior	to	imaging	at	a	density	of	2000	cells/well.1	Hour	before	imaging	
cells	were	washed	with	100uL	HBS	and	then	incubated	with	HBS	with	TMRM	25nM	and	
Hoechst	2ug/ml	was	added	Cells	were	imaged,	HBS	was	removed	and	then	100uL	5uM	
oligomycin	with	25nM	TMRM	was	added	and	cells	reimaged.		Demographics	and	passage	
numbers	of	cell	lines	used	are	listed	below.		
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10.14		GCase	activity	cerebrospinal	fluid	
	
cerebrospinal	fluid	was	centrifuged	at	2200G	for	10min	and	frozen	at	-80	degrees	within	an	
hour	of	collection	in	250ul	aliquots.	Upon	defrosting	cerebrospinal	fluid	was	vortexed	and	
centrifuged	at	8000rpm	for	10	second.	10	repeats	of	20ul	of	cerebrospinal	fluid	was	added		
to	a	96	well	plate.	The	reaction	was	commenced	by	adding	40ul	of	5uM	4-MU-β-D-
glucopyranoside	solution	dissolved	in	McIlvaine	citrate	buffer	(0.15M,	pH	5.9).	The	plate	
was	covered	and	incubated	at	38	degrees	for	3	hours	whereupon	the	reaction	was	stopped	
using	240ul	Glycine	stopping	buffer	(1M,	pH	10.4).	A	standard	was	prepared	by	preparing	5	
repeats	of	200ul	1mM	4-methylumbelliferone	in	distilled	water	and	adding	100ul	Glycine	
buffer.	The	plate	was	measured	at	excitation	of	365nm,	emission	of	450nm	with	a	
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PerkinElmer	(Waltham,	MA)	fluorescence	spectrometer.	GCase	assays	were	expressed	as	
nanomoles	of	substrate	catalysed	per	millilitre	of	cerebrospinal	fluid	per	hour.	
	Gain	settings		
The	fluorescence	readings	for	GCase	are	very	low	in	cerebrospinal	fluid.	Therefore,	in	the	
initial	trial	of	this	assay,	the	same	plate	was	read	at	several	different	gain	settings	(50,	55,	
60,	65	and	75)	in	order	to	obtain	a	signal	that	could	be	better	discriminated	from	the	water	
blank	wells.	However,	the	choice	of	gain	was	constrained	by	the	very	high	fluorescence	for	
the	standard	solution.	In	the	end	we	settled	for	a	gain	adjustment	of	55	for	all	subsequent	
assays	and	also	decided	to	use	a	4-fold	diluted	standard	solution	in	the	plates,	which	was	
then	accounted	for	in	the	final	activity	calculations.		
	
Negative	controls		
	
Condruitol	beta	expoxide	(CBE)	is	a	known	potent	inhibitor	of	GCase.	CBE	stock	solution	
(10mM)	was	made	by	dissolving	the	solute	in	dH2O	and	was	subsequently	aliquoted	and	
stored	at	-20°C.	For	the	assay,	the	CBE	was	added	in	a	1:10	dilution	directly	to	cerebrospinal	
fluid	to	obtain	a	working	concentration	of	1mM	and	incubated	at	37°C	for	15min	before	
adding	to	the	plate.	As	a	second	negative	control,	some	of	the	cerebrospinal	fluid	sample	
was	denatured	prior	to	performing	the	assay.	Denaturing	was	achieved	by	heating	the	
cerebrospinal	fluid	to	80°C	for	a	minimum	of	15min	in	a	dry	bath	incubator.		
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10.15	Small	molecular	chaperones	in	vitro	studies	
	
Both	ambroxol	and	Isophagamine	were	dissolved	in	dimethyl	sulfoxide	(DMSO)	to	make	a	
stock	solution	of	10mM.	An	intermediate	stock	of	100μM	was	made,	aliquoted	and	stored	
at	-20°C.	For	the	assay	ABX/IFG	was	added	in	a	1:200	dilution	directly	to	cerebrospinal	fluid	
to	obtain	a	working	concentration	of	500nM	and	incubated	at	37°C	for	15min	before	adding	
to	the	plate.	The	concentration	of	500nM	was	chosen	and	rounded	to	a	workable	
concentration	based	on	the	cerebrospinal	fluid	penetration	of	ABX	in	Gaucher	
diseasepatients	reported	from	the	results	of	a	recent	clinical	trial302	
	
10.16	GCase	activity	leucocyte	pellets		
	
Leucocyte	pellets	were	lysed	in	Fermantas	ProteoJET	Mammalian	Cell	Lysis	Reagent	and	
diluted	8X	in	McIlvaine	citrate	buffer	(0.15M,	pH	5.9).	The	reaction	was	commenced	by	
adding	40ul	of	5uM	4-MU-β-D-glucopyranoside	solution	dissolved	in	McIlvaine	citrate	buffer	
(0.15M,	pH	5.9).	The	plate	was	covered	and	incubated	at	38	degrees	for	3	hours	whereupon	
the	reaction	was	stopped	using	240ul	Glycine	stopping	buffer	(1M,	pH	10.4).	A	standard	was	
prepared	by	preparing	5	repeats	of	200ul	1mM	4-methylumbelliferone	in	distilled	water	and	
adding	100ul	Glycine	buffer.	The	plate	was	measured	at	excitation	of	365nm,	emission	of	
450nm	with	a	PerkinElmer	(Waltham,	MA)	fluorescence	spectrometer.	Protein	
concentration	was	determined	using	a	Pierce	BCA	Protein	Assay.	GCase	assays	were	
expressed	as	nanomoles	of	substrate	catalysed	per	milligram	of	protein	per	hour.	
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